<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
 xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:owl="http://www.w3.org/2002/07/owl#"
 xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"
 xml:base="http://www.reactome.org/biopax/91/5663202#">
<owl:Ontology rdf:about="">
 <owl:imports rdf:resource="http://www.biopax.org/release/biopax-level3.owl#" />
</owl:Ontology>

<bp:Evidence rdf:ID="Evidence176">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence175">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence178">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence177">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence172">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence171">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence174">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence173">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence58">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence59">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence56">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence170">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence57">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence54">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence55">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence52">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence53">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence50">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence51">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence169">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence168">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence187">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence186">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence189">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence188">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence183">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence182">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence49">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence185">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence184">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence47">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence48">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence45">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence181">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence46">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence180">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence43">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence44">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence41">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence42">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence40">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence179">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence198">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence197">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence199">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence194">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence193">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence196">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence195">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence190">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence78">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence192">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence79">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence191">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence76">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence77">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence74">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence75">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence72">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence73">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence70">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence71">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence69">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence67">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence68">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence65">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence66">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence63">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence64">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence61">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence62">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence60">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep87">
 <bp:stepProcess rdf:resource="#BiochemicalReaction72" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep86">
 <bp:stepProcess rdf:resource="#Pathway16" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep89">
 <bp:stepProcess rdf:resource="#Pathway17" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep88">
 <bp:stepProcess rdf:resource="#BiochemicalReaction73" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence18">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence19">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence16">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence17">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence14">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence15">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence12">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep81">
 <bp:stepProcess rdf:resource="#BiochemicalReaction70" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence13">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep80">
 <bp:stepProcess rdf:resource="#Pathway12" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence10">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep83">
 <bp:stepProcess rdf:resource="#BiochemicalReaction71" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence11">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep82">
 <bp:stepProcess rdf:resource="#Pathway13" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep85">
 <bp:stepProcess rdf:resource="#Pathway15" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep84">
 <bp:stepProcess rdf:resource="#Pathway14" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep98">
 <bp:stepProcess rdf:resource="#BiochemicalReaction81" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep97">
 <bp:stepProcess rdf:resource="#Catalysis11" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction80" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep99">
 <bp:stepProcess rdf:resource="#BiochemicalReaction82" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep90">
 <bp:stepProcess rdf:resource="#Pathway18" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep92">
 <bp:stepProcess rdf:resource="#BiochemicalReaction75" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep91">
 <bp:stepProcess rdf:resource="#BiochemicalReaction74" />
 <bp:stepProcess rdf:resource="#Catalysis10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep94">
 <bp:stepProcess rdf:resource="#BiochemicalReaction77" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep93">
 <bp:stepProcess rdf:resource="#BiochemicalReaction76" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep96">
 <bp:stepProcess rdf:resource="#BiochemicalReaction79" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep95">
 <bp:stepProcess rdf:resource="#BiochemicalReaction78" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence38">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence39">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence36">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence37">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence34">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence35">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence32">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence33">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence30">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence31">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence29">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence27">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence28">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence25">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence26">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence23">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence24">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence21">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence22">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence20">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep43">
 <bp:stepProcess rdf:resource="#BiochemicalReaction40" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence572">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep42">
 <bp:stepProcess rdf:resource="#BiochemicalReaction39" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence571">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep45">
 <bp:stepProcess rdf:resource="#BiochemicalReaction42" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence574">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep44">
 <bp:stepProcess rdf:resource="#BiochemicalReaction41" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence573">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep47">
 <bp:stepProcess rdf:resource="#BiochemicalReaction44" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep46">
 <bp:stepProcess rdf:resource="#BiochemicalReaction43" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep49">
 <bp:stepProcess rdf:resource="#BiochemicalReaction46" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence570">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep48">
 <bp:stepProcess rdf:resource="#BiochemicalReaction45" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep41">
 <bp:stepProcess rdf:resource="#BiochemicalReaction38" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep40">
 <bp:stepProcess rdf:resource="#BiochemicalReaction37" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence569">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep39">
 <bp:stepProcess rdf:resource="#BiochemicalReaction36" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence568">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence565">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence564">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence567">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence566">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep54">
 <bp:stepProcess rdf:resource="#BiochemicalReaction51" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence583">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep53">
 <bp:stepProcess rdf:resource="#BiochemicalReaction50" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence582">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep56">
 <bp:stepProcess rdf:resource="#BiochemicalReaction53" />
 <bp:stepProcess rdf:resource="#Catalysis8" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence101">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence585">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep55">
 <bp:stepProcess rdf:resource="#BiochemicalReaction52" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence100">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence584">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep58">
 <bp:stepProcess rdf:resource="#BiochemicalReaction55" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep57">
 <bp:stepProcess rdf:resource="#BiochemicalReaction54" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence581">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep59">
 <bp:stepProcess rdf:resource="#BiochemicalReaction56" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence580">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep50">
 <bp:stepProcess rdf:resource="#BiochemicalReaction47" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep52">
 <bp:stepProcess rdf:resource="#BiochemicalReaction49" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep51">
 <bp:stepProcess rdf:resource="#BiochemicalReaction48" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence579">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence576">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence575">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence578">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence577">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep65">
 <bp:stepProcess rdf:resource="#BiochemicalReaction62" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence110">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence594">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep64">
 <bp:stepProcess rdf:resource="#BiochemicalReaction61" />
 <bp:stepProcess rdf:resource="#Catalysis9" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence593">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep67">
 <bp:stepProcess rdf:resource="#Pathway5" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence112">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence596">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep66">
 <bp:stepProcess rdf:resource="#BiochemicalReaction63" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence111">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence595">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep69">
 <bp:stepProcess rdf:resource="#BiochemicalReaction64" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence590">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep68">
 <bp:stepProcess rdf:resource="#Pathway6" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence592">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence591">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep61">
 <bp:stepProcess rdf:resource="#BiochemicalReaction58" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep60">
 <bp:stepProcess rdf:resource="#BiochemicalReaction57" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep63">
 <bp:stepProcess rdf:resource="#BiochemicalReaction60" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep62">
 <bp:stepProcess rdf:resource="#BiochemicalReaction59" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence107">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence106">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence109">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence108">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence103">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence587">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence102">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence586">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence105">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence589">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence104">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence588">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep76">
 <bp:stepProcess rdf:resource="#Pathway10" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence121">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep75">
 <bp:stepProcess rdf:resource="#BiochemicalReaction67" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence120">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep78">
 <bp:stepProcess rdf:resource="#Pathway11" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence123">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep77">
 <bp:stepProcess rdf:resource="#BiochemicalReaction68" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence122">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep79">
 <bp:stepProcess rdf:resource="#BiochemicalReaction69" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep70">
 <bp:stepProcess rdf:resource="#Pathway7" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep72">
 <bp:stepProcess rdf:resource="#Pathway8" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep71">
 <bp:stepProcess rdf:resource="#BiochemicalReaction65" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep74">
 <bp:stepProcess rdf:resource="#Pathway9" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep73">
 <bp:stepProcess rdf:resource="#BiochemicalReaction66" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence6">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence118">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence5">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence117">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence4">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence3">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence119">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence114">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence598">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence9">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence113">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence597">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence8">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence116">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence7">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence115">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence599">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence132">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence131">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence134">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence133">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence130">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence98">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence99">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence96">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence97">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence94">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence95">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence92">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence93">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence90">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence91">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence129">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence128">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence125">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence124">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence127">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence126">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep10">
 <bp:stepProcess rdf:resource="#BiochemicalReaction8" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence143">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence142">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep12">
 <bp:stepProcess rdf:resource="#BiochemicalReaction10" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence145">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep11">
 <bp:stepProcess rdf:resource="#BiochemicalReaction9" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence144">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep14">
 <bp:stepProcess rdf:resource="#BiochemicalReaction12" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep13">
 <bp:stepProcess rdf:resource="#BiochemicalReaction11" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep16">
 <bp:stepProcess rdf:resource="#BiochemicalReaction14" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence141">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep15">
 <bp:stepProcess rdf:resource="#BiochemicalReaction13" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence140">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence89">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence87">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence88">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence85">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence86">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence83">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence84">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence81">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence82">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence80">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence139">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence136">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence135">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence138">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence137">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep21">
 <bp:stepProcess rdf:resource="#BiochemicalReaction19" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence154">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep20">
 <bp:stepProcess rdf:resource="#BiochemicalReaction18" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence153">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep23">
 <bp:stepProcess rdf:resource="#BiochemicalReaction21" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence156">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep22">
 <bp:stepProcess rdf:resource="#BiochemicalReaction20" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence155">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep25">
 <bp:stepProcess rdf:resource="#BiochemicalReaction23" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence150">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep24">
 <bp:stepProcess rdf:resource="#BiochemicalReaction22" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep27">
 <bp:stepProcess rdf:resource="#BiochemicalReaction25" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence152">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep26">
 <bp:stepProcess rdf:resource="#BiochemicalReaction24" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence151">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep18">
 <bp:stepProcess rdf:resource="#BiochemicalReaction16" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep17">
 <bp:stepProcess rdf:resource="#Catalysis7" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction15" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep19">
 <bp:stepProcess rdf:resource="#BiochemicalReaction17" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence147">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence146">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence149">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence148">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep32">
 <bp:stepProcess rdf:resource="#BiochemicalReaction29" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence165">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep31">
 <bp:stepProcess rdf:resource="#Pathway4" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence164">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep34">
 <bp:stepProcess rdf:resource="#BiochemicalReaction31" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence167">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep33">
 <bp:stepProcess rdf:resource="#BiochemicalReaction30" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence166">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep36">
 <bp:stepProcess rdf:resource="#BiochemicalReaction33" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence161">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep35">
 <bp:stepProcess rdf:resource="#BiochemicalReaction32" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence160">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep38">
 <bp:stepProcess rdf:resource="#BiochemicalReaction35" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence163">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep37">
 <bp:stepProcess rdf:resource="#BiochemicalReaction34" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence162">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep30">
 <bp:stepProcess rdf:resource="#BiochemicalReaction28" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep29">
 <bp:stepProcess rdf:resource="#BiochemicalReaction27" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep28">
 <bp:stepProcess rdf:resource="#BiochemicalReaction26" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence158">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence157">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence159">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep387">
 <bp:stepProcess rdf:resource="#BiochemicalReaction296" />
 <bp:stepProcess rdf:resource="#Catalysis89" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep388">
 <bp:stepProcess rdf:resource="#BiochemicalReaction297" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence609">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep389">
 <bp:stepProcess rdf:resource="#BiochemicalReaction298" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence606">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence605">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence608">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence607">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence602">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep380">
 <bp:stepProcess rdf:resource="#BiochemicalReaction292" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence601">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep381">
 <bp:stepProcess rdf:resource="#Pathway90" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence604">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep382">
 <bp:stepProcess rdf:resource="#BiochemicalReaction293" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence603">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep383">
 <bp:stepProcess rdf:resource="#Pathway91" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep384">
 <bp:stepProcess rdf:resource="#BiochemicalReaction294" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep385">
 <bp:stepProcess rdf:resource="#Pathway92" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence600">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep386">
 <bp:stepProcess rdf:resource="#BiochemicalReaction295" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction508">
 <bp:evidence rdf:resource="#Evidence673" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants:p-FRS2:GRB2:GAB1:PIK3R1 binds PIK3CA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction509">
 <bp:evidence rdf:resource="#Evidence674" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction506">
 <bp:evidence rdf:resource="#Evidence671" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutant-associated PI3K phosphorylates PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction507">
 <bp:evidence rdf:resource="#Evidence672" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants and fusions bind PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction504">
 <bp:evidence rdf:resource="#Evidence668" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point, translocation and fusion mutant-associated PI3K phosphorylates PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction505">
 <bp:evidence rdf:resource="#Evidence670" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants:p-FRS2 binds GRB2:GAB1:PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction502">
 <bp:evidence rdf:resource="#Evidence666" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point, translocation and fusion mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction503">
 <bp:evidence rdf:resource="#Evidence667" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point and translocation mutants phosphorylate PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep398">
 <bp:stepProcess rdf:resource="#BiochemicalReaction307" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction500">
 <bp:evidence rdf:resource="#Evidence664" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-4Y-PLCG1 dissociates from activated FGFR3 point and translocation mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis162">
 <bp:controlled rdf:resource="#BiochemicalReaction533" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep399">
 <bp:stepProcess rdf:resource="#BiochemicalReaction308" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction501">
 <bp:evidence rdf:resource="#Evidence665" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point and translocation mutants bind PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis163">
 <bp:controlled rdf:resource="#BiochemicalReaction536" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence617">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence616">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence619">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis160">
 <bp:controlled rdf:resource="#BiochemicalReaction529" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence618">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis161">
 <bp:controlled rdf:resource="#BiochemicalReaction532" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep390">
 <bp:stepProcess rdf:resource="#BiochemicalReaction299" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence613">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep391">
 <bp:stepProcess rdf:resource="#BiochemicalReaction300" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence612">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep392">
 <bp:stepProcess rdf:resource="#BiochemicalReaction301" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence615">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep393">
 <bp:stepProcess rdf:resource="#BiochemicalReaction302" />
 <bp:stepProcess rdf:resource="#Catalysis90" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence614">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep394">
 <bp:stepProcess rdf:resource="#BiochemicalReaction303" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep395">
 <bp:stepProcess rdf:resource="#BiochemicalReaction304" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep396">
 <bp:stepProcess rdf:resource="#Catalysis91" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction305" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence611">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep397">
 <bp:stepProcess rdf:resource="#Catalysis92" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction306" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence610">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction519">
 <bp:evidence rdf:resource="#Evidence688" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tyrosine kinase inhibitors bind and inhibit overexpressed FGFR1 dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction517">
 <bp:evidence rdf:resource="#Evidence686" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of overexpressed FGFR1b</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction518">
 <bp:evidence rdf:resource="#Evidence687" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent phosphorylation of overexpressed FGFR1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction515">
 <bp:evidence rdf:resource="#Evidence683" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR1c P252X mutants bind ligand with enhanced affinity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction516">
 <bp:evidence rdf:resource="#Evidence684" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR1c P252X mutant dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction513">
 <bp:evidence rdf:resource="#Evidence681" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of FGFR1 point mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction514">
 <bp:evidence rdf:resource="#Evidence682" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR1 mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction511">
 <bp:evidence rdf:resource="#Evidence678" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Plasma membrane FGFR1 fusions dimerize</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis151">
 <bp:controlled rdf:resource="#BiochemicalReaction512" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction512">
 <bp:evidence rdf:resource="#Evidence679" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Plasma membrane FGFR1 fusions autophosphorylate</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis152">
 <bp:controlled rdf:resource="#BiochemicalReaction514" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis153">
 <bp:controlled rdf:resource="#BiochemicalReaction516" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction510">
 <bp:evidence rdf:resource="#Evidence675" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants phosphorylate FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis154">
 <bp:controlled rdf:resource="#BiochemicalReaction518" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence628">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence627">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence629">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis150">
 <bp:controlled rdf:resource="#BiochemicalReaction510" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence624">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis159">
 <bp:controlled rdf:resource="#BiochemicalReaction527" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence623">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence626">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence625">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence620">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis155">
 <bp:controlled rdf:resource="#BiochemicalReaction520" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis156">
 <bp:controlled rdf:resource="#BiochemicalReaction522" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence622">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis157">
 <bp:controlled rdf:resource="#BiochemicalReaction523" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence621">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis158">
 <bp:controlled rdf:resource="#BiochemicalReaction524" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence640">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction528">
 <bp:evidence rdf:resource="#Evidence698" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated cytosolic FGFR1 fusions bind PIK3CA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction529">
 <bp:evidence rdf:resource="#Evidence699" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytosolic FGFR1 fusion protein-associated PI3K phosphorylates PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction526">
 <bp:evidence rdf:resource="#Evidence696" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BCR-FGFR1:GRB2:p-GAB2 binds PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction527">
 <bp:evidence rdf:resource="#Evidence697" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of STAT5 by cytosolic FGFR1 fusions</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction524">
 <bp:evidence rdf:resource="#Evidence694" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-BCR-p-FGFR1 phosphorylates GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction525">
 <bp:evidence rdf:resource="#Evidence695" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytosolic FGFR1 fusion proteins bind PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis140">
 <bp:controlled rdf:resource="#BiochemicalReaction487" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction522">
 <bp:evidence rdf:resource="#Evidence692" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BCR-FGFR1-associated PI3K phosphorylates PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis141">
 <bp:controlled rdf:resource="#BiochemicalReaction490" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction523">
 <bp:evidence rdf:resource="#Evidence693" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR1OP-FGFR1 phosphorylates STAT1 and STAT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis142">
 <bp:controlled rdf:resource="#BiochemicalReaction492" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction520">
 <bp:evidence rdf:resource="#Evidence689" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent phosphorylation of overexpressed FGFR1c</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis143">
 <bp:controlled rdf:resource="#BiochemicalReaction494" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction521">
 <bp:evidence rdf:resource="#Evidence690" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of overexpressed FGFR1c</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence639">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence638">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence635">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis148">
 <bp:controlled rdf:resource="#BiochemicalReaction506" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence634">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis149">
 <bp:controlled rdf:resource="#BiochemicalReaction509" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence637">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence636">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence631">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis144">
 <bp:controlled rdf:resource="#BiochemicalReaction495" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence630">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis145">
 <bp:controlled rdf:resource="#BiochemicalReaction502" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence633">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis146">
 <bp:controlled rdf:resource="#BiochemicalReaction503" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence632">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis147">
 <bp:controlled rdf:resource="#BiochemicalReaction504" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence651">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence650">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction539">
 <bp:evidence rdf:resource="#Evidence709" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-4Y- PLCG1 dissociates from activated FGFR1 mutants and fusions</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction537">
 <bp:evidence rdf:resource="#Evidence707" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants:p-FRS2 binds GRB2-SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction538">
 <bp:evidence rdf:resource="#Evidence708" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants bind FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction535">
 <bp:evidence rdf:resource="#Evidence705" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BCR-FGFR1 fusion:GRB2:p-GAB2:PIK3R1 binds PIK3CA </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction536">
 <bp:evidence rdf:resource="#Evidence706" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants and fusions phosphorylate PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep343">
 <bp:stepProcess rdf:resource="#BiochemicalReaction267" />
 <bp:stepProcess rdf:resource="#Catalysis79" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction533">
 <bp:evidence rdf:resource="#Evidence703" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of cytosolic FGFR1 fusion dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep344">
 <bp:stepProcess rdf:resource="#Catalysis80" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction268" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction534">
 <bp:evidence rdf:resource="#Evidence704" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tyrosine kinase inhibitors bind and inhibit cytosolic FGFR1 fusion dimer phosphorylation</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep345">
 <bp:stepProcess rdf:resource="#BiochemicalReaction269" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction531">
 <bp:evidence rdf:resource="#Evidence701" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of cytosolic FGFR1 fusion proteins</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep346">
 <bp:stepProcess rdf:resource="#Catalysis81" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction270" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction532">
 <bp:evidence rdf:resource="#Evidence702" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of BCR moiety of BCR-FGFR1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep347">
 <bp:stepProcess rdf:resource="#Catalysis82" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction271" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep348">
 <bp:stepProcess rdf:resource="#Catalysis83" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction272" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence649">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction530">
 <bp:evidence rdf:resource="#Evidence700" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-BCR-pFGFR1 binds GRB2:GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep349">
 <bp:stepProcess rdf:resource="#Pathway78" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence646">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence645">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence648">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence647">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence642">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep340">
 <bp:stepProcess rdf:resource="#BiochemicalReaction264" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence641">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep341">
 <bp:stepProcess rdf:resource="#BiochemicalReaction265" />
 <bp:stepProcess rdf:resource="#Catalysis78" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence644">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep342">
 <bp:stepProcess rdf:resource="#BiochemicalReaction266" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence643">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence660">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence662">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence661">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep354">
 <bp:stepProcess rdf:resource="#BiochemicalReaction276" />
 <bp:stepProcess rdf:resource="#Catalysis85" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep355">
 <bp:stepProcess rdf:resource="#BiochemicalReaction277" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep356">
 <bp:stepProcess rdf:resource="#Pathway80" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep357">
 <bp:stepProcess rdf:resource="#Pathway81" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep358">
 <bp:stepProcess rdf:resource="#BiochemicalReaction278" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep359">
 <bp:stepProcess rdf:resource="#BiochemicalReaction279" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence657">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence656">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence659">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence658">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep350">
 <bp:stepProcess rdf:resource="#Catalysis84" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction273" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence653">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep351">
 <bp:stepProcess rdf:resource="#Pathway79" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence652">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep352">
 <bp:stepProcess rdf:resource="#BiochemicalReaction274" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence655">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep353">
 <bp:stepProcess rdf:resource="#BiochemicalReaction275" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence654">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence671">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence670">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence673">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence672">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep365">
 <bp:stepProcess rdf:resource="#BiochemicalReaction285" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep366">
 <bp:stepProcess rdf:resource="#Pathway82" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep367">
 <bp:stepProcess rdf:resource="#Pathway83" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep368">
 <bp:stepProcess rdf:resource="#BiochemicalReaction286" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep369">
 <bp:stepProcess rdf:resource="#Pathway84" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence668">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence667">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep360">
 <bp:stepProcess rdf:resource="#BiochemicalReaction280" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence669">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep361">
 <bp:stepProcess rdf:resource="#Catalysis86" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction281" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence664">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep362">
 <bp:stepProcess rdf:resource="#Catalysis87" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction282" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence663">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep363">
 <bp:stepProcess rdf:resource="#BiochemicalReaction283" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence666">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep364">
 <bp:stepProcess rdf:resource="#BiochemicalReaction284" />
 <bp:stepProcess rdf:resource="#Catalysis88" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence665">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence682">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence681">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence200">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence684">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence683">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence680">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep376">
 <bp:stepProcess rdf:resource="#BiochemicalReaction290" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep377">
 <bp:stepProcess rdf:resource="#Pathway88" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep378">
 <bp:stepProcess rdf:resource="#BiochemicalReaction291" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep379">
 <bp:stepProcess rdf:resource="#Pathway89" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence679">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence678">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep370">
 <bp:stepProcess rdf:resource="#BiochemicalReaction287" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep371">
 <bp:stepProcess rdf:resource="#Pathway85" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep372">
 <bp:stepProcess rdf:resource="#BiochemicalReaction288" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence675">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep373">
 <bp:stepProcess rdf:resource="#Pathway86" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence674">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep374">
 <bp:stepProcess rdf:resource="#BiochemicalReaction289" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence677">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep375">
 <bp:stepProcess rdf:resource="#Pathway87" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence676">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep300">
 <bp:stepProcess rdf:resource="#BiochemicalReaction234" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep301">
 <bp:stepProcess rdf:resource="#BiochemicalReaction235" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep302">
 <bp:stepProcess rdf:resource="#BiochemicalReaction236" />
 <bp:stepProcess rdf:resource="#Catalysis62" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep303">
 <bp:stepProcess rdf:resource="#Pathway68" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep304">
 <bp:stepProcess rdf:resource="#BiochemicalReaction237" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep305">
 <bp:stepProcess rdf:resource="#BiochemicalReaction238" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep306">
 <bp:stepProcess rdf:resource="#Catalysis63" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction239" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep307">
 <bp:stepProcess rdf:resource="#Catalysis64" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction240" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep308">
 <bp:stepProcess rdf:resource="#BiochemicalReaction241" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep309">
 <bp:stepProcess rdf:resource="#BiochemicalReaction242" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction108">
 <bp:evidence rdf:resource="#Evidence128" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">EGF-induced dimerization of ligand-responsive EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction109">
 <bp:evidence rdf:resource="#Evidence129" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with phosphorylated SHC1 and ligand-responsive p-6Y-EGFR mutants)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction106">
 <bp:evidence rdf:resource="#Evidence126" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of EGF to ligand-responsive EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction107">
 <bp:evidence rdf:resource="#Evidence127" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Inefficient ubiquitination of ligand-responsive p-6Y-EGFR mutants by p-Y371-CBL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction104">
 <bp:evidence rdf:resource="#Evidence124" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PLCG1 binds to ligand-responsive p-6Y-EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep310">
 <bp:stepProcess rdf:resource="#Pathway69" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction105">
 <bp:evidence rdf:resource="#Evidence125" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Spontaneous dimerization of ligand-responsive EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep311">
 <bp:stepProcess rdf:resource="#BiochemicalReaction243" />
 <bp:stepProcess rdf:resource="#Catalysis65" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction102">
 <bp:evidence rdf:resource="#Evidence122" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of SHC1 by ligand-responsive p-6Y-EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep312">
 <bp:stepProcess rdf:resource="#Pathway70" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction103">
 <bp:evidence rdf:resource="#Evidence123" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of GRB2:GAB1 complex to ligand-responsive p-6Y-EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep313">
 <bp:stepProcess rdf:resource="#Pathway71" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction100">
 <bp:evidence rdf:resource="#Evidence120" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of phosphorylated PLCG1 from ligand-responsive p-6Y-EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep314">
 <bp:stepProcess rdf:resource="#BiochemicalReaction244" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction101">
 <bp:evidence rdf:resource="#Evidence121" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Covalent tyrosine kinase inhibitors bind and inactivate EGFR kinase domain mutant dimers resistant to non-covalent tyrosine kinase inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep315">
 <bp:stepProcess rdf:resource="#BiochemicalReaction245" />
 <bp:stepProcess rdf:resource="#Catalysis66" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep316">
 <bp:stepProcess rdf:resource="#BiochemicalReaction246" />
 <bp:stepProcess rdf:resource="#Catalysis67" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep317">
 <bp:stepProcess rdf:resource="#BiochemicalReaction247" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep318">
 <bp:stepProcess rdf:resource="#BiochemicalReaction248" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep319">
 <bp:stepProcess rdf:resource="#Catalysis68" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction249" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction119">
 <bp:evidence rdf:resource="#Evidence142" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 HD domain mutants bind JAG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction117">
 <bp:evidence rdf:resource="#Evidence140" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ubiquitination of DLL/JAG ligands upon binding to NOTCH1 HD domain mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction118">
 <bp:evidence rdf:resource="#Evidence141" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 HD domain mutants bind JAG2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction115">
 <bp:evidence rdf:resource="#Evidence138" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 HD domain mutants bind DLL1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep321">
 <bp:stepProcess rdf:resource="#Pathway72" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction116">
 <bp:evidence rdf:resource="#Evidence139" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 HD domain mutants are cleaved to produce NEXT1 irrespective of ligand binding</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep322">
 <bp:stepProcess rdf:resource="#Pathway73" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction113">
 <bp:evidence rdf:resource="#Evidence133" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated SHC1 in complex with ligand-responsive p-6Y-EGFR mutants recruits GRB2:SOS1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep323">
 <bp:stepProcess rdf:resource="#BiochemicalReaction251" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction114">
 <bp:evidence rdf:resource="#Evidence134" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Trans-autophosphorylation of activated ligand-responsive EGFR mutant dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep324">
 <bp:stepProcess rdf:resource="#Pathway74" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction111">
 <bp:evidence rdf:resource="#Evidence131" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of CBL by ligand-responsive p-6Y-EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep325">
 <bp:stepProcess rdf:resource="#BiochemicalReaction252" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction112">
 <bp:evidence rdf:resource="#Evidence132" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HSP90 is inactivated by binding to benzaquinoid ansamycins</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep326">
 <bp:stepProcess rdf:resource="#Pathway75" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep327">
 <bp:stepProcess rdf:resource="#Pathway76" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction110">
 <bp:evidence rdf:resource="#Evidence130" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of PLCG1 by ligand-responsive p-6Y-EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep328">
 <bp:stepProcess rdf:resource="#BiochemicalReaction253" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep320">
 <bp:stepProcess rdf:resource="#BiochemicalReaction250" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep329">
 <bp:stepProcess rdf:resource="#BiochemicalReaction254" />
 <bp:stepProcess rdf:resource="#Catalysis69" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction128">
 <bp:evidence rdf:resource="#Evidence153" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants bind HES5 promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction129">
 <bp:evidence rdf:resource="#Evidence154" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants stimulate HES1 transcription</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction126">
 <bp:evidence rdf:resource="#Evidence151" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NICD1 PEST domain mutants displace co-repressor complex from RBPJ (CSL)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep332">
 <bp:stepProcess rdf:resource="#BiochemicalReaction256" />
 <bp:stepProcess rdf:resource="#Catalysis71" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction127">
 <bp:evidence rdf:resource="#Evidence152" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants stimulate HEY transcription</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep333">
 <bp:stepProcess rdf:resource="#BiochemicalReaction257" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction124">
 <bp:evidence rdf:resource="#Evidence149" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants stimulate MYC transcription</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep334">
 <bp:stepProcess rdf:resource="#BiochemicalReaction258" />
 <bp:stepProcess rdf:resource="#Catalysis72" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction125">
 <bp:evidence rdf:resource="#Evidence150" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 HD+PEST domain mutants bind JAG2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep335">
 <bp:stepProcess rdf:resource="#BiochemicalReaction259" />
 <bp:stepProcess rdf:resource="#Catalysis73" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction122">
 <bp:evidence rdf:resource="#Evidence147" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEXT1 PEST domain mutants are cleaved to produce NICD1 PEST domain mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep336">
 <bp:stepProcess rdf:resource="#Catalysis74" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction260" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction123">
 <bp:evidence rdf:resource="#Evidence148" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants coactivator complex binds CDK8:CCNC</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep337">
 <bp:stepProcess rdf:resource="#Catalysis75" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction261" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction120">
 <bp:evidence rdf:resource="#Evidence143" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 HD domain mutants bind DLL4</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep338">
 <bp:stepProcess rdf:resource="#Catalysis76" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction262" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction121">
 <bp:evidence rdf:resource="#Evidence146" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NICD1 PEST domain mutants translocate from cytosol to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep339">
 <bp:stepProcess rdf:resource="#BiochemicalReaction263" />
 <bp:stepProcess rdf:resource="#Catalysis77" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep330">
 <bp:stepProcess rdf:resource="#Pathway77" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep331">
 <bp:stepProcess rdf:resource="#Catalysis70" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction255" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction139">
 <bp:evidence rdf:resource="#Evidence164" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-NICD1 PEST domain mutants do not bind FBXW7</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction137">
 <bp:evidence rdf:resource="#Evidence162" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants stimulate HES5 transcription</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction138">
 <bp:evidence rdf:resource="#Evidence163" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 HD+PEST domain mutants bind DLL4</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis130">
 <bp:controlled rdf:resource="#BiochemicalReaction458" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction135">
 <bp:evidence rdf:resource="#Evidence160" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CDK8 phosphorylates NICD1 PEST domain mutants </bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis131">
 <bp:controlled rdf:resource="#BiochemicalReaction465" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction136">
 <bp:evidence rdf:resource="#Evidence161" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants bind MYC promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis132">
 <bp:controlled rdf:resource="#BiochemicalReaction468" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction133">
 <bp:evidence rdf:resource="#Evidence158" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants bind HES1 promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction134">
 <bp:evidence rdf:resource="#Evidence159" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 HD+PEST domain mutants bind JAG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction131">
 <bp:evidence rdf:resource="#Evidence156" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 HD+PEST domain mutants are cleaved by ADAM10/17 irrespective of ligand binding</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction132">
 <bp:evidence rdf:resource="#Evidence157" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ubiquitination of DLL/JAG ligands upon binding to NOTCH1 HD+PEST domain mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis137">
 <bp:controlled rdf:resource="#BiochemicalReaction482" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction130">
 <bp:evidence rdf:resource="#Evidence155" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants bind promoters of HEY genes</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis138">
 <bp:controlled rdf:resource="#BiochemicalReaction483" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis139">
 <bp:controlled rdf:resource="#BiochemicalReaction484" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis133">
 <bp:controlled rdf:resource="#BiochemicalReaction472" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis134">
 <bp:controlled rdf:resource="#BiochemicalReaction473" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis135">
 <bp:controlled rdf:resource="#BiochemicalReaction474" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis136">
 <bp:controlled rdf:resource="#BiochemicalReaction478" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2">
 <bp:stepProcess rdf:resource="#Pathway3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep3">
 <bp:stepProcess rdf:resource="#Catalysis1" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep4">
 <bp:stepProcess rdf:resource="#Catalysis2" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep5">
 <bp:stepProcess rdf:resource="#Catalysis3" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep6">
 <bp:stepProcess rdf:resource="#Catalysis4" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction4" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep7">
 <bp:stepProcess rdf:resource="#Catalysis5" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction5" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep8">
 <bp:stepProcess rdf:resource="#BiochemicalReaction6" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep9">
 <bp:stepProcess rdf:resource="#Catalysis6" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction7" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1">
 <bp:stepProcess rdf:resource="#Pathway2" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction148">
 <bp:evidence rdf:resource="#Evidence177" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NICD1 PEST domain mutants displace co-repressor complex from RBPJ (CSL)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction149">
 <bp:evidence rdf:resource="#Evidence178" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants stimulate HEY transcription</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction146">
 <bp:evidence rdf:resource="#Evidence175" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants bind DLL1 </bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis120">
 <bp:controlled rdf:resource="#BiochemicalReaction426" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction147">
 <bp:evidence rdf:resource="#Evidence176" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants stimulate MYC transcription</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis121">
 <bp:controlled rdf:resource="#BiochemicalReaction429" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction144">
 <bp:evidence rdf:resource="#Evidence173" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEXT1 PEST domain mutants are cleaved to produce NICD1 PEST domain mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction145">
 <bp:evidence rdf:resource="#Evidence174" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants coactivator complex binds CDK8:CCNC</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction142">
 <bp:evidence rdf:resource="#Evidence169" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FBXW7 WD mutants do not bind NICD1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction143">
 <bp:evidence rdf:resource="#Evidence172" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NICD1 PEST domain mutants translocate from cytosol to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction140">
 <bp:evidence rdf:resource="#Evidence165" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NICD1 PEST domain mutants in complex with RBPJ (CSL) bind MAML</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis126">
 <bp:controlled rdf:resource="#BiochemicalReaction447" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction141">
 <bp:evidence rdf:resource="#Evidence166" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 HD+PEST domain mutants bind DLL1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis127">
 <bp:controlled rdf:resource="#BiochemicalReaction449" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis128">
 <bp:controlled rdf:resource="#BiochemicalReaction454" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis129">
 <bp:controlled rdf:resource="#BiochemicalReaction456" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis122">
 <bp:controlled rdf:resource="#BiochemicalReaction430" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis123">
 <bp:controlled rdf:resource="#BiochemicalReaction442" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis124">
 <bp:controlled rdf:resource="#BiochemicalReaction445" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis125">
 <bp:controlled rdf:resource="#BiochemicalReaction446" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis119">
 <bp:controlled rdf:resource="#BiochemicalReaction420" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction159">
 <bp:evidence rdf:resource="#Evidence188" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants stimulate HES5 transcription</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction157">
 <bp:evidence rdf:resource="#Evidence186" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CDK8 phosphorylates NICD1 PEST domain mutants </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction158">
 <bp:evidence rdf:resource="#Evidence187" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants bind MYC promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis110">
 <bp:controlled rdf:resource="#BiochemicalReaction372" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction155">
 <bp:evidence rdf:resource="#Evidence184" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants bind HES1 promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction156">
 <bp:evidence rdf:resource="#Evidence185" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants bind JAG2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction153">
 <bp:evidence rdf:resource="#Evidence182" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ADAM10/17 cleaves ligand-bound NOTCH1 PEST domain mutants to produce NEXT1 PEST domain mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction154">
 <bp:evidence rdf:resource="#Evidence183" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants bind JAG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction151">
 <bp:evidence rdf:resource="#Evidence180" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants stimulate HES1 transcription</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis115">
 <bp:controlled rdf:resource="#BiochemicalReaction398" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction152">
 <bp:evidence rdf:resource="#Evidence181" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants bind promoters of HEY genes</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis116">
 <bp:controlled rdf:resource="#BiochemicalReaction415" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis117">
 <bp:controlled rdf:resource="#BiochemicalReaction416" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction150">
 <bp:evidence rdf:resource="#Evidence179" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants bind HES5 promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis118">
 <bp:controlled rdf:resource="#BiochemicalReaction418" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis111">
 <bp:controlled rdf:resource="#BiochemicalReaction375" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis112">
 <bp:controlled rdf:resource="#BiochemicalReaction379" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis113">
 <bp:controlled rdf:resource="#BiochemicalReaction387" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis114">
 <bp:controlled rdf:resource="#BiochemicalReaction393" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis108">
 <bp:controlled rdf:resource="#BiochemicalReaction363" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis109">
 <bp:controlled rdf:resource="#BiochemicalReaction369" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction168">
 <bp:evidence rdf:resource="#Evidence199" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 t(7;9)(NOTCH1:M1580_K2555) does not bind DLL4</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction169">
 <bp:evidence rdf:resource="#Evidence202" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PDGFR mutants bind type II TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction166">
 <bp:evidence rdf:resource="#Evidence197" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 t(7;9)(NOTCH1:M1580_K2555) does not bind DLL1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction167">
 <bp:evidence rdf:resource="#Evidence198" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 t(7;9)(NOTCH1:M1580_K2555) does not bind JAG2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction164">
 <bp:evidence rdf:resource="#Evidence195" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 t(7;9)(NOTCH1:M1580_K2555) is cleaved to produce NEXT1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction165">
 <bp:evidence rdf:resource="#Evidence196" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 t(7;9)(NOTCH1:M1580_K2555) does not bind JAG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction162">
 <bp:evidence rdf:resource="#Evidence191" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ubiquitination of DLL/JAG ligands upon binding to NOTCH1 PEST domain mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis104">
 <bp:controlled rdf:resource="#BiochemicalReaction331" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction163">
 <bp:evidence rdf:resource="#Evidence192" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants bind DLL4</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis105">
 <bp:controlled rdf:resource="#BiochemicalReaction332" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction160">
 <bp:evidence rdf:resource="#Evidence189" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-NICD1 PEST domain mutants do not bind FBXW7</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis106">
 <bp:controlled rdf:resource="#BiochemicalReaction359" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction161">
 <bp:evidence rdf:resource="#Evidence190" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NICD1 PEST domain mutants in complex with RBPJ (CSL) bind MAML</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis107">
 <bp:controlled rdf:resource="#BiochemicalReaction361" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis100">
 <bp:controlled rdf:resource="#BiochemicalReaction326" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis101">
 <bp:controlled rdf:resource="#BiochemicalReaction327" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis102">
 <bp:controlled rdf:resource="#BiochemicalReaction328" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis103">
 <bp:controlled rdf:resource="#BiochemicalReaction329" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway105">
 <bp:pathwayOrder rdf:resource="#PathwayStep452" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction348" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence452" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">gilteritinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Gilteritinib is a second-generation type I tyrosine kinase inhibitor with activity against FLT3 (reviewed in Daver et al, 2019; Hassanein et l, 2016; Lim et al, 2017; Luxkin et al, 2017). This pathway describes FLT3 mutants that are resistant to inhibition by gilteritinib.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway106">
 <bp:pathwayOrder rdf:resource="#PathwayStep454" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction349" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence454" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">quizartinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Quizartinib is a type II tyrosine kinase inhibitor that is in phase III clinical trials for treatment of acute myeloid leukemias with FLT3 internal tandem duplications (ITDs). This pathway describes FLT3 mutants that display resistance to quizartinib (reviewed in Kazi and Roonstrand, 2019; Daver et al, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction179">
 <bp:evidence rdf:resource="#Evidence219" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of PDGFRA extracellular domain mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway107">
 <bp:pathwayOrder rdf:resource="#PathwayStep456" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction350" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence456" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">semaxanib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Semaxanib, also known as SU5614, is an investigational type I tyrosine kinase inhibitor with activity against a wide range of receptor tyrosine kinases. It is not currently approved for clinical use. This pathway describes FLT3 mutants that show resistance to semaxanib-mediated inhibition (Yee et al, 2002; Spiekermann et al, 2003).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway108">
 <bp:pathwayOrder rdf:resource="#PathwayStep458" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction351" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence458" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">linifanib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Linifanib is a type I tyrosine kinase inhibitor with activity against a broad range of receptor tyrosine kinases including FLT3. This pathway describes FLT3 mutants that are resistant to inhibition by linifanib (Hernandez-Davies et al, 2011; Nguyen et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction177">
 <bp:evidence rdf:resource="#Evidence217" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autophosphorylation of PDGFRA extracellular domain dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway109">
 <bp:pathwayOrder rdf:resource="#PathwayStep460" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction352" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence460" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ponatinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ponatinib is a first generation tyrosine kinase inhibitor with activity against a broad range of receptor tyrosine kinases, including FLT3 (reviewed Pemmeraju et al, 2014; Kazi and Roonstrand, 2019). This pathway describes FLT3 mutants that are resistant to inhibition by ponatinib.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction178">
 <bp:evidence rdf:resource="#Evidence218" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GRB2:SOS1 complex binds to PDGFRA extracellular domain dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction175">
 <bp:evidence rdf:resource="#Evidence214" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of membrane-tethered fusions of PDGFRA or PDGFRB</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction176">
 <bp:evidence rdf:resource="#Evidence215" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autophosphorylation of membrane-tethered fusions of PDGFRA or PDGFRB</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction173">
 <bp:evidence rdf:resource="#Evidence210" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">D842V PDGFRA doesn&apos;t bind sunitinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction174">
 <bp:evidence rdf:resource="#Evidence212" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regorafenib-resistant PDGFR mutants don&apos;t bind regorafenib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction171">
 <bp:evidence rdf:resource="#Evidence206" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Imatinib-resistant PDGFR mutants don&apos;t bind imatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction172">
 <bp:evidence rdf:resource="#Evidence208" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sorafenib-resistant PDGFR mutants don&apos;t bind sorefenib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway100">
 <bp:pathwayOrder rdf:resource="#PathwayStep442" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction343" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence442" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">pexidartinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pexidartinib is a type II tyrosine kinase inhibitor that is active against FLT3, including the quizartinib-resistant gatekeeper mutation F691L. Activating mutations at TKD aspartic acid residue 835 are resistant to pexidartinib-mediated inhibition, however (Smith et al, 2015a, b). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway101">
 <bp:pathwayOrder rdf:resource="#PathwayStep444" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction344" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence444" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">tandutinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tandutinib, also known as MLN519, is a type II tyrosine kinase inhibitor with activity against FLT3 (Clark et al, 2004; reviewed in Staudt et al, 2018; Daver et al, 2019). This pathway describes FLT3 mutants that are resistant to tandutinib-mediated inhibition.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction170">
 <bp:evidence rdf:resource="#Evidence203" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PDGFR mutants bind type I TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway102">
 <bp:pathwayOrder rdf:resource="#PathwayStep446" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction345" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence446" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">tamatinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tamatinib is a type I tyrosine kinase inhibitor with activity against FLT3. This pathway describes FLT3 mutants that are resistant to inhibition by tamatinib (Nguyen et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway103">
 <bp:pathwayOrder rdf:resource="#PathwayStep448" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction346" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence448" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">sorafenib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sorafenib is a first generation type II tyrosine kinase inhibitor with broad specificity for receptor tyrosine kinases including FLT3. This pathway describes FLT3 mutants that are resistant to sorafenib-mediated inhibition (Nguyen et al 2017; Linblad et al, 2017;reviewed in Kazi and Roonstrand, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway104">
 <bp:pathwayOrder rdf:resource="#PathwayStep450" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction347" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence450" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">lestaurtinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Lestaurtinib is a first-generation, type I tyrosine kinase inhibitor with activity against a range of receptor tyrosine kinases including FLT3 (reviewed in Larrosa-Garcia and Baer, 2017; Staudt et al, 2018; Daver et al, 2019). This pathway describes FLT3 mutants that are resistant to lestaurtinib-mediated inhibition.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway116">
 <bp:pathwayOrder rdf:resource="#PathwayStep521" />
 <bp:pathwayOrder rdf:resource="#PathwayStep533" />
 <bp:pathwayOrder rdf:resource="#PathwayStep544" />
 <bp:pathwayOrder rdf:resource="#PathwayStep535" />
 <bp:pathwayOrder rdf:resource="#PathwayStep546" />
 <bp:pathwayOrder rdf:resource="#PathwayStep514" />
 <bp:pathwayOrder rdf:resource="#PathwayStep526" />
 <bp:pathwayOrder rdf:resource="#PathwayStep548" />
 <bp:pathwayOrder rdf:resource="#PathwayStep528" />
 <bp:pathwayOrder rdf:resource="#PathwayStep519" />
 <bp:pathwayComponent rdf:resource="#Pathway117" />
 <bp:pathwayComponent rdf:resource="#Pathway128" />
 <bp:pathwayComponent rdf:resource="#Pathway129" />
 <bp:pathwayComponent rdf:resource="#Pathway120" />
 <bp:pathwayComponent rdf:resource="#Pathway121" />
 <bp:pathwayComponent rdf:resource="#Pathway134" />
 <bp:pathwayComponent rdf:resource="#Pathway124" />
 <bp:pathwayComponent rdf:resource="#Pathway135" />
 <bp:pathwayComponent rdf:resource="#Pathway125" />
 <bp:pathwayComponent rdf:resource="#Pathway136" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence514" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by WNT in cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The WNT signaling pathway has been linked with cancer ever since the identification of the first WNT as a gene activated by integration of mouse mammary tumor virus proviral DNA in virally-induced breast tumors (Nusse et al, 1984).  The most well known example of aberrant WNT signaling in cancer is in colorectal cancer, where an activating mutation in a WNT pathway component is seen in 90% of sporadic cases.  Inappropriate WNT pathway activation has also been implicated in most other solid human cancers but is not always associated with mutations in WNT pathway components (reviewed in Polakis, 2012). Both tumor suppressors and oncogenes have been identified in the so-called canonical WNT pathway, which regulates WNT-dependent transcription by promoting the degradation of beta-catenin in the absence of ligand (reviewed in Polakis, 2012).  Loss-of-function mutations in the destruction complex components APC, Axin and AMER1 and gain-of-function mutations in beta-catenin itself cause constitutive signaling and are found in cancers of the intestine, kidney, liver and stomach, among others (Polakis, 1995; Segiditsas and Tomlinson, 2006; Peifer and Polakis, 2000; Laurent-Puig et al, 2001; Liu et al, 2000; Satoh et al, 2000; Major et al, 2007; Ruteshouser et al, 2008). WNTs and WNT pathway components are also frequently over- or under-expressed in various cancers, and these changes are correlated with epigenetic regulation of promoter activity.  In some contexts, both the canonical and non-canonical WNT signaling, which governs processes such as cell polarity and morphogenesis, may also contribute to tumor formation by promoting cell migration, invasiveness and metastasis.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway117">
 <bp:pathwayOrder rdf:resource="#PathwayStep515" />
 <bp:pathwayOrder rdf:resource="#PathwayStep517" />
 <bp:pathwayComponent rdf:resource="#Pathway118" />
 <bp:pathwayComponent rdf:resource="#Pathway119" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence515" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by AXIN mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AXIN1 and AXIN2 are critical scaffolding proteins of the beta-catenin destruction complex and make protein-protein interactions with several of the other complex components including APC, GSK3, CK1 and beta-catenin itself through specific domains (reviewed in Saito-Diaz et al, 2013). Because of its role in promoting the degradation of beta-catenin and thereby restricting WNT signaling, AXIN1 is regarded as a tumor suppressor; consistent with this, biallelic mutations in AXIN1 that abrogate its expression or result in the production of truncated proteins have been identified in some human cancers, notably in hepatocellular and  colorectal carcinomas and medullobalstoma (Satoh et al, 2000; Taniguchi et al, 2002; Shimizu et al, 2002; Dahmen et al, 2001; reviewed in Salahshor and Woodgett, 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway118">
 <bp:pathwayOrder rdf:resource="#PathwayStep516" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction399" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence516" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AXIN missense mutants destabilize the destruction complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Alterations in AXIN1 have been detected in a number of different cancers including liver and colorectal cancer and medullablastoma, among others (reviewed in Salahshor and Woodgett, 2005).  Missense and nonsense mutations that disrupt or remove protein-protein interaction domains are common, and AXIN variants in cancers tend to disrupt the formation of a functional destruction complex (Satoh et al, 2000; Taniguchi et al, 2002;  Webster et al, 2000; Shimizu et al, 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway119">
 <bp:pathwayOrder rdf:resource="#PathwayStep518" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction400" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence518" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Deletions in the AXIN1 gene destabilize the destruction complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Deletions in the AXIN1 gene have been identified in 2 hepatocellular carcinoma cell lines.  These deletions, which remove the N-terminal exons of the gene,  compromise AXIN1 expression and result in elevated expression of a TCF-dependent reporter (Satoh et al, 2000, reviewed in Salahshor and Woodgett, 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction188">
 <bp:evidence rdf:resource="#Evidence230" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of PDGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction189">
 <bp:evidence rdf:resource="#Evidence231" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SOS-mediated nucleotide exchange of RAS downstream of mutant PDGFR receptors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction186">
 <bp:evidence rdf:resource="#Evidence228" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3-kinase binds to mutant PDGFR receptor</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction187">
 <bp:evidence rdf:resource="#Evidence229" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autophosphorylation of PDGFR mutant dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction184">
 <bp:evidence rdf:resource="#Evidence225" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autophosphorylation of cytosolic PDGFRA and PDGFRB fusion proteins</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction185">
 <bp:evidence rdf:resource="#Evidence226" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of cytosolic PDGFRA and PDGFRB fusion proteins</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction182">
 <bp:evidence rdf:resource="#Evidence222" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3-kinase binds to PDGFRA extracellular domain dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway110">
 <bp:pathwayOrder rdf:resource="#PathwayStep462" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction353" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence462" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">crenolanib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Crenolanib is a second-generation type I tyrosine kinase inhibitor with activity against FLT3 (reviewed in Daver et al, 2019; Staudt et al, 2018; Larrosa-Garcia and Bauer, 2017). This pathway describes FLT3 mutants that are resistant to crenolanib-mediated inhibition.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction183">
 <bp:evidence rdf:resource="#Evidence223" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SOS-mediated nucleotide exchange on RAS downstream of PDGFRA extracellular domain dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway111">
 <bp:pathwayOrder rdf:resource="#PathwayStep464" />
 <bp:pathwayOrder rdf:resource="#PathwayStep475" />
 <bp:pathwayOrder rdf:resource="#PathwayStep465" />
 <bp:pathwayOrder rdf:resource="#PathwayStep476" />
 <bp:pathwayOrder rdf:resource="#PathwayStep466" />
 <bp:pathwayOrder rdf:resource="#PathwayStep477" />
 <bp:pathwayOrder rdf:resource="#PathwayStep467" />
 <bp:pathwayOrder rdf:resource="#PathwayStep478" />
 <bp:pathwayOrder rdf:resource="#PathwayStep468" />
 <bp:pathwayOrder rdf:resource="#PathwayStep479" />
 <bp:pathwayOrder rdf:resource="#PathwayStep469" />
 <bp:pathwayOrder rdf:resource="#PathwayStep480" />
 <bp:pathwayOrder rdf:resource="#PathwayStep470" />
 <bp:pathwayOrder rdf:resource="#PathwayStep481" />
 <bp:pathwayOrder rdf:resource="#PathwayStep471" />
 <bp:pathwayOrder rdf:resource="#PathwayStep472" />
 <bp:pathwayOrder rdf:resource="#PathwayStep473" />
 <bp:pathwayOrder rdf:resource="#PathwayStep474" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction359" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction357" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction368" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction358" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction369" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction355" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction366" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction356" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction367" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction364" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction354" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction365" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction362" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction363" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction360" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction371" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction361" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction370" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence464" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FLT3 fusion proteins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In addition to internal tandem duplications and activating point mutations, FLT3 is also subject at low frequency to translocations that generate fusion proteins. These fusion proteins occur in some chronic myeloid leukemias as well as myeloid neoplasms with eosinophilia, and generate constitutively active proteins by virtue of fusing a N-terminal partner encoding a dimerization domain with the intracellular region of FLT3 (reviewed in Reiter and Gotlib, 2017; Kazi and Roonstrand, 2019). To date, 6 fusion partner genes of FLT3 have been identified: ETV6, TRIP11, MYO18A, SPTBN1, GOLGB1 and ZMYM2 (Balwin et al, 2007; Vu et al, 2006; Walz et al, 2011; Falchi et al, 2014; Chung et al, 2017; Troadec et al, 2017; Grand et al, 2007; Jawhar et al, 2017; Zhang et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction180">
 <bp:evidence rdf:resource="#Evidence220" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT binds to p-11Y PDGFRA extracellular domain dimers </bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway112">
 <bp:pathwayOrder rdf:resource="#PathwayStep483" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction372" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence483" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 signaling by CBL mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Missense and splicing mutants have been identified in the E3 ubiquitin ligase CBL in a number of cancers including acute and chronic myeloid leukemias, among others. These cancers show elevated signaling through FLT3 as a result of impaired CBL-mediated downregulation of the receptor (Sargin et al, 2007; Reindl et al, 2009; Caligiuri et al, 2007; Abbas et al, 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction181">
 <bp:evidence rdf:resource="#Evidence221" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3K catalyses the phosphorylation of PIP2 to PIP3 downstream of PDGFRA extracellular domain dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway113">
 <bp:pathwayOrder rdf:resource="#PathwayStep486" />
 <bp:pathwayOrder rdf:resource="#PathwayStep485" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction373" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction374" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence485" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutants bind TKIs</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aberrant signaling by activated forms of FLT3 can be inhibited by tyrosine kinase inhibitors (TKIs). FLT3 receptors are class III receptor tyrosine kinase receptors, also known as dual-switch. Dual-switch receptors are activated through a series of phosphorylation and conformational changes that move the receptor from the inactive form to the fully activated form. Type II TKIs bind to the inactive form of the receptor at a site adjacent to the ATP-binding cleft, while type I TKIs bind to the active form (reviewed in Klug et al, 2018; Daver et al, 2019).  FLT3 internal tandem duplications (ITDs) are found in ~25-30% of acute myeloid leukemias, and are present at lower frequencies in other cancers (reviewed in Kazi and Roostrand, 2019; Patnaik et al, 2018). These ITDs generally occur in a tyrosine-rich region of exon 14, encoding the juxtamembrane domain region of the protein; at a lower frequency, ITDs are found in the first tyrosine kinase domain (TKD1). In addition to ITDs, a number of point mutations in the juxtamembrane domain have also been identified. Juxtamembrane domain mutations affect an autoinhibitory loop, shifting the equilibrium of the receptor towards the activated state; despite this, however, juxtamembrane domain mutants remain predominantly in the inactive state and as such are susceptible to inhibition by type II TKIs (reviewed in Patnaik et al, 2018; Kazi and Roonstrand et al, 2019).   Activation loop mutations more strongly favor the active conformation of the receptor and are susceptible to inhibition by both type II and type I TKIs. The most prevalent FLT3 mutation, D835Y, promotes the active conformation strongly enough to be resistant to type II TKIs (Patnaik et al, 2017; Klug et al, 2018; Daver et al, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway114">
 <bp:pathwayOrder rdf:resource="#PathwayStep488" />
 <bp:pathwayOrder rdf:resource="#PathwayStep510" />
 <bp:pathwayOrder rdf:resource="#PathwayStep489" />
 <bp:pathwayOrder rdf:resource="#PathwayStep511" />
 <bp:pathwayOrder rdf:resource="#PathwayStep512" />
 <bp:pathwayOrder rdf:resource="#PathwayStep490" />
 <bp:pathwayOrder rdf:resource="#PathwayStep491" />
 <bp:pathwayOrder rdf:resource="#PathwayStep492" />
 <bp:pathwayOrder rdf:resource="#PathwayStep493" />
 <bp:pathwayOrder rdf:resource="#PathwayStep494" />
 <bp:pathwayOrder rdf:resource="#PathwayStep495" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction379" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction377" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction378" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction375" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction397" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction376" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction398" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction396" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction380" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction381" />
 <bp:pathwayComponent rdf:resource="#Pathway115" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence488" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FLT3 ITD and TKD mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 is subject to internal tandem duplications (ITDs) of lengths varying from 3 to 1236 base pairs (Nakao et al, 1996; Kiyoi et al 1997, Meshinchi et al, 2008; reviewed in Kazi and Roonstrand, 2019). These ITDs are generally found in the juxtamembrane domain, or more rarely, the first tyrosine kinase domain (TKD) and disrupt the autoinhibitory loop of the receptor, constitutively activating it (Kiyoi et al, 2002; Griffith et al, 2004; reviewed in Lagunas-Rangel and Chavez-Valencia, 2017; Kazi and Roonstrand, 2019). FLT3 ITDs are found in ~25% of acute myeloid leukemias (AMLs) and represent the most frequent mutation of this cancer (reviewed in Kazi and Roonstrand, 2019, Klug et al, 2018) At lower frequency, FLT3 is subject to activating point mutations (~7% of AML cases). These mutations tend to cluster in the TKD, with mutation of the activation loop residue D835 and the gatekeeper F691 residue the most common sites (Griffin et al, 2001; Jiang et al, 2004; reviewed in Kazi and Roonstrand, 2019).  FLT3 ITD and TKD mutants support cellular transformation through activation of downstream signaling pathways such as the MAP kinase, PI3K/AKT and STAT5 cascades. There is some debate about the extent to which the pathways activated by the ITD and TKD mutants are distinct, with some evidence that STAT5 signaling, in particular, is more characteristic of FLT3 ITD activation (Hayakawa et al, 2000; Choudhary et al, 2005; Grundler et al, 2005; Choudhary et al, 2007; Yoshimoto et al, 2009; Leischner et al, 2012; Janke et al, 2014; Marhall et al, 2018; reviewed in Chan, 2011; Kazi and Roonstrand, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway115">
 <bp:pathwayOrder rdf:resource="#PathwayStep505" />
 <bp:pathwayOrder rdf:resource="#PathwayStep506" />
 <bp:pathwayOrder rdf:resource="#PathwayStep507" />
 <bp:pathwayOrder rdf:resource="#PathwayStep508" />
 <bp:pathwayOrder rdf:resource="#PathwayStep509" />
 <bp:pathwayOrder rdf:resource="#PathwayStep497" />
 <bp:pathwayOrder rdf:resource="#PathwayStep498" />
 <bp:pathwayOrder rdf:resource="#PathwayStep499" />
 <bp:pathwayOrder rdf:resource="#PathwayStep500" />
 <bp:pathwayOrder rdf:resource="#PathwayStep501" />
 <bp:pathwayOrder rdf:resource="#PathwayStep502" />
 <bp:pathwayOrder rdf:resource="#PathwayStep503" />
 <bp:pathwayOrder rdf:resource="#PathwayStep504" />
 <bp:pathwayOrder rdf:resource="#PathwayStep496" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction388" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction389" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction386" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction387" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction384" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction395" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction385" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction382" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction393" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction383" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction394" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction391" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction392" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction390" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence496" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT5 activation downstream of FLT3 ITD mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT5 signaling appears to be preferentially activated downstream of FLT3 ITD mutants relative to the wild-type or FLT3 TKD mutants, although this is subject to some debate (Choudhary et al, 2005; Reindl et al, 2006; Bagrintseva et al, 2005; Grundler et al, 2003; Choudhary et al, 2007; Marhall et al, 2018; reviewed in Choudhary et al, 2005). STAT5 activation contributes to oncogenesis by promoting the transcription of a number of factors involved in regulating cell cycle progression, proliferation and apoptosis, among others (Kim et al, 2005; Nabinger et al, 2013; Takahashi et al, 2004; Godfrey et al, 2012; Hayakawa et al, 2000; reviewed in Murphy and Rani, 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway127">
 <bp:pathwayOrder rdf:resource="#PathwayStep532" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction406" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence532" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">APC truncation mutants are not K63 polyubiquitinated</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">APC has been shown to be reversibly modified with K63-linked polyubiquitin chains.  This modification is required for the assembly of the destruction complex and subsequent degradation of beta-catenin in the absence of WNT ligand.  K63-polyubiquitination of APC is lacking in a number of colorectal cancer cell lines expressing truncated forms of APC, and these lines have aberrantly high beta-catenin levels and WNT pathway activation (Tran and Polakis, 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway128">
 <bp:pathwayOrder rdf:resource="#PathwayStep534" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction407" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence534" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">XAV939 stabilizes AXIN</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">XAV939 binds to the catalytic sites of tankyrase 1 and 2 and inhibits the ADP-ribosylation of AXIN1 and 2. Treatment of cells with XAV939 significantly increases the protein, but not the mRNA levels of AXIN1 and 2 and supports a strong increase in the level of GSK3beta-AXIN complexes.  These cells also show increased phosphorylation of beta-catenin, decreased beta-catenin protein levels and a corresponding decrease in beta-catenin dependent transcription.  Treatment of DLD-1 cells with XAV939 has also been shown to inhibit proliferation (Huang et al, 2009).  XAV939 has not been tested in a clinical setting.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway129">
 <bp:pathwayOrder rdf:resource="#PathwayStep542" />
 <bp:pathwayOrder rdf:resource="#PathwayStep536" />
 <bp:pathwayOrder rdf:resource="#PathwayStep538" />
 <bp:pathwayOrder rdf:resource="#PathwayStep540" />
 <bp:pathwayComponent rdf:resource="#Pathway130" />
 <bp:pathwayComponent rdf:resource="#Pathway131" />
 <bp:pathwayComponent rdf:resource="#Pathway132" />
 <bp:pathwayComponent rdf:resource="#Pathway133" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence536" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by CTNNB1 phospho-site mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in exon 3 of the beta-catenin gene have been identified in a number of human cancers (Morin et al, 1997; Rubinfeld et al, 1997; reviewed in Polakis, 2000; Polakis, 2007).  These mutations generally affect serine and threonine residues (S33, S37, T41, S45) that are the sites of phosphorylation by CK1 and GSK3; phosphorylation of these residues is required for the ubiquitin-mediated degradation of beta-catenin.  Hence mutation of these phospho-acceptor sites stabilizes beta-catenin, allowing it to accumulate, translocate to the nucleus and activate WNT signaling through association with LEF1/TCF DNA binding partners (Hart et al, 1999; Peifer and Polakis, 2000; Laurent-Puig et al, 2001; reviewed in Saito-Diaz et al, 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction199">
 <bp:evidence rdf:resource="#Evidence253" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimeric TGFB1 does not bind TGFBR2 MSI frameshift mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction197">
 <bp:evidence rdf:resource="#Evidence248" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TGFBR2 does not recruit TGFBR1 LBD Mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction198">
 <bp:evidence rdf:resource="#Evidence251" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TGFBR2 KD mutants do not phosphorylate TGFBR1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction195">
 <bp:evidence rdf:resource="#Evidence243" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SMAD4 MH2 Domain Mutants do not bind phosphorylated SMAD2 and SMAD3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction196">
 <bp:evidence rdf:resource="#Evidence246" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">An anchoring protein ZFYVE9 (SARA) does not recruit SMAD2/3 to TGFB1:TGFBR2:p-TGFBR1 KD Mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway120">
 <bp:pathwayOrder rdf:resource="#PathwayStep520" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction401" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence520" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by RNF43 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RNF43 and related protein ZNRF3 are E3 ubiquitin ligases that negatively regulate WNT signaling by downregulating FZD receptors at the cell surface (Mukai et al, 2010; Hao et al, 2012).  Frameshift loss-of-function mutations in RNF43 that enhance WNT signaling have been identified in pancreatic and colorectal cancers; the proliferation of these cells is dependent on the presence of secreted WNT, as their growth is abrogated by treatment of cells with the Porcupine inhibitor LGK974 (Koo et al, 2012; Jiang et al, 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction193">
 <bp:evidence rdf:resource="#Evidence238" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated SMAD2/3 MH2 Domain Mutants do not bind SMAD4</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway121">
 <bp:pathwayOrder rdf:resource="#PathwayStep522" />
 <bp:pathwayOrder rdf:resource="#PathwayStep524" />
 <bp:pathwayComponent rdf:resource="#Pathway122" />
 <bp:pathwayComponent rdf:resource="#Pathway123" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence522" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by AMER1 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AMER1/WTX is a component of the destruction complex that interacts directly with beta-catenin through its C-terminal half.  Depletion of AMER1 through siRNA stabilizes cellular beta-catenin levels and increases transcriptional activity in a reporter assay consistent with a role for AMER1 in the degradation of beta-catenin (Major et al, 2007).  Deletions of the entire AMER1 gene have been reported in Wilms tumor, as have nonsense and missense mutations that truncate the protein before the beta-catenin interaction domain.  These mutations are predicted to stabilize beta-catenin and increase WNT signaling (reviewed in Saito-Diaz et al, 2013; Huff, 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction194">
 <bp:evidence rdf:resource="#Evidence240" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TGFBR1 cannot phosphorylate SMAD2 and SMAD3 Phosphorylation Motif Mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway122">
 <bp:pathwayOrder rdf:resource="#PathwayStep523" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction402" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence523" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Deletions in the AMER1 gene destabilize the destruction complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Genomic deletions of the entire AMER1/WTX gene occur in about 12% of Wilms tumors, a pediatric kidney cancer.  Nonsense and missense mutations have also been identified (Ruteshouser et al, 2008; Wegert et al, 2009).  AMER1 is a known component of the destruction complex and interacts directly with beta-catenin through the C-terminal half (Major et al, 2007).  siRNA depletion of AMER1 in mammalian cells stabilizes cellular beta-catenin levels and increases the expression of a beta-catenin-dependent reporter gene, suggesting that AMER1 is a tumor suppressor gene (Major et al, 2007; reviewed in Huff, 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction191">
 <bp:evidence rdf:resource="#Evidence233" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT binds to the mutant PDGFRA receptor</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway123">
 <bp:pathwayOrder rdf:resource="#PathwayStep525" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction403" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence525" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Truncations of AMER1 destabilize the destruction complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AMER1/WTX is a known component of the destruction complex and interacts directly with beta-catenin through the C-terminal half (Major et al, 2007).  siRNA depletion of AMER1 in mammalian cells stabilizes cellular beta-catenin levels and increases the expression of a beta-catenin-dependent reporter gene, suggesting that AMER1 is a tumor suppressor gene (Major et al, 2007; reviewed in Huff, 2011).  Consistent with this, nonsense and missense mutations that truncate AMER1 and result in loss of the beta-catenin binding region have been identified in Wilms tumor, a pediatric kidney cancer (Ruteshouser et al, 2008; Wegert et al, 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction192">
 <bp:evidence rdf:resource="#Evidence234" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3K catalyses the phosphorylation of PIP2 to PIP3 downstream of mutant PDGFR</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway124">
 <bp:pathwayOrder rdf:resource="#PathwayStep527" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction404" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence527" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LGK974 inhibits PORCN</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aberrant WNT signaling is associated with the development of numerous cancers, and strategies for targeting this pathway are under intense investigation (reviewed in Polakis, 2012; Polakis, 2000; Yao et al, 2011).  Secretion of WNT ligand depends on its PORCN-dependent palmitoleoylation in the ER, making PORCN a attractive therapeutic target in cases where WNT is aberrantly over-expressed (reviewed in MacDonald et al, 2009).  LGK974 is a PORCN-inhibitor that was identified in a screen for compounds that abrogate the secretion of WNT ligands, and is in Phase I clinical trials for the treatment of WNT-dependent cancers (Liu et al, 2013)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway125">
 <bp:pathwayOrder rdf:resource="#PathwayStep531" />
 <bp:pathwayOrder rdf:resource="#PathwayStep529" />
 <bp:pathwayComponent rdf:resource="#Pathway127" />
 <bp:pathwayComponent rdf:resource="#Pathway126" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence529" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by APC mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">APC is a large and central component of the destruction complex, which limits signaling in the absence of WNT ligand by promoting the ubiquitin-mediated degradation of beta-catenin.  APC interacts with numerous components of the destruction complex, including AXINs (AXIN1 and AXIN2), GSK3s (GSK3alpha and GSK3beta), CK1, PP2A and beta-catenin, and these interactions are critical for the phosphorylation and degradation of beta-catenin (reviewed in Saito-Diaz et al, 2013).  APC is itself the target of phosphorylation and K63 ubiquitination in the absence of WNT signaling and these modifications are required for its interactions with other components of the destruction complex (Tran and Polakis, 2012; Ha et al, 2004; reviewed in Stamos and Weis, 2013).  More than 85% of sporadic and hereditary colorectal tumors carry loss-of-function mutations in APC.  Most of the mutations are frameshifts and result in truncated proteins that lack the SAMP motifs and the 15 and 20 aa repeats that are implicated in binding AXIN and regulating beta-catenin binding and degradation (Miyoshi et al, 1992; Nagase and Nakamura, 1993; reviewed in Segditas and Tomlinson, 2006).  Cancers expressing truncated APC have high levels of cytoplasmic beta-catenin and deregulated expression of WNT target genes (Korinek et al, 1997).  Approximately 15% of the colorectal tumors with wild-type APC harbor phosphodegron mutations of beta-catenin; interestingly, mutations in APC and beta-catenin are mutually exclusive events.  Similar to APC-mutant tumors, beta-catenin is stabilized in these tumors and constitutive WNT target activation is detected  (Morin et al, 1997; reviewed in Polakis, 2000).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction190">
 <bp:evidence rdf:resource="#Evidence232" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GRB2:SOS1 complex binds to mutant PDGFR receptor</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway126">
 <bp:pathwayOrder rdf:resource="#PathwayStep530" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction405" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence530" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">APC truncation mutants have impaired AXIN binding</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the APC tumor suppressor gene are common in  colorectal and other cancers and cluster in the central mutation cluster region (MCR) of the gene (Miyoshi et al, 1992; Nagase and Nakamura, 1993; Dihlmann et al, 1999; reviewed in Bienz and Clevers, 2000).  These mutations generally result in truncated proteins that destabilize the destruction complex and result in elevated WNT pathway activation (reviewed in Polakis, 2000).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway140">
 <bp:pathwayOrder rdf:resource="#PathwayStep557" />
 <bp:pathwayOrder rdf:resource="#PathwayStep558" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction418" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction419" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence557" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by extracellular domain mutants of KIT</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Many of the described KIT mutations are located in the fifth Ig-like domain, encoded by exon 8 and 9. The fifth Ig-like domain of KIT plays a critical role in stabilizing the receptor dimers formed upon SCF binding, allowing these mutations to support constitutive activation of the receptor (Yuzawa et al, 2007; reviewed in Lennartsson and Ronnstrand, 2012)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway138">
 <bp:pathwayOrder rdf:resource="#PathwayStep552" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction415" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence552" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by kinase domain mutants of KIT</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activating mutations in the kinase domain of KIT are found in a small number of cases of AML and melanoma, as well as in myeloproliferative syndromes, mastocytosis and germ cell tumors (Longley et al, 1996; 1999; Nagata et al, 1995; Beghini et al, 2000; Ning et al, 2001; Tian et al, 1999; Kemmer et al, 2004; reviewed in Roskoski, 2018; Meng and Carvajal, 2019). Mutations in the kinase domain and activation loop of KIT (encoded by exons 13, 14 and 17) also arise in gastrointestinal stromal tumors (GIST) as primary mutations ( 1%) and as secondary resistance mutations in response to treatment with imatinib (Chen et al, 2004; Serrano et al, 2019; Gajiwala et al, 2008; McLean et al, 2008; reviewed in Antonescu, 2006; Roskoski, 2018; Wu et al, 2019; Corless et al, 2011). Activating kinase mutants of KIT are constitutively active in the absence of ligand and can be tyrosine phosphorylated in the absence of dimerization (Furitsu et al, 1993; Hirota et al, 1998; Tsujimura et al, 1994).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway139">
 <bp:pathwayOrder rdf:resource="#PathwayStep554" />
 <bp:pathwayOrder rdf:resource="#PathwayStep555" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction416" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction417" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence554" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by juxtamembrane domain KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the juxtamembrane region of KIT, encoded by exon 11, are especially prevalent as initiating events in gastrointestinal stromal tumors (GIST), but are also found at lower frequency in other cancers such as AML and melanoma (reviewed in Antonescu, 2006; Roskoski, 2018). Mutations in this region of KIT are believed to disrupt an auto-inhibitory function, leading to constitutive enzyme activation (Ma et al, 1999; Chan et al, 2003; Mol et al, 2004; reviewed in Roskoski, 2018). Unlike kinase domain mutants, juxtamembrane domain KIT mutants still undergo dimerization, although in a ligand-independent manner (Hirota et al, 1998; Furitsu et al, 1993; reviewed in Lennartsson and Roonstrand, 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway130">
 <bp:pathwayOrder rdf:resource="#PathwayStep537" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction408" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence537" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CTNNB1 S45 mutants aren&apos;t phosphorylated</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">S45 mutants of beta-catenin have been identified in colorectal and hepatocellular carcinomas, soft tissue cancer and Wilms Tumors, among others (reviewed in Polakis, 2000). These mutations abolish the CK1alpha phosphorylation site of beta-catenin which acts as a critical priming site for GSK3 phosphorylation of T41( and subsequently S37 and S33) thus  preventing its ubiquitin-mediated degradation (Morin et al, 1997; Amit et al, 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway131">
 <bp:pathwayOrder rdf:resource="#PathwayStep539" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction409" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence539" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CTNNB1 S37 mutants aren&apos;t phosphorylated</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">S37 mutations of beta-catenin interfere with GSK3 phosphorylation and stabilize the protein, resulting in enhanced WNT pathway signaling (Nhieu et al, 1999; Clements et al, 2002; reviewed in Polakis, 2000).  S37 mutations have been identified in cancers of the brain, liver, ovary and large intestine, among others (reviewed in Polakis, 2000).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway132">
 <bp:pathwayOrder rdf:resource="#PathwayStep541" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction410" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence541" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CTNNB1 S33 mutants aren&apos;t phosphorylated</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">S33 mutations of beta-catenin interfere with GSK3 phosphorylation and result in stabilization and nuclear localization of the protein and enhanced WNT signaling (Groen et al, 2008; Nhieu et al, 1999; Clements et al, 2002; reviewed in Polakis, 2000).  S33 mutations have been identified in cancers of the central nervous system, liver, endometrium and stomach, among others (reviewed in Polakis, 2000).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway133">
 <bp:pathwayOrder rdf:resource="#PathwayStep543" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction411" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence543" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CTNNB1 T41 mutants aren&apos;t phosphorylated</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">T41 mutations of beta-catenin interfere with GSK3 phosphorylation and result in stabilization and nuclear accumulation of the protein (Moreno-Bueno et al, 2002; Taniguchi et al, 2002; reviewed in Polakis, 2012).  T41 mutations have been identified in cancers of the liver and brain, as well as in the pituitary, endometrium, large intestine and skin, among others (reviewed in Polakis, 2000; Saito-Diaz et al, 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway134">
 <bp:pathwayOrder rdf:resource="#PathwayStep545" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction412" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence545" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by TCF7L2 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">~50% of colorectal cancers with microsatellite instability show frameshift mutations in TCF7L2 that result in the loss of the CTBP-binding region (Duval et al, 1999; Cuillliere-Dartigues et al, 2006).  These cancer cells show decreased colocalization of CTBP and TCF7L2 and have increased expression of a TCF-dependent reporter gene (Cuilliere-Dartigues et al, 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway135">
 <bp:pathwayOrder rdf:resource="#PathwayStep547" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction413" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence547" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by GSK3beta mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GSK3beta is subject to in-frame missplicing in CML stem cells resulting in the production of mutant protein that lacks the AXIN and FRAT binding domains.  Cells containing this mutant GSK3beta show elevated levels of nuclear beta-catenin and enhanced TCF-dependent reporter activity (Jamieson et al, 2008; Abrahamsson et al, 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway136">
 <bp:pathwayOrder rdf:resource="#PathwayStep549" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction414" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence549" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by LRP5 mutants </bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LRP5 is subject to an in-frame missplicing event in breast and parathyroid cancers that renders the protein insensitive to inhibition by the WNT antagonist DKK1.  Expression of the mutant protein results in elevated levels of active, unphosphorylated beta-catenin and enhanced TCF-dependent WNT-signaling, promoting cellular proliferation (Bjorklund et al 2007a, b; Bjorklund et al, 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway137">
 <bp:pathwayOrder rdf:resource="#PathwayStep553" />
 <bp:pathwayOrder rdf:resource="#PathwayStep586" />
 <bp:pathwayOrder rdf:resource="#PathwayStep556" />
 <bp:pathwayOrder rdf:resource="#PathwayStep559" />
 <bp:pathwayOrder rdf:resource="#PathwayStep571" />
 <bp:pathwayOrder rdf:resource="#PathwayStep551" />
 <bp:pathwayComponent rdf:resource="#Pathway138" />
 <bp:pathwayComponent rdf:resource="#Pathway139" />
 <bp:pathwayComponent rdf:resource="#Pathway150" />
 <bp:pathwayComponent rdf:resource="#Pathway140" />
 <bp:pathwayComponent rdf:resource="#Pathway141" />
 <bp:pathwayComponent rdf:resource="#Pathway142" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence551" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by KIT in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT signaling is important in several processes including stem cell maintenance, erythropoiesis, mast cell development, lymphopoiesis, melanogenesis and maintenance of interstitial cell of Cajal (Hirota et al, 1998; Chi et al, 2010). Gain-of-function mutations in KIT have been identified at low frequency in a number of diseases, including AML, melanoma and mast and germ cell tumors, and at higher frequency in gastrointesinal stromal tumors (reviewed in Lennartsson and Roonstrand, 2012; Abbaspour Babaei et al, 2016; Roskoski, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence451">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence450">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence453">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence452">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence448">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence447">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence449">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence444">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence443">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence446">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence445">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence462">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence461">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence464">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence463">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence460">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence459">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence458">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence455">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence454">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence457">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence456">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence473">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence472">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence475">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence474">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence471">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence470">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence469">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence466">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence465">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence468">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence467">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence484">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence483">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence486">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence485">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence480">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence482">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence481">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence477">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence476">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence479">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence478">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence495">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence494">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence497">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence496">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence491">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence490">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence493">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway150">
 <bp:pathwayOrder rdf:resource="#PathwayStep587" />
 <bp:pathwayOrder rdf:resource="#PathwayStep588" />
 <bp:pathwayOrder rdf:resource="#PathwayStep589" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction440" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction438" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction439" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence587" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT mutants bind TKIs</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aberrant signaling by activated forms of KIT can be inhibited by tyrosine kinase inhibitors. Primary mutations in KIT are frequently found in exon 11, encoding the juxtamembrane domain responsible for autoinhibition of the kinase. These mutations are generally sensitive to tyrosine kinase inhibitors such as imatinib. Accumulation of secondary mutations in the ATP-binding pocket and the activation loop of the kinase domain contributes to resistance to first line tyrosine kinase inhibitors. KIT receptors with in these regions are sensitive to a panel of additional tyrosine kinase inhibitors such as sunitinib and regorafenib (Serrano et al, 2019; reviewed in Roskoski, 2018; Klug et al, 2018; Serrano et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence492">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway151">
 <bp:pathwayOrder rdf:resource="#PathwayStep642" />
 <bp:pathwayOrder rdf:resource="#PathwayStep668" />
 <bp:pathwayOrder rdf:resource="#PathwayStep591" />
 <bp:pathwayOrder rdf:resource="#PathwayStep608" />
 <bp:pathwayComponent rdf:resource="#Pathway160" />
 <bp:pathwayComponent rdf:resource="#Pathway152" />
 <bp:pathwayComponent rdf:resource="#Pathway154" />
 <bp:pathwayComponent rdf:resource="#Pathway165" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence591" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A number of skeletal and developmental diseases have been shown to arise as a result of mutations in the FGFR1, 2 and 3 genes.  These include dwarfism syndromes (achondroplasia, hypochondroplasia and the neonatal lethal disorders thanatophoric dysplasia I and II), as well as craniosynostosis disorders such as Pfeiffer, Apert, Crouzon, Jackson-Weiss and Muenke syndromes (reviewed in Webster and Donoghue 1997; Burke, 1998, Cunningham, 2007; Harada, 2009).  These mutations fall into four general regions of the receptor: a) the immunoglobulin (Ig)-like domain II-III linker region,  b) the alternatively spliced second half of the Ig III domain, c) the transmembrane domain and d) the tyrosine kinase domain (reviewed in Webster and Donoghue, 1997).  With the exception of mutations in class b), which affect only the relevant splice variant, these mutations may be present in either the &apos;b&apos; or &apos;c&apos; isoforms. These activating mutations affect FGFR function by altering or expanding the ligand-binding range of the receptors (see for instance Ibrahimi, 2004a), by promoting ligand-independent dimerization (for instance, Galvin,1996; Neilson and Friesel, 1996; d&apos;Avis,1998) or by increasing the activity of the kinase domain (for instance, Webster, 1996; Naski, 1996; Tavormina, 1999; Bellus, 2000).  Thus, a number of the point mutations found in FGFR receptors alter their activity without altering their intrinsic kinase activity.  Many of the mutations that promote constitutive dimerization do so by creating or removing cysteine residues; the presence of an unpaired cysteine in the receptor is believed to promote dimerization through the formation of intramolecular disulphide bonds (Galvin, 1996; Robertson, 1998). Paralogous mutations at equivalent positions have been identified in more than one FGF receptor, sometimes giving rise to different diseases.  For instance, mutation of the highly conserved FGFR2 Ser252-Pro253 dipeptide in the region between the second and third Ig domain is responsible for virtually all cases of Apert Syndrome (Wilkie, 1995), while paralogous mutations in FGFR1 (S252R) and FGFR3 (P250R) are associated with Pfeiffer and Crouzon syndromes, respectively (Bellus, 1996).  FGFR4 is unique in that mutations of this gene are not known to be associated with any developmental disorders.  Recently, many of the same activating mutations in the FGFR genes that have been characterized in skeletal and developmental disorders have begun to be identified in a range of cancers (reviewed in  Turner and Gross, 2010; Greulich and Pollock, 2011; Wesche, 2011).  The best established link between a somatic mutation of an FGFR and the development of cancer is in the case of FGFR3, where 50% of bladder cancers have mutations in the FGFR3 coding sequence.  Of these mutations, which largely match the activating mutations seen in thanatophoric dysplasias, over half occur at a single residue (S249C) (Cappellen, 1999; van Rhijn, 2002).  Activating mutations have also been identified in the coding sequences of FGFR1, 2 and 4 (for review, see Wesche, 2011)  In addition to activating point mutations, the FGFR1, 2 and 3 genes are subject to misregulation in cancer through gene amplification and translocation events, which are thought to lead to overexpression and ligand-independent dimerization (Weiss, 2010; Turner, 2010; Kunii, 2008; Takeda, 2007; Chesi, 1997; Avet-Loiseau, 1998; Ronchetti, 2001).  It is important to note, however, that in each of these cases, the amplification or translocation involve large genomic regions encompassing additional genes, and the definitive roles of the FGFR genes in promoting oncogenesis has not been totally established. In the case of FGFR1, translocation events also give rise to FGFR1 fusion proteins that contain the intracellular kinase domain of the receptor fused to a dimerization domain from the partner gene.  These fusions, which are expressed in a pre-leukemic myeloproliferative syndrome, dimerize constitutively based on the dimerization domain provided by the fusion partner and are constitutively active (reviewed in Jackson, 2010).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway149">
 <bp:pathwayOrder rdf:resource="#PathwayStep585" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction437" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence585" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sorafenib-resistant KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sorafenib is a type II tyrosine kinase inhibitor that is approved for use in hepatocellular and renal cell carcinoma. It is active against KIT receptors with mutations in the ATP-binding cleft and the activation loop, with the exception of substitutions at D816, which are resistant (Guida et al, 2007; Heinrich et al, 2012; Serrano et al, 2019; Weisberg et al, 2019; reviewed in Roskoski, 2018; Klug et al, 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway141">
 <bp:pathwayOrder rdf:resource="#PathwayStep563" />
 <bp:pathwayOrder rdf:resource="#PathwayStep564" />
 <bp:pathwayOrder rdf:resource="#PathwayStep565" />
 <bp:pathwayOrder rdf:resource="#PathwayStep566" />
 <bp:pathwayOrder rdf:resource="#PathwayStep567" />
 <bp:pathwayOrder rdf:resource="#PathwayStep568" />
 <bp:pathwayOrder rdf:resource="#PathwayStep569" />
 <bp:pathwayOrder rdf:resource="#PathwayStep570" />
 <bp:pathwayOrder rdf:resource="#PathwayStep560" />
 <bp:pathwayOrder rdf:resource="#PathwayStep561" />
 <bp:pathwayOrder rdf:resource="#PathwayStep562" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction423" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction424" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction421" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction422" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction430" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction420" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction429" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction427" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction428" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction425" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction426" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence560" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activation of the PI3K/mTOR, RAS/MAPK and STAT signaling pathways has been observed downstream of activated extracellular, juxtamembrane and kinase domain mutants of KIT, although downstream signaling has not been studied in great detail in all cases. Activation of these pathways contributes to cellular proliferation, avoidance of apoptosis, and actin cytoskeletal organization (Dunesing et al, 2004; Bauer et al, 2007; Chi et al, 2010; Bosbach et al, 2017; reviewed in Lennartsson and Roonstrand, 2012; Corless et al, 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway142">
 <bp:pathwayOrder rdf:resource="#PathwayStep574" />
 <bp:pathwayOrder rdf:resource="#PathwayStep576" />
 <bp:pathwayOrder rdf:resource="#PathwayStep578" />
 <bp:pathwayOrder rdf:resource="#PathwayStep580" />
 <bp:pathwayOrder rdf:resource="#PathwayStep582" />
 <bp:pathwayOrder rdf:resource="#PathwayStep572" />
 <bp:pathwayOrder rdf:resource="#PathwayStep584" />
 <bp:pathwayComponent rdf:resource="#Pathway149" />
 <bp:pathwayComponent rdf:resource="#Pathway143" />
 <bp:pathwayComponent rdf:resource="#Pathway144" />
 <bp:pathwayComponent rdf:resource="#Pathway145" />
 <bp:pathwayComponent rdf:resource="#Pathway146" />
 <bp:pathwayComponent rdf:resource="#Pathway147" />
 <bp:pathwayComponent rdf:resource="#Pathway148" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence572" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Drug resistance of KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activating mutations in the juxtamembrane domain of KIT are common in some cancers, including gastrointestinal stromal tumors, melanoma and acute myeloid leukemia (reviewed in Roskoski, 2018). These mutations are sensitive to inhibition with imatinib, which in 2001 was the first tyrosine kinase inhibitor approved for treatment of cancer (Demetri et al, 2002; Corless et al, 2011; reviewed in Zitvogel, 2016). Although highly successful in prolonging survival, imatinib-resistance develops in most patients due to appearance of secondary mutations, often in the ATP-binding pocket or in the activation loop of the kinase domain (Gajiwala et al, 2008; Serrano et al, 2019; reviewed in Roskoski, 2018; Napolitano and Vincenzi, 2019)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway143">
 <bp:pathwayOrder rdf:resource="#PathwayStep573" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction431" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence573" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Imatinib-resistant KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Imatinib is approved for treatment of cancers carrying primary mutations in the KIT receptor. Imatinib binds and inhibits the inactive state of the receptor, including the conformation promoted by exon 11 mutations that relieve the auto-inhibition of the WT protein. Resistance to imatinib arises due to the polyclonal expansion of subpopulations bearing secondary KIT mutations in the ATP binding pocket or the activation loop of the protein (Serrano et al, 2019; reviewed in Roskoski, 2018; Klug et al, 2018; Corless et al, 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway144">
 <bp:pathwayOrder rdf:resource="#PathwayStep575" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction432" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence575" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sunitinib-resistant KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sunitinib is a class II tyrosine kinase inhibitor that is often used as a second line treatment in KIT-mutated cancers that develop resistance to imatinib (Heinrich et al, 2008; Serrano et al, 2017; reviewed in Roskoski, 2018; Corless et al, 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence488">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway145">
 <bp:pathwayOrder rdf:resource="#PathwayStep577" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction433" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence577" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regorafenib-resistant KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regorafenib is a type II tyrosine kinase inhibitor that is approved for treatment of advanced gastrointestinal stromal tumors with KIT mutations. Regorafenib is effective in imatinib-resistant tumors carrying secondary mutations in exon 14 (gatekeeper mutation), and most KIT secondary mutations encoded by exons 17 and 18 (the activation loop) (Demetri et al, 2013; Serrano et al, 2017, Serrano et al, 2019; reviewed in Roskoski, 2018; Klug et al, 2018; ).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence487">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway146">
 <bp:pathwayOrder rdf:resource="#PathwayStep579" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction434" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence579" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dasatinib-resistant KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dasatinib is a type II tyrosine kinase inhibitor that is active against KIT receptors with mutations in the juxtamembrane and activation loop domains, but shows only partial activity against KIT receptors with mutations at residue V654 (Schittenhelm et al, 2006; Serrano et al, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway147">
 <bp:pathwayOrder rdf:resource="#PathwayStep581" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction435" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence581" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Masitinib-resistant KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mastinib is a class II tyrosine kinase inhibitor that targets mutant and wild-type FGFR3, PDGFR and c-KIT (Dubreuil, 2009). Masitinib, like imatinib, is effective in inhibiting the activity of juxtamembrane mutant forms of KIT, but is ineffective against many of the mutations in the activation loop and ATP-binding cleft of the receptor (Dubreuil, 2009; Serrano et al, 2019; reviewed in Demetri, 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence489">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway148">
 <bp:pathwayOrder rdf:resource="#PathwayStep583" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction436" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence583" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nilotinib-resistant KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nilotinib is a type II tyrosine kinase inhibitor currently in clinical trials for treatment of KIT-mutant cancers, and shows variable effectiveness against mutations in exon 11, 13, 17 and 18. Nilotinib is ineffective against the gatekeeper mutation T670I (Kissova et al, 2016; Guo et al, 2007; Roberts et al, 2007; Serrano et al, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway160">
 <bp:pathwayOrder rdf:resource="#PathwayStep662" />
 <bp:pathwayOrder rdf:resource="#PathwayStep663" />
 <bp:pathwayOrder rdf:resource="#PathwayStep664" />
 <bp:pathwayOrder rdf:resource="#PathwayStep643" />
 <bp:pathwayOrder rdf:resource="#PathwayStep665" />
 <bp:pathwayOrder rdf:resource="#PathwayStep644" />
 <bp:pathwayOrder rdf:resource="#PathwayStep666" />
 <bp:pathwayOrder rdf:resource="#PathwayStep645" />
 <bp:pathwayOrder rdf:resource="#PathwayStep667" />
 <bp:pathwayOrder rdf:resource="#PathwayStep646" />
 <bp:pathwayOrder rdf:resource="#PathwayStep660" />
 <bp:pathwayOrder rdf:resource="#PathwayStep661" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction500" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction501" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction498" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction499" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction485" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction486" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction497" />
 <bp:pathwayComponent rdf:resource="#Pathway161" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction484" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction504" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction502" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction503" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence643" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR3 in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The FGFR3 gene has been shown to be subject to activating mutations and gene amplification leading to a variety of proliferative and developmental disorders depending on whether these events occur in the germline or arise somatically.    Activating mutations in FGFR3 are associated with the development of a range of skeletal dysplasias that result in dwarfism (reviewed in Webster and Donoghue, 1997; Burke et al, 1998; Harada et al, 2009).  The most common form of human dwarfism is achondroplasia (ACH), which is caused by mutations G380R and G375C in the transmembrane domain of FGFR3 that are thought to promote ligand-independent dimerization (Rousseau et al, 1994; Shiang et al, 1994; Bellus et al, 1995a)  Hypochondroplasia (HCH) is a milder form dwarfism that is the result of mutations in the tyrosine kinase domain of FGFR3 (Bellus et al, 1995b).  Two neonatal lethal conditions, thanatophoric dysplasia type I and II (TDI and TDII) are also the result of mutations in FGFR3; TDI arises from a range of mutations that either result in the formation of unpaired cysteine residues in the extracellular region that promote aberrant ligand-independent dimerization or by mutations that introduce stop codons (Rousseau et al, 1995; Rousseau et al, 1996, D&apos;Avis et al,1998).  A single mutation, K650E in the second tyrosine kinase domain of FGFR3 is responsible for all identified cases of TDII (Tavormina et al, 1995a, b).  Other missense mutations at the same K650 residue give rise to Severe Achondroplasia with Developmental Disorders and Acanthosis Nigricans (SADDAN) syndrome (Tavormina et al, 1999; Bellus et al, 1999).   The severity of the phenotype arising from many of the activating FGFR3 mutations has recently been shown to correlate with the extent to which the mutations activate the receptor (Naski et al, 1996; Bellus et al, 2000)   In addition to mutations that cause dwarfism syndromes, a Pro250Arg mutation in the conserved dipeptide between the IgII and IgIII domains has been identified in an atypical craniosynostosis condition (Bellus et al, 1996; Reardon et al, 1997).  This mutation, which is paralogous to mutations seen in FGFR1 and 2 in Pfeiffer and Apert Syndrome, respectively, results in an increase in ligand-binding affinity for the receptor (Ibrahimi et al, 2004b).   Of all the FGF receptors, FGFR3 has perhaps the best established link to the development in cancer.  50% of bladder cancers have somatic mutations in the coding sequence of FGFR3; of these, more than half occur in the extracellular region at a single position (S249C) (Cappellen et al, 1999; Naski et al, 1996; di Martino et al, 2009, Sibley et al, 2001).  Activating mutations are also seen in the juxta- and trans-membrane domains, as well as in the kinase domain (reviewed in Weshe et al, 2011).  As is the case for the other receptors, many of the activating mutations that are seen in FGFR3-related cancers mimic the germline FGFR3 mutations that give rise to autosomal skeletal disorders and include both ligand-dependent and independent mechanisms (reviewed in Webster and Donoghue, 1997; Burke et al, 1998). In addition to activating mutations, the FGFR3 gene is subject to a translocation event in 15% of multiple myelomas (Avet-Loiseau et al, 1998; Chesi et al, 1997).  This chromosomal rearrangement puts the FGFR3 gene under the control of the highly active IGH promoter and promotes overexpression and constitutive activation of FGFR3.  In a small proportion of multiple myelomas, the translocation event is accompanied by activating mutations in the FGFR3 coding sequence (Chesi et al, 1997).  More recently, a number of fusion proteins of FGFR3 have been identified in various cancers (Singh et al, 2012; Williams et al, 2013; Parker et al, 2013; Wu et al, 2013; Wang et al, 2014; Yuan et al, 2014; reviewed in Parker et al, 2014). The most common fusion protein is TACC3, a coiled coil protein involved in mitotic spindle assembly.  FGFR3 fusion proteins are constitutively active and appear to contribute to proliferation and tumorigenesis through activation of the ERK and AKT signaling pathways (reviewed in Parker et al, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway161">
 <bp:pathwayOrder rdf:resource="#PathwayStep654" />
 <bp:pathwayOrder rdf:resource="#PathwayStep657" />
 <bp:pathwayOrder rdf:resource="#PathwayStep647" />
 <bp:pathwayComponent rdf:resource="#Pathway162" />
 <bp:pathwayComponent rdf:resource="#Pathway163" />
 <bp:pathwayComponent rdf:resource="#Pathway164" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence647" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR3 mutant receptor activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The FGFR3 gene has been shown to be subject to activating mutations and gene amplification leading to a variety of proliferative and developmental disorders depending on whether these events occur in the germline or arise somatically.  As is the case for the other receptors, many of the activating mutations that are seen in FGFR3-related cancers mimic the germline FGFR3 mutations that give rise to autosomal skeletal disorders and include both ligand-dependent and independent mechanisms (reviewed in Webster and Donoghue, 1997; Burke et al, 1998; Wesche et al, 2011). In addition to activating mutations, the FGFR3 gene is subject to a translocation event in 15% of multiple myelomas (Avet-Loiseau et al, 1998; Chesi et al, 1997). This chromosomal rearrangement puts the FGFR3 gene under the control of the highly active IGH promoter and promotes overexpression and constitutive activation of FGFR3 (Otsuki et al, 1999).  In a small proportion of multiple myelomas, the translocation event is accompanied by activating mutations in the FGFR3 coding sequence (Chesi et al, 1997; Onwuazor et al, 2003; Ronchetti et al, 2001). Finally, FGFR3 is subject to fusion events in a number of cancers, including lung, bladder and glioblastoma (Singh et al, 2012; Parker et al, 2013; Williams et al, 2013; Wu et al, 2013; Capelletti et al, 2014; Yuan et al, 2014; Wang et al, 2014; Carneiro et al, 2015; reviewed in Parker et al, 2014). These fusions are constitutively active based on dimerization domains provided by the fusion partners and support transformation and proliferation through downstream signaling pathways such as ERK and AKT (Singh et al, 2012; Williams et al, 2013; Parker et al, 2013; reviewed in Parker et al, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway162">
 <bp:pathwayOrder rdf:resource="#PathwayStep651" />
 <bp:pathwayOrder rdf:resource="#PathwayStep652" />
 <bp:pathwayOrder rdf:resource="#PathwayStep653" />
 <bp:pathwayOrder rdf:resource="#PathwayStep648" />
 <bp:pathwayOrder rdf:resource="#PathwayStep649" />
 <bp:pathwayOrder rdf:resource="#PathwayStep650" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction489" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction487" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction488" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction492" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction490" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction491" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence648" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by activated point mutants of FGFR3</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activating point mutations in FGFR3 are found in the extracellular ligand-binding domain, the transmembrane region and the tyrosine kinase domain and are believed to result in ligand-independent activation of the receptor (Webster and Donoghue, 1996; Wenbster, 1997).  These mutations, although initially characterized in the context of autosomal skeletal disorders, are now being identified in a range of cancers including bladder, cervical, breast, prostate, head and neck, and multiple myeloma (reviewed in Wesche, 2011). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway152">
 <bp:pathwayOrder rdf:resource="#PathwayStep596" />
 <bp:pathwayOrder rdf:resource="#PathwayStep597" />
 <bp:pathwayOrder rdf:resource="#PathwayStep598" />
 <bp:pathwayOrder rdf:resource="#PathwayStep604" />
 <bp:pathwayOrder rdf:resource="#PathwayStep605" />
 <bp:pathwayOrder rdf:resource="#PathwayStep606" />
 <bp:pathwayOrder rdf:resource="#PathwayStep607" />
 <bp:pathwayOrder rdf:resource="#PathwayStep592" />
 <bp:pathwayOrder rdf:resource="#PathwayStep593" />
 <bp:pathwayOrder rdf:resource="#PathwayStep594" />
 <bp:pathwayOrder rdf:resource="#PathwayStep595" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction445" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction446" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction443" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction454" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction444" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction455" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction441" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction452" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction442" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction453" />
 <bp:pathwayComponent rdf:resource="#Pathway153" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence592" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR4 in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR4 is perhaps the least well studied of the FGF receptors, and unlike the case for the other FGFR genes, mutations in FGFR4 are not known to be associated with any developmental disorders.  Recently, however, somatically arising mutations in the FGFR4 coding sequence have begun to be identified in some cancers.  8% of rhabdomyosarcomas have activating mutations in the kinase domain of FGFR4.  Two of these mutations - N535K (paralogous to the FGFR2 N550K allele found in endometrial cancers) and V550E - have been shown to support the oncogenic transformation of NIH 3T3 cells (Taylor, 2009).  An FGFR4 Y367C mutation has also been identified in breast cancers (Ruhe, 2007; Roidl, 2010); mutations of paralogous residues in FGFR2 and FGFR3 are associated with both skeletal dysplasias and the development of diverse cancers (Pollock, 2007; Ruhe, 2007; Rousseau, 1996; Chesi, 1997, 2001).   Finally, a SNP at position 388 of FGFR4 is associated with aggressive disease development.  Expression of the G388R allele in breast, colorectal and prostate cancers is correlated with rapid progression times and increased rates of recurrence and metastasis (Bange, 2002; Spinola, 2005; Wang, 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway153">
 <bp:pathwayOrder rdf:resource="#PathwayStep599" />
 <bp:pathwayOrder rdf:resource="#PathwayStep600" />
 <bp:pathwayOrder rdf:resource="#PathwayStep601" />
 <bp:pathwayOrder rdf:resource="#PathwayStep602" />
 <bp:pathwayOrder rdf:resource="#PathwayStep603" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction450" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction451" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction449" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction447" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction448" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence599" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR4 mutant receptor activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR4 is perhaps the least well studied of the FGF receptors, and unlike the case for the other FGFR genes, mutations in FGFR4 are not known to be associated with any developmental disorders.  Recently, however, somatically arising mutations in the FGFR4 coding sequence have begun to be identified in some cancers.  (Taylor, 2009; Ruhe, 2007; Roidl, 2010).  The resulting mutant versions of FGFR4 promote aberrant signaling through ligand-independent dimerization and enhanced autophosphorylation, among other mechanisms (Roidl, 2009; Taylor, 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway154">
 <bp:pathwayOrder rdf:resource="#PathwayStep640" />
 <bp:pathwayOrder rdf:resource="#PathwayStep641" />
 <bp:pathwayOrder rdf:resource="#PathwayStep610" />
 <bp:pathwayOrder rdf:resource="#PathwayStep611" />
 <bp:pathwayOrder rdf:resource="#PathwayStep612" />
 <bp:pathwayOrder rdf:resource="#PathwayStep613" />
 <bp:pathwayOrder rdf:resource="#PathwayStep614" />
 <bp:pathwayOrder rdf:resource="#PathwayStep615" />
 <bp:pathwayOrder rdf:resource="#PathwayStep638" />
 <bp:pathwayOrder rdf:resource="#PathwayStep639" />
 <bp:pathwayOrder rdf:resource="#PathwayStep609" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction456" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction457" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction461" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction483" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction481" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction460" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction482" />
 <bp:pathwayComponent rdf:resource="#Pathway155" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction480" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction458" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction459" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence609" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR2 in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The FGFR2 gene has been shown to be subject to activating mutations and gene amplification leading to a variety of proliferative and developmental disorders depending on whether these events occur in the germline or arise somatically.  Activating FGFR2 mutations in the germline give rise to a range of craniosynostotic conditions including Pfeiffer, Apert, Jackson-Weiss, Crouzon and Beare-Stevensen Cutis Gyrata syndromes.  These autosomal dominant skeletal disorders are characterized by premature fusion of several sutures in the skull, and in some cases also involve syndactyly (abnormal bone fusions in the hands and feet) (reviewed in Webster and Donoghue, 1997; Burke, 1998; Cunningham, 2007).   Activating FGFR2 mutations arising somatically have been linked to the development of gastric and endometrial cancers (reviewed in Greulich and Pollock, 2011; Wesche, 2011).  Many of these mutations are similar or identical to those that contribute to the autosomal disorders described above.  Notably, loss-of-function mutations in FGFR2 have also been recently described in melanoma (Gartside, 2009).  FGFR2 may also contribute to tumorigenesis through overexpression, as FGFR2 has been identified as a target of gene amplification in gastric and breast cancers (Kunii, 2008; Takeda, 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway155">
 <bp:pathwayOrder rdf:resource="#PathwayStep624" />
 <bp:pathwayOrder rdf:resource="#PathwayStep616" />
 <bp:pathwayOrder rdf:resource="#PathwayStep627" />
 <bp:pathwayOrder rdf:resource="#PathwayStep619" />
 <bp:pathwayComponent rdf:resource="#Pathway156" />
 <bp:pathwayComponent rdf:resource="#Pathway157" />
 <bp:pathwayComponent rdf:resource="#Pathway158" />
 <bp:pathwayComponent rdf:resource="#Pathway159" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence616" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2 mutant receptor activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autosomal dominant mutations in FGFR2 are associated with the development of a range of skeletal disorders including Beare-Stevensen cutis gyrata syndrome, Pfeiffer syndrome, Jackson-Weiss syndrome, Crouzon syndrome and Apert Syndrome (reveiwed in Burke, 1998; Webster and Donoghue 1997; Cunningham, 2007).  Activating point mutations have also been identified in FGFR2 in ~15% of endometrial cancers, as well as to a lesser extent in ovarian and gastric cancers (Dutt, 2008; Pollock, 2007; Byron, 2010; Jang, 2001).  Activating mutations in FGFR2 are thought to contribute to receptor activation through diverse mechanisms, including constitutive ligand-independent dimerization (Robertson, 1998), expanded range and affinity for ligand (Ibrahimi, 2004b; Yu, 2000) and enhanced kinase activity (Byron, 2008; Chen, 2007).  FGFR2 amplifications have been identified in 10% of gastric cancers, where they are associated with poor prognosis diffuse cancers (Hattori, 1996; Ueda, 1999; Shin, 2000; Kunii, 2008) , and in ~1% of breast cancers (Turner, 2010; Tannheimer, 2000).   FGFR2 amplification often occur in conjunction with deletions of C-terminal exons, resulting in expression of a internalization- and degradation-resistant form of the receptor (Takeda, 2007; Cha, 2008, 2009). Signaling through overexpressed FGFR2 shows evidence of being ligand-independent and sensitive to FGFR inhibitors  (Lorenzi, 1997; Takeda, 2007; Cha, 2009). More recently, FGFR2 fusion proteins have been identified in a number of cancers; these are thought to form constitutive ligand-independent dimers based on the dimerization domains of the 3&apos; fusion partners and contribute to cellular proliferation and tumorigenesis in a kinase-inhibitor sensitive manner (Wu, 2013; Arai, 2013; Seo, 2012; reviewed in Parker, 2014). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence499">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway156">
 <bp:pathwayOrder rdf:resource="#PathwayStep617" />
 <bp:pathwayOrder rdf:resource="#PathwayStep618" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction463" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction462" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence617" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR2 IIIa TM</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A soluble truncated form of FGFR2 is aberrantly expressed in an Apert Syndrome mouse model and inhibits FGFR signaling in vitro and in vivo.  This variant, termed FGFR IIIa TM, arises from an misspliced transcript that fuses exon 7 to exon 10 and that escapes nonsense-mediated decay.  FGFR2 IIIa TM may inhibit signaling by sequestering FGF ligand and/or by forming nonfunctional heterodimers with full-length receptors at the cell surface (Wheldon et al, 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence498">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway157">
 <bp:pathwayOrder rdf:resource="#PathwayStep620" />
 <bp:pathwayOrder rdf:resource="#PathwayStep621" />
 <bp:pathwayOrder rdf:resource="#PathwayStep622" />
 <bp:pathwayOrder rdf:resource="#PathwayStep623" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction467" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction465" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction466" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction464" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence620" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR2 amplification mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2 amplifications have been identified in 10% of gastric cancers, where they are associated with poor prognosis diffuse cancers (Hattori, 1996; Ueda, 1999; Shin, 2000; Kunii, 2008) , and in ~1% of breast cancers (Turner, 2010; Tannheimer, 2000).   FGFR2 amplification often occur in conjunction with deletions of C-terminal exons, resulting in expression of a internalization- and degradation-resistant form of the receptor (Takeda, 1999; Cha, 2008, 2009). Amplification affects signaling without altering the intrinsic kinase activity of the receptor. Signaling through overexpressed FGFR2 also shows evidence of being ligand-independent and sensitive to FGFR inhibitors  (Lorenzi, 1997; Takeda, 1999; Cha, 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway158">
 <bp:pathwayOrder rdf:resource="#PathwayStep625" />
 <bp:pathwayOrder rdf:resource="#PathwayStep626" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction468" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction469" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence625" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR2 fusions</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2 fusions have been identified in cancers such as lung, breast, thyroid and cholangiocarcinoma (Wu et al, 2013; Seo et al, 2012; Arai et al, 2013).  Of all the FGF receptors, FGFR2 shows the broadest range of 3&apos; fusion partners, including BICC1, AHCYL1, CIT, CCDC6, CASP7, AFF3, OFD1 and CCAR2.  Many of these fusion partners contain dimerization domains, suggesting that the resulting fusions may demonstrate constitutive ligand-independent activation (Wu et al, 2013; Arai et al, 2013; Seo et al, 2012; reviewed in Parker et al, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway159">
 <bp:pathwayOrder rdf:resource="#PathwayStep630" />
 <bp:pathwayOrder rdf:resource="#PathwayStep631" />
 <bp:pathwayOrder rdf:resource="#PathwayStep632" />
 <bp:pathwayOrder rdf:resource="#PathwayStep633" />
 <bp:pathwayOrder rdf:resource="#PathwayStep634" />
 <bp:pathwayOrder rdf:resource="#PathwayStep635" />
 <bp:pathwayOrder rdf:resource="#PathwayStep636" />
 <bp:pathwayOrder rdf:resource="#PathwayStep637" />
 <bp:pathwayOrder rdf:resource="#PathwayStep628" />
 <bp:pathwayOrder rdf:resource="#PathwayStep629" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction478" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction479" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction476" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction477" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction474" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction475" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction472" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction473" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction470" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction471" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence628" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated point mutants of FGFR2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autosomal dominant mutations in FGFR2 are associated with the development of a range of skeletal disorders including Beare-Stevensen cutis gyrata syndrome, Pfeiffer syndrome, Jackson-Weiss syndrome, Crouzon syndrome and Apert Syndrome (reveiwed in Burke, 1998; Webster and Donoghue 1997; Cunningham, 2007).  Mutations that give rise to Crouzon, Jackson-Weiss and Pfeiffer syndromes tend to cluster in the third Ig-like domain of the receptor, either in exon IIIa (shared by the IIIb and the IIIc isoforms) or in the FGFR2c-specific exon IIIc.  These mutations frequently involve creation or removal of a cysteine residue, leading to the formation of an unpaired cysteine residue that is thought to promote intramolecular dimerization and thus constitutive, ligand-independent activation (reviewed in Burke, 1998; Webster and Donoghue, 1997; Cunningham, 2007).  Mutations in FGFR2 that give rise to Apert Syndrome cluster to the highly conserved Pro-Ser dipeptide in the IgII-Ig III linker; mutations in the paralogous residues of FGFR1 and 3 give rise to Pfeiffer and Muenke syndromes, respectively (Muenke, 1994; Wilkie, 1995; Bellus, 1996). Development of Beare-Stevensen cutis gyrata is associated with mutations in the transmembrane-proximal region of the receptor (Przylepa, 1996), and similar mutations in FGFR3 are linked to the development of thanatophoric dysplasia I (Tavormina, 1995a).  These mutations all affect FGFR2 signaling without altering the intrinsic kinase activity of the receptor.   Activating point mutations have also been identified in FGFR2 in ~15% of endometrial cancers, as well as to a lesser extent in ovarian and gastric cancers (Dutt, 2008; Pollock, 2007; Byron, 2010; Jang, 2001).  These mutations are found largely in the extracellular region and in the kinase domain of the receptor, and parallel activating mutations seen in autosomal dominant disorders described above.   Activating mutations in FGFR2 are thought to contribute to receptor activation through diverse mechanisms, including constitutive ligand-independent dimerization (Robertson, 1998), expanded range and affinity for ligand (Ibrahimi, 2004b; Yu, 2000) and enhanced kinase activity (Byron, 2008; Chen, 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway170">
 <bp:pathwayOrder rdf:resource="#PathwayStep703" />
 <bp:pathwayOrder rdf:resource="#PathwayStep704" />
 <bp:pathwayOrder rdf:resource="#PathwayStep695" />
 <bp:pathwayOrder rdf:resource="#PathwayStep696" />
 <bp:pathwayOrder rdf:resource="#PathwayStep697" />
 <bp:pathwayOrder rdf:resource="#PathwayStep698" />
 <bp:pathwayOrder rdf:resource="#PathwayStep699" />
 <bp:pathwayOrder rdf:resource="#PathwayStep700" />
 <bp:pathwayOrder rdf:resource="#PathwayStep701" />
 <bp:pathwayOrder rdf:resource="#PathwayStep702" />
 <bp:pathwayOrder rdf:resource="#PathwayStep691" />
 <bp:pathwayOrder rdf:resource="#PathwayStep692" />
 <bp:pathwayOrder rdf:resource="#PathwayStep693" />
 <bp:pathwayOrder rdf:resource="#PathwayStep694" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction528" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction529" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction526" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction527" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction524" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction535" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction525" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction522" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction533" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction523" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction534" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction531" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction532" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction530" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence691" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by cytosolic FGFR1 fusion mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">8p11 myeloproliferative syndrome (EMS) is an aggressive disorder that is associated with a translocation event at the FGFR1 gene on chromosome 8p11.  Typical symptoms upon diagnosis include eosinophilia and associated T-cell lymphoblastic lymphoma; the disease rapidly advances to acute leukemia, usually of myeloid lineage.  At present the only effective treatment is allogenic stem cell transplantation (reviewed in Jackson, 2010).    At the molecular level, EMS appears to be caused by translocation events on chromosome 8 that create gene fusions between the intracellular domain of FGFR1 and an N-terminal partner gene that encodes a dimerization domain.  The resulting fusion protein dimerizes in a ligand-independent fashion based the N-terminal domain provided by the partner protein and stimulates constititutive downstream FGFR1 signaling without altering the intrisic kinase activity of the receptor.  To date, 11 partner genes have been identified: ZMYM2, FGFR1OP, FGFR1OP2, HERVK, TRIM24, CUX1, BCR, CEP110, LRRFIP1, MYO18A and CPSF6, although not all have been functionally characterized (reviewed in Jackson, 2010, Turner and Grose, 2010; Wesche, 2011).   Where examined, cell lines carrying FGFR1 fusion genes have been shown to be transforming  and to support IL3-independent proliferation through anti-apoptotic, prosurvival pathways(Lelievre, 2008; Ollendorff, 1999; Chase, 2007; Guasch, 2001; Wasag 2011; Roumiantsev, 2004; Demiroglu, 2001; Smedley, 1999).  Signaling appears to occur predominantly through PLCgamma, PI3K and STAT signaling, with a more minor contribution from MAPK activation.  Because the fusion proteins lack the FRS2-binding site, the mechanism of MAPK activation is unclear.  Recruitment of  GRB2:SOS1 through recruitment of SHC is one possibility (Guasch, 2001).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway163">
 <bp:pathwayOrder rdf:resource="#PathwayStep655" />
 <bp:pathwayOrder rdf:resource="#PathwayStep656" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction494" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction493" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence655" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">t(4;14) translocations of FGFR3</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Translocations which put the FGFR3 gene under the control of the strong IGH promoter have been identified in 15% of multiple myelomas (Avet-Loiseau, 1998; Chesi, 1997; Chesi, 2001).  This translocation, which occurs 70kb upstream of the FGFR3 gene, also involves the nearby multiple myeloma SET-domain containing (MMSET) gene (Lauring, 2008), and although the contribution of each of these genes to the development of cancer has not been fully elucidated, several studies have shown that t(4:14) myeloma cell lines are sensitive to FGFR3 inhibitors (Trudel, 2006; Qing, 2009).  In ~5% of cases, the translocation is accompanied by activating mutations of FGFR3 (Onwuazor, 2003; Ronchetti, 2001).  The t(4;14) translocation results in overexpression of FGFR3 and subsequent ligand independent or anomalous ligand-dependent signaling (Otsuki, 1999).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway164">
 <bp:pathwayOrder rdf:resource="#PathwayStep658" />
 <bp:pathwayOrder rdf:resource="#PathwayStep659" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction496" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction495" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence658" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR3 fusions in cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In recent years, recurrent fusions of FGFR3 have been identified in a number of cancers, including glioblastoma and cancers of the lung and bladder, among others (Singh et al, 2012; Parker et al, 2013; Williams et al, 2013; Wu et al, 2013; Capelletti et al, 2014; Yuan et al, 2014; Wang et al, 2014; Carneiro et al, 2015; reviewed in Parker et al, 2014). The most common fusion partner of FGFR3 is TACC3 (transforming acidic coiled coil protein 3), a protein involved in mitotic spindle assembly and chromosome segregation (Lin et al, 2010; Burgess et al, 2015).  FGFR3 fusions are constitutively active and may form oligomers in a ligand-independent manner based on dimerization domains provided by the fusion partner (Singh et al, 2012; Williams et al, 2013; Parker et al, 2013; reviewed in Parker et al, 2014). Transformation and proliferation appear to be promoted through activation of the ERK and AKT signaling pathways. In contrast, PLC gamma signaling is not stimulated downstream of FGFR3 fusions, as the PLC gamma docking site is not present in the fusion.  FGFR3 fusions are sensitive to protein kinase inhibitors, suggesting their potential as therapeutic targets (Singh et al, 2012; Williams et al, 2013; Wu et al, 2013; reviewed in Parker et al, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway165">
 <bp:pathwayOrder rdf:resource="#PathwayStep673" />
 <bp:pathwayOrder rdf:resource="#PathwayStep674" />
 <bp:pathwayOrder rdf:resource="#PathwayStep675" />
 <bp:pathwayOrder rdf:resource="#PathwayStep669" />
 <bp:pathwayOrder rdf:resource="#PathwayStep705" />
 <bp:pathwayOrder rdf:resource="#PathwayStep706" />
 <bp:pathwayOrder rdf:resource="#PathwayStep707" />
 <bp:pathwayOrder rdf:resource="#PathwayStep670" />
 <bp:pathwayOrder rdf:resource="#PathwayStep708" />
 <bp:pathwayOrder rdf:resource="#PathwayStep671" />
 <bp:pathwayOrder rdf:resource="#PathwayStep672" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction510" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction508" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction509" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction506" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction539" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction507" />
 <bp:pathwayComponent rdf:resource="#Pathway166" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction537" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction505" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction538" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction536" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence669" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR1 in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The FGFR1 gene has been shown to be subject to activating mutations, chromosomal rearrangements and gene amplification leading to a variety of proliferative and developmental disorders depending on whether these events occur in the germline or arise somatically (reviewed in Webster and Donoghue, 1997; Burke, 1998; Cunningham, 2007; Wesche, 2011; Greulich and Pollock, 2011).     Activating mutation P252R in FGFR1 is associated with the development of Pfeiffer syndrome, characterized by craniosynostosis (premature fusion of several sutures in the skull) and broadened thumbs and toes (Muenke, 1994; reviewed in Cunningham, 2007).  This residue falls in a highly conserved Pro-Ser dipeptide between the second and third Ig domains of the extracellular region of the receptor. The mutation is thought to increase the number of hydrogen bonds formed with the ligand and to thereby increase ligand-binding affinity (Ibrahimi, 2004a). Unlike other FGF receptors, few activating point mutations in the FGFR1 coding sequence have been identified in cancer.  Point mutations in the Ig II-III linker analagous to the P252R Pfeiffer syndrome mutation have been identified in lung cancer and melanoma (Ruhe, 2007; Davies, 2005), and two kinase-domain mutations in FGFR1 have been identified in glioblastoma (Rand, 2005, Network TCGA, 2008).  In contrast,  FGFR1 is a target of chromosomal rearrangements in a number of cancers.  FGFR1 has been shown to be recurrently translocated in the 8p11 myeloproliferative syndrome (EMS), a pre-leukemic condition also known as stem cell leukemia/lymphoma (SCLL) that rapidly progresses to leukemia.  This translocation fuses the kinase domain of FGFR1 with the dimerization domain of one of 10 identified fusion partners, resulting in the constitutive dimerization and activation of the kinase (reviewed in Jackson, 2010).    Amplification of the FGFR1 gene has been implicated as a oncogenic factor in a range of cancers, including breast, ovarian, bladder, lung, oral squamous carcinomas, and rhabdomyosarcoma (reviewed in Turner and Grose, 2010; Wesche, 2011; Greulich and Pollock, 2011), although there are other candidate genes in the amplified region and the definitive role of FGFR1 has not been fully established. More recently, FGFR1 fusion proteins have been identified in a number of cancers; these are thought to undergo constitutive ligand-independent dimerization and activation based on dimerization motifs found in the fusion partners (reviewed in Parker, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway166">
 <bp:pathwayOrder rdf:resource="#PathwayStep684" />
 <bp:pathwayOrder rdf:resource="#PathwayStep676" />
 <bp:pathwayOrder rdf:resource="#PathwayStep679" />
 <bp:pathwayOrder rdf:resource="#PathwayStep690" />
 <bp:pathwayComponent rdf:resource="#Pathway170" />
 <bp:pathwayComponent rdf:resource="#Pathway167" />
 <bp:pathwayComponent rdf:resource="#Pathway168" />
 <bp:pathwayComponent rdf:resource="#Pathway169" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence676" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR1 mutant receptor activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The FGFR1 gene has been shown to be subject to activating mutations, chromosomal rearrangements and gene amplification leading to a variety of proliferative and developmental disorders depending on whether these events occur in the germline or arise somatically (reviewed in Webster and Donoghue, 1997; Burke, 1998; Cunningham, 2007; Wesche, 2011; Greulich and Pollock, 2011). Many of the resulting mutant FGFR1 proteins can dimerize and promote signaling in a ligand-independent fashion, although signal transduction may still be amplified in the presence of ligand (reviewed in Turner and Gross, 2010; Greulich and Pollock, 2011; Wesche et al, 2011).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway167">
 <bp:pathwayOrder rdf:resource="#PathwayStep677" />
 <bp:pathwayOrder rdf:resource="#PathwayStep678" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction511" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction512" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence677" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by plasma membrane FGFR1 fusions</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In addition to the cytosolic FGFR1 fusions identified in 8 myeloproliferative syndrome, plasma membrane localized FGFR1 fusions have been identified in glioblastoma, breast cancer and non small cell lung cancers (Singh et al, 2012; Wu et al, 2013; Wang et al, 2014).  A FGFR1:TACC1 fusion identified in glioblastoma promotes anchorage independent growth when expressed in Rat1A cells, while an ERLIN2:FGFR1 fusion in breast cancer shows constitutive autophosphorylation when expressed in HEK 293 cells (Singh et al, 2012; Wu et al, 2013).  All FGFR1 fusions tested also shown increased sensitivity to growth inhibition upon treatment with kinase inhibitors (Singh et al, 2012; Wu et al, 2013; Wang et al, 2014; reviewed in Parker et al, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway168">
 <bp:pathwayOrder rdf:resource="#PathwayStep680" />
 <bp:pathwayOrder rdf:resource="#PathwayStep681" />
 <bp:pathwayOrder rdf:resource="#PathwayStep682" />
 <bp:pathwayOrder rdf:resource="#PathwayStep683" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction515" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction516" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction513" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction514" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence680" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by activated point mutants of FGFR1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Unlike FGFR2 and FGFR3, FGFR1 appears not to be a frequent target of activating point mutations (reviewed in Wesche, 2011; Turner and Grose, 2010).  Germline point mutations at residue P252 have been identified in Pfeiffer syndrome (reviewed in Webster and Donoghue, 1997; Burke, 1998; Cunningham, 2007) while mutation of the same residue arising somatically has been identified in melanoma and lung cancer (Ruhe, 2007; Davies, 2005).  Two kinase domain mutations have been characterized in glioblastoma (Rand, 2005; Network TCGA, 2008), both at positions that are also mutated in an autosomal disorder in one of the FGFR family members (Muenke, 1994; Bellus, 1995a; Bellus, 2000; Tavormina, 1995a; Tavormina, 1999).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway169">
 <bp:pathwayOrder rdf:resource="#PathwayStep685" />
 <bp:pathwayOrder rdf:resource="#PathwayStep686" />
 <bp:pathwayOrder rdf:resource="#PathwayStep687" />
 <bp:pathwayOrder rdf:resource="#PathwayStep688" />
 <bp:pathwayOrder rdf:resource="#PathwayStep689" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction520" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction521" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction519" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction517" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction518" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence685" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR1 amplification mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Amplification or activation of FGFR1 has been reported in  lung cancer (Weiss, 2001; Marek, 2009; Dutt, 2011), breast cancer (Reis-Filho, 2006; Turner, 2010), oral squamous carcinoma (Freier, 2007), esophageal squamous cell carcinomas (Ishizuka, 2002), ovarian cancer (Gorringe, 2007), bladder cancer (Simon, 2001), prostate cancer (Edwards, 2003; Acevedo, 2007) and rhabodomyosarcoma (Missiaglia, 2009).  Unlike the case for FGFR2 amplifications, FGFR1 amplifications are not associated with additional point mutations and affect signaling without altering the intrinsic kinase activity of the receptor.  Overexpressed FGFR1 appears to signal at a basal level in a ligand-independent fashion, but is also able to be stimulated by exogenous ligand.  Downstream activation may be the result of aberrant paracrine or autocrine stimulation (reviewed in Turner and Gross, 2010; Greulich and Pollock, 2011).  FGFR1 amplification has not been conclusively demonstrated to be the causative oncogenic agent in all of the cancer types mentioned above, and other genes in the 8p11 region may also be candidates in some cases (Bass, 2009; Bernard-Pierrot, 2008; Ray, 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence507">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence506">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence509">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence508">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence503">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence502">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence505">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence504">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence501">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence500">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence518">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence517">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence519">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence514">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence513">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence516">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence515">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence510">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence512">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence511">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence530">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep464">
 <bp:stepProcess rdf:resource="#BiochemicalReaction354" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep465">
 <bp:stepProcess rdf:resource="#BiochemicalReaction355" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep466">
 <bp:stepProcess rdf:resource="#BiochemicalReaction356" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep467">
 <bp:stepProcess rdf:resource="#BiochemicalReaction357" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep468">
 <bp:stepProcess rdf:resource="#BiochemicalReaction358" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence529">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep469">
 <bp:stepProcess rdf:resource="#Catalysis106" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction359" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence528">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence525">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence524">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence527">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence526">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep460">
 <bp:stepProcess rdf:resource="#BiochemicalReaction352" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence521">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep461">
 <bp:stepProcess rdf:resource="#Pathway110" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence520">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep462">
 <bp:stepProcess rdf:resource="#BiochemicalReaction353" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence523">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep463">
 <bp:stepProcess rdf:resource="#Pathway111" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence522">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence541">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence540">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep475">
 <bp:stepProcess rdf:resource="#BiochemicalReaction365" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep476">
 <bp:stepProcess rdf:resource="#BiochemicalReaction366" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep477">
 <bp:stepProcess rdf:resource="#BiochemicalReaction367" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep478">
 <bp:stepProcess rdf:resource="#BiochemicalReaction368" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep479">
 <bp:stepProcess rdf:resource="#BiochemicalReaction369" />
 <bp:stepProcess rdf:resource="#Catalysis109" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence539">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence536">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence535">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence538">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep470">
 <bp:stepProcess rdf:resource="#BiochemicalReaction360" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence537">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep471">
 <bp:stepProcess rdf:resource="#BiochemicalReaction361" />
 <bp:stepProcess rdf:resource="#Catalysis107" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence532">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep472">
 <bp:stepProcess rdf:resource="#BiochemicalReaction362" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence531">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep473">
 <bp:stepProcess rdf:resource="#Catalysis108" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction363" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence534">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep474">
 <bp:stepProcess rdf:resource="#BiochemicalReaction364" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence533">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence550">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence552">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence551">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep486">
 <bp:stepProcess rdf:resource="#BiochemicalReaction374" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep487">
 <bp:stepProcess rdf:resource="#Pathway114" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep488">
 <bp:stepProcess rdf:resource="#BiochemicalReaction375" />
 <bp:stepProcess rdf:resource="#Catalysis111" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep489">
 <bp:stepProcess rdf:resource="#BiochemicalReaction376" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence547">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence546">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep480">
 <bp:stepProcess rdf:resource="#BiochemicalReaction370" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence549">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep481">
 <bp:stepProcess rdf:resource="#BiochemicalReaction371" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence548">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep482">
 <bp:stepProcess rdf:resource="#Pathway112" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence543">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep483">
 <bp:stepProcess rdf:resource="#Catalysis110" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction372" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence542">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep484">
 <bp:stepProcess rdf:resource="#Pathway113" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence545">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep485">
 <bp:stepProcess rdf:resource="#BiochemicalReaction373" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence544">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence561">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence560">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence563">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence562">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction209">
 <bp:evidence rdf:resource="#Evidence268" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-BRAF and RAF fusion dimers phosphorylate MAP2Ks</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction207">
 <bp:evidence rdf:resource="#Evidence266" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPKs are phosphorylated downstream of BRAF and RAF fusion dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction208">
 <bp:evidence rdf:resource="#Evidence267" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-BRAF and RAF fusion dimers bind MAP2Ks and MAPKs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction205">
 <bp:evidence rdf:resource="#Evidence262" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hh processing variants bind lectins</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction206">
 <bp:evidence rdf:resource="#Evidence263" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">processing defective Hh variants are degraded by the proteasome</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction203">
 <bp:evidence rdf:resource="#Evidence260" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hh processing variants are recruited to SEL1:SYVN at the ER membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep497">
 <bp:stepProcess rdf:resource="#BiochemicalReaction383" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction204">
 <bp:evidence rdf:resource="#Evidence261" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hh processing variants are ubiquitinated</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep498">
 <bp:stepProcess rdf:resource="#BiochemicalReaction384" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction201">
 <bp:evidence rdf:resource="#Evidence258" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hh processing variants are translocated to the cytosol in a VCP-dependent manner</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep499">
 <bp:stepProcess rdf:resource="#BiochemicalReaction385" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction202">
 <bp:evidence rdf:resource="#Evidence259" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HPE SHH variants don&apos;t undergo autoproteolytic cleavage</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction200">
 <bp:evidence rdf:resource="#Evidence256" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HHAT G287V doesn&apos;t palmitoylate Hh-Np</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence558">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep490">
 <bp:stepProcess rdf:resource="#BiochemicalReaction377" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence557">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep491">
 <bp:stepProcess rdf:resource="#BiochemicalReaction378" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep492">
 <bp:stepProcess rdf:resource="#BiochemicalReaction379" />
 <bp:stepProcess rdf:resource="#Catalysis112" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence559">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep493">
 <bp:stepProcess rdf:resource="#BiochemicalReaction380" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence554">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep494">
 <bp:stepProcess rdf:resource="#BiochemicalReaction381" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence553">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep495">
 <bp:stepProcess rdf:resource="#Pathway115" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence556">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep496">
 <bp:stepProcess rdf:resource="#BiochemicalReaction382" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence555">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep417">
 <bp:stepProcess rdf:resource="#BiochemicalReaction325" />
 <bp:stepProcess rdf:resource="#Catalysis99" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep418">
 <bp:stepProcess rdf:resource="#Catalysis100" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction326" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep419">
 <bp:stepProcess rdf:resource="#Pathway94" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction218">
 <bp:evidence rdf:resource="#Evidence279" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of RAS:RAF1 mutant complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction219">
 <bp:evidence rdf:resource="#Evidence280" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP2Ks and MAPKs bind to the activated mutant RAF1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction216">
 <bp:evidence rdf:resource="#Evidence277" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP2Ks phosphorylate MAPKs downstream of RAF1 mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction217">
 <bp:evidence rdf:resource="#Evidence278" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAF1 mutant complexes phosphorylate MAP2K dimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction214">
 <bp:evidence rdf:resource="#Evidence275" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of RAF1 mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep420">
 <bp:stepProcess rdf:resource="#Catalysis101" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction327" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction215">
 <bp:evidence rdf:resource="#Evidence276" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAF1 mutants show enhanced heterodimerization with BRAF</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep421">
 <bp:stepProcess rdf:resource="#BiochemicalReaction328" />
 <bp:stepProcess rdf:resource="#Catalysis102" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction212">
 <bp:evidence rdf:resource="#Evidence272" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function NF1 variants don&apos;t stimulate RAS GTPase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep422">
 <bp:stepProcess rdf:resource="#BiochemicalReaction329" />
 <bp:stepProcess rdf:resource="#Catalysis103" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction213">
 <bp:evidence rdf:resource="#Evidence274" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CR2 RAF1 mutants don&apos;t bind YWHAB</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep423">
 <bp:stepProcess rdf:resource="#BiochemicalReaction330" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction210">
 <bp:evidence rdf:resource="#Evidence269" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of BRAF/RAF fusion complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep424">
 <bp:stepProcess rdf:resource="#BiochemicalReaction331" />
 <bp:stepProcess rdf:resource="#Catalysis104" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction211">
 <bp:evidence rdf:resource="#Evidence270" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BRAF and RAF fusion mutant dimers are phosphorylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep425">
 <bp:stepProcess rdf:resource="#BiochemicalReaction332" />
 <bp:stepProcess rdf:resource="#Catalysis105" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep426">
 <bp:stepProcess rdf:resource="#BiochemicalReaction333" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep427">
 <bp:stepProcess rdf:resource="#BiochemicalReaction334" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep428">
 <bp:stepProcess rdf:resource="#BiochemicalReaction335" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep429">
 <bp:stepProcess rdf:resource="#BiochemicalReaction336" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction229">
 <bp:evidence rdf:resource="#Evidence295" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP2K mutants constitutively phosphorylate MAPKs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction227">
 <bp:evidence rdf:resource="#Evidence291" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutant MRAS:SHOC2:PPP1CC complexes dephosphorylate inactive RAFs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction228">
 <bp:evidence rdf:resource="#Evidence293" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SHOC2 M173I disrupts the SHOC2:MRAS:PP1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction225">
 <bp:evidence rdf:resource="#Evidence287" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAF is paradoxically phosphorylated downstream of kinase-inactive RAF</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep431">
 <bp:stepProcess rdf:resource="#BiochemicalReaction338" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction226">
 <bp:evidence rdf:resource="#Evidence288" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Inactive BRAF mutants bind mutant RAS:GTP</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep432">
 <bp:stepProcess rdf:resource="#BiochemicalReaction339" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction223">
 <bp:evidence rdf:resource="#Evidence285" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS:GTP:inactive p-RAF complexes phosphorylate MAP2Ks</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep433">
 <bp:stepProcess rdf:resource="#Pathway95" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction224">
 <bp:evidence rdf:resource="#Evidence286" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS:GTP:p-RAF complexes paradoxically bind MAP2Ks and MAPKs</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep434">
 <bp:stepProcess rdf:resource="#Pathway96" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction221">
 <bp:evidence rdf:resource="#Evidence283" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Inactive BRAF mutants:mutant RAS:GTP bind RAF1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep435">
 <bp:stepProcess rdf:resource="#Pathway97" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction222">
 <bp:evidence rdf:resource="#Evidence284" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of paradoxically activated RAS:BRAF complexes</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep436">
 <bp:stepProcess rdf:resource="#BiochemicalReaction340" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep437">
 <bp:stepProcess rdf:resource="#Pathway98" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction220">
 <bp:evidence rdf:resource="#Evidence282" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated MAP2Ks phosphorylate MAPKs downstream of inactive BRAF mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep438">
 <bp:stepProcess rdf:resource="#BiochemicalReaction341" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep430">
 <bp:stepProcess rdf:resource="#BiochemicalReaction337" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep439">
 <bp:stepProcess rdf:resource="#Pathway99" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction238">
 <bp:evidence rdf:resource="#Evidence306" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">High kinase activity BRAF mutants bind MAP2Ks and MAPKs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction239">
 <bp:evidence rdf:resource="#Evidence307" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">High kinase activity BRAF complexes phosphorylate MAP2Ks</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction236">
 <bp:evidence rdf:resource="#Evidence303" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated MAP2Ks phosphorylate MAPKs downstream of moderate kinase activity BRAF mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep442">
 <bp:stepProcess rdf:resource="#BiochemicalReaction343" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction237">
 <bp:evidence rdf:resource="#Evidence305" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of BRAF V600E splice variants contributes to BRAF inhibitor resistance</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep443">
 <bp:stepProcess rdf:resource="#Pathway101" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction234">
 <bp:evidence rdf:resource="#Evidence301" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of moderate activity BRAF complexes</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep444">
 <bp:stepProcess rdf:resource="#BiochemicalReaction344" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction235">
 <bp:evidence rdf:resource="#Evidence302" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Moderate kinase activity BRAF mutants:RAS:GTP homo/heterodimerize</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep445">
 <bp:stepProcess rdf:resource="#Pathway102" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction232">
 <bp:evidence rdf:resource="#Evidence299" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Moderate kinase activity BRAF mutants bind RAS:GTP</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep446">
 <bp:stepProcess rdf:resource="#BiochemicalReaction345" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction233">
 <bp:evidence rdf:resource="#Evidence300" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS:GTP:moderate kinase activity p-RAF complexes bind MAP2Ks and MAPKs</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep447">
 <bp:stepProcess rdf:resource="#Pathway103" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction230">
 <bp:evidence rdf:resource="#Evidence297" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS:GTP:moderate kinase activity p-RAF complexes phosphorylate MAP2Ks</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep448">
 <bp:stepProcess rdf:resource="#BiochemicalReaction346" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction231">
 <bp:evidence rdf:resource="#Evidence298" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAF is phosphorylated downstream of moderate kinase activity BRAF mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep449">
 <bp:stepProcess rdf:resource="#Pathway104" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep440">
 <bp:stepProcess rdf:resource="#BiochemicalReaction342" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep441">
 <bp:stepProcess rdf:resource="#Pathway100" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction249">
 <bp:evidence rdf:resource="#Evidence320" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutant RAS:p-RAF complexes phosphorylate MAP2Ks</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction247">
 <bp:evidence rdf:resource="#Evidence318" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS mutants bind inactive RAF</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep453">
 <bp:stepProcess rdf:resource="#Pathway106" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction248">
 <bp:evidence rdf:resource="#Evidence319" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutant RAS:p-RAF complexes bind MAP2Ks and MAPKs</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep454">
 <bp:stepProcess rdf:resource="#BiochemicalReaction349" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction245">
 <bp:evidence rdf:resource="#Evidence316" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated MAP2Ks phosphorylate MAPKs downstream of oncogenic RAS</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep455">
 <bp:stepProcess rdf:resource="#Pathway107" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction246">
 <bp:evidence rdf:resource="#Evidence317" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAF is phosphorylated downstream of oncogenic RAS </bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep456">
 <bp:stepProcess rdf:resource="#BiochemicalReaction350" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction243">
 <bp:evidence rdf:resource="#Evidence312" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutively active MAPK1 mutants are not dephosphorylated by DUSPs</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep457">
 <bp:stepProcess rdf:resource="#Pathway108" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction244">
 <bp:evidence rdf:resource="#Evidence315" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Homo- or heterodimerization of RAF downstream of mutant RAS</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep458">
 <bp:stepProcess rdf:resource="#BiochemicalReaction351" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction241">
 <bp:evidence rdf:resource="#Evidence309" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of high activity BRAF complexes</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep459">
 <bp:stepProcess rdf:resource="#Pathway109" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction242">
 <bp:evidence rdf:resource="#Evidence310" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Inhibitors bind and inhibit highly active BRAF mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction240">
 <bp:evidence rdf:resource="#Evidence308" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated MAP2Ks phosphorylate MAPKs downstream of high kinase activity BRAF mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep450">
 <bp:stepProcess rdf:resource="#BiochemicalReaction347" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep451">
 <bp:stepProcess rdf:resource="#Pathway105" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep452">
 <bp:stepProcess rdf:resource="#BiochemicalReaction348" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction258">
 <bp:evidence rdf:resource="#Evidence335" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PDPK1 phosphorylates AKT1 E17K mutant</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction259">
 <bp:evidence rdf:resource="#Evidence336" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates p21Cip1 and p27Kip1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction256">
 <bp:evidence rdf:resource="#Evidence333" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates BAD</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction257">
 <bp:evidence rdf:resource="#Evidence334" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PIP2-bound p-S473-AKT1 mutant binds PIP2-bound PDPK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction254">
 <bp:evidence rdf:resource="#Evidence330" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3K gain of function mutants phosphorylate PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction255">
 <bp:evidence rdf:resource="#Evidence332" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant is phosphorylated by TORC2 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction252">
 <bp:evidence rdf:resource="#Evidence326" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS GAP mutants aren&apos;t stimulated by GAPs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction253">
 <bp:evidence rdf:resource="#Evidence329" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3K inhibitors block PI3K catalytic activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction250">
 <bp:evidence rdf:resource="#Evidence321" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of oncogenic RAS:RAF complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction251">
 <bp:evidence rdf:resource="#Evidence324" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS GTPase mutants don&apos;t hydrolyze GTP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction269">
 <bp:evidence rdf:resource="#Evidence346" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant translocates to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction267">
 <bp:evidence rdf:resource="#Evidence344" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates caspase-9</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction268">
 <bp:evidence rdf:resource="#Evidence345" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates CREB1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction265">
 <bp:evidence rdf:resource="#Evidence342" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates NR4A1 (NUR77)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction266">
 <bp:evidence rdf:resource="#Evidence343" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant binds PIP2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction263">
 <bp:evidence rdf:resource="#Evidence340" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates AKT1S1 (PRAS40)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction264">
 <bp:evidence rdf:resource="#Evidence341" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT inhibitors block AKT membrane recruitment</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction261">
 <bp:evidence rdf:resource="#Evidence338" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates MDM2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction262">
 <bp:evidence rdf:resource="#Evidence339" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates TSC2, inhibiting it</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction260">
 <bp:evidence rdf:resource="#Evidence337" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates CHUK (IKKalpha)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction278">
 <bp:evidence rdf:resource="#Evidence359" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 homodimerization</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep400">
 <bp:stepProcess rdf:resource="#Catalysis93" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction309" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction279">
 <bp:evidence rdf:resource="#Evidence360" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 binds TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep401">
 <bp:stepProcess rdf:resource="#Pathway93" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction276">
 <bp:evidence rdf:resource="#Evidence355" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CLIP1-LTK fusion autophosphorylates</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep402">
 <bp:stepProcess rdf:resource="#Catalysis94" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction310" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction277">
 <bp:evidence rdf:resource="#Evidence356" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CLIP1(1-1083)-LTK(488-864) fusion dimerizes</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep403">
 <bp:stepProcess rdf:resource="#BiochemicalReaction311" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction274">
 <bp:evidence rdf:resource="#Evidence353" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CLIP1-LTK promotes MAPK1 and MAPK3 phosphorylation</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep404">
 <bp:stepProcess rdf:resource="#BiochemicalReaction312" />
 <bp:stepProcess rdf:resource="#Catalysis95" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction275">
 <bp:evidence rdf:resource="#Evidence354" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CLIP1-LTK fusion binds PI3K to activate AKT</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep405">
 <bp:stepProcess rdf:resource="#BiochemicalReaction313" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction272">
 <bp:evidence rdf:resource="#Evidence349" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates forkhead box transcription factors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction273">
 <bp:evidence rdf:resource="#Evidence351" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PTEN cancer mutants do not dephosphorylate PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction270">
 <bp:evidence rdf:resource="#Evidence347" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates GSK3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction271">
 <bp:evidence rdf:resource="#Evidence348" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates RSK</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep406">
 <bp:stepProcess rdf:resource="#BiochemicalReaction314" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep407">
 <bp:stepProcess rdf:resource="#BiochemicalReaction315" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep408">
 <bp:stepProcess rdf:resource="#BiochemicalReaction316" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep409">
 <bp:stepProcess rdf:resource="#Catalysis96" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction317" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep410">
 <bp:stepProcess rdf:resource="#Catalysis97" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction318" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction289">
 <bp:evidence rdf:resource="#Evidence375" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 KD mutants do not bind osimertinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep411">
 <bp:stepProcess rdf:resource="#BiochemicalReaction319" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep412">
 <bp:stepProcess rdf:resource="#BiochemicalReaction320" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction287">
 <bp:evidence rdf:resource="#Evidence371" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 T733I does not bind tesevatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep413">
 <bp:stepProcess rdf:resource="#BiochemicalReaction321" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction288">
 <bp:evidence rdf:resource="#Evidence373" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistant ERBB2 KD mutants do not bind neratinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep414">
 <bp:stepProcess rdf:resource="#BiochemicalReaction322" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction285">
 <bp:evidence rdf:resource="#Evidence366" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recruitment of GRB2:SOS1 to p-SHC1 in complex with phosphorylated ERBB2 homodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep415">
 <bp:stepProcess rdf:resource="#BiochemicalReaction323" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction286">
 <bp:evidence rdf:resource="#Evidence369" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 T862A does not bind sapitinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep416">
 <bp:stepProcess rdf:resource="#BiochemicalReaction324" />
 <bp:stepProcess rdf:resource="#Catalysis98" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction283">
 <bp:evidence rdf:resource="#Evidence364" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SHC1 binds phosphorylated ERBB2 homodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction284">
 <bp:evidence rdf:resource="#Evidence365" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS guanyl-nucleotide exchange mediated by SOS1 in complex with GRB2 and ERBB2 homodimer:p-SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction281">
 <bp:evidence rdf:resource="#Evidence362" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 homodimer phosphorylates SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction282">
 <bp:evidence rdf:resource="#Evidence363" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Trans-autophosphorylation of ERBB2 homodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction280">
 <bp:evidence rdf:resource="#Evidence361" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 binds trastuzumab</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction298">
 <bp:evidence rdf:resource="#Evidence390" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 ECD mutants and EGFR bind GRB2:GAB1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction299">
 <bp:evidence rdf:resource="#Evidence391" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 ECD mutants bind TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction296">
 <bp:evidence rdf:resource="#Evidence388" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Heterodimers of ERBB2 ECD mutants and EGFR trans-autophosphorylate</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction297">
 <bp:evidence rdf:resource="#Evidence389" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 ECD mutants and EGFR bind SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction294">
 <bp:evidence rdf:resource="#Evidence385" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 TMD/JMD mutants do not bind pertuzumab</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction295">
 <bp:evidence rdf:resource="#Evidence387" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 ECD mutants heterodimerize with EGFR</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction292">
 <bp:evidence rdf:resource="#Evidence381" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistant ERBB2 KD mutants do not bind AEE788</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction293">
 <bp:evidence rdf:resource="#Evidence383" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistant ERBB2 KD mutants do not bind lapatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction290">
 <bp:evidence rdf:resource="#Evidence377" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 T798M does not bind afatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction291">
 <bp:evidence rdf:resource="#Evidence379" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistant ERBB2 KD mutants do not bind trastuzumab</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep600">
 <bp:stepProcess rdf:resource="#BiochemicalReaction448" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep601">
 <bp:stepProcess rdf:resource="#Catalysis127" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction449" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep602">
 <bp:stepProcess rdf:resource="#BiochemicalReaction450" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep603">
 <bp:stepProcess rdf:resource="#BiochemicalReaction451" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep604">
 <bp:stepProcess rdf:resource="#BiochemicalReaction452" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep605">
 <bp:stepProcess rdf:resource="#BiochemicalReaction453" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep606">
 <bp:stepProcess rdf:resource="#BiochemicalReaction454" />
 <bp:stepProcess rdf:resource="#Catalysis128" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep607">
 <bp:stepProcess rdf:resource="#BiochemicalReaction455" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep608">
 <bp:stepProcess rdf:resource="#Pathway154" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep609">
 <bp:stepProcess rdf:resource="#BiochemicalReaction456" />
 <bp:stepProcess rdf:resource="#Catalysis129" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep610">
 <bp:stepProcess rdf:resource="#BiochemicalReaction457" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep611">
 <bp:stepProcess rdf:resource="#Catalysis130" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction458" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep612">
 <bp:stepProcess rdf:resource="#BiochemicalReaction459" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep613">
 <bp:stepProcess rdf:resource="#BiochemicalReaction460" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep614">
 <bp:stepProcess rdf:resource="#BiochemicalReaction461" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence330">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence332">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence331">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence327">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence326">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence329">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence328">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence323">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence322">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence325">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence324">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence341">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence340">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence343">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence342">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction9">
 <bp:evidence rdf:resource="#Evidence12" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK mutants bind PI3KCA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction8">
 <bp:evidence rdf:resource="#Evidence11" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of ALK fusions</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction7">
 <bp:evidence rdf:resource="#Evidence10" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK fusions phosphorylate IRS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction6">
 <bp:evidence rdf:resource="#Evidence9" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK fusions bind FRS</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence338">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction5">
 <bp:evidence rdf:resource="#Evidence8" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK fusions phosphorylate FRS</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence337">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction4">
 <bp:evidence rdf:resource="#Evidence7" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK fusions phosphorylate PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction3">
 <bp:evidence rdf:resource="#Evidence6" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK mutants phosphorylate STAT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence339">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction2">
 <bp:evidence rdf:resource="#Evidence5" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autophosphorylation of ALK fusions</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence334">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1">
 <bp:evidence rdf:resource="#Evidence4" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3K synthesizes PIP3 downstream of ALK mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence333">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence336">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence335">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence352">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence351">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence354">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence353">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence350">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence349">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence348">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence345">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence344">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence347">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence346">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence363">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence362">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence365">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence364">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence361">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence360">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence359">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence356">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence355">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence358">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence357">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence374">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction20">
 <bp:evidence rdf:resource="#Evidence23" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-T,Y MAPK8,9 translocate to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence373">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction21">
 <bp:evidence rdf:resource="#Evidence24" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-T,Y MAPK8,9 bind TP53</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence376">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction22">
 <bp:evidence rdf:resource="#Evidence25" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">JNK-dependent inhibition of TP53 ubiquitination</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence375">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence370">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence372">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep180">
 <bp:stepProcess rdf:resource="#BiochemicalReaction152" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence371">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction27">
 <bp:evidence rdf:resource="#Evidence30" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK mutants bind STAT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction28">
 <bp:evidence rdf:resource="#Evidence31" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MYH9- and RNF213-ALK fusions are phosphorylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction29">
 <bp:evidence rdf:resource="#Evidence33" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK and FOXM1-dependent CCNB1 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction23">
 <bp:evidence rdf:resource="#Evidence26" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK fusions bind GRB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction24">
 <bp:evidence rdf:resource="#Evidence27" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK mutants:p-3Y SHC binds GRB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis9">
 <bp:controlled rdf:resource="#BiochemicalReaction61" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction25">
 <bp:evidence rdf:resource="#Evidence28" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">pY-STAT3 dimer translocates to the nucleus downstream of ALK mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction26">
 <bp:evidence rdf:resource="#Evidence29" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK mutants bind PI3KR1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis6">
 <bp:controlled rdf:resource="#BiochemicalReaction7" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep189">
 <bp:stepProcess rdf:resource="#BiochemicalReaction161" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis5">
 <bp:controlled rdf:resource="#BiochemicalReaction5" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis8">
 <bp:controlled rdf:resource="#BiochemicalReaction53" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis7">
 <bp:controlled rdf:resource="#BiochemicalReaction15" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis2">
 <bp:controlled rdf:resource="#BiochemicalReaction2" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis1">
 <bp:controlled rdf:resource="#BiochemicalReaction1" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis4">
 <bp:controlled rdf:resource="#BiochemicalReaction4" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis3">
 <bp:controlled rdf:resource="#BiochemicalReaction3" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep181">
 <bp:stepProcess rdf:resource="#BiochemicalReaction153" />
 <bp:stepProcess rdf:resource="#Catalysis31" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep182">
 <bp:stepProcess rdf:resource="#BiochemicalReaction154" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep183">
 <bp:stepProcess rdf:resource="#BiochemicalReaction155" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep184">
 <bp:stepProcess rdf:resource="#BiochemicalReaction156" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep185">
 <bp:stepProcess rdf:resource="#BiochemicalReaction157" />
 <bp:stepProcess rdf:resource="#Catalysis32" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence367">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep186">
 <bp:stepProcess rdf:resource="#BiochemicalReaction158" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence366">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep187">
 <bp:stepProcess rdf:resource="#BiochemicalReaction159" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence369">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep188">
 <bp:stepProcess rdf:resource="#BiochemicalReaction160" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence368">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence385">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence384">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction10">
 <bp:evidence rdf:resource="#Evidence13" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK- and PI3K-dependent MDM2 phosphorylation</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence387">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction11">
 <bp:evidence rdf:resource="#Evidence14" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK mutants bind SHC</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence386">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence381">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence380">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep190">
 <bp:stepProcess rdf:resource="#BiochemicalReaction162" />
 <bp:stepProcess rdf:resource="#Catalysis33" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence383">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep191">
 <bp:stepProcess rdf:resource="#BiochemicalReaction163" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence382">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction16">
 <bp:evidence rdf:resource="#Evidence19" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK- and JNK-dependent JUN phosphorylation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction17">
 <bp:evidence rdf:resource="#Evidence20" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TYK2-dependent STAT1 and STAT3 phosphorylation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction18">
 <bp:evidence rdf:resource="#Evidence21" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK-dependent MAPK8,9 phosphorylation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction19">
 <bp:evidence rdf:resource="#Evidence22" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK fusion proteins bind PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction12">
 <bp:evidence rdf:resource="#Evidence15" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of point mutants of ALK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction13">
 <bp:evidence rdf:resource="#Evidence16" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK fusion proteins bind IRS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction14">
 <bp:evidence rdf:resource="#Evidence17" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK- and JUN-dependent CDKN1A gene repression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction15">
 <bp:evidence rdf:resource="#Evidence18" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autophosphorylation of point mutants of ALK</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep192">
 <bp:stepProcess rdf:resource="#Pathway30" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep193">
 <bp:stepProcess rdf:resource="#Pathway31" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep194">
 <bp:stepProcess rdf:resource="#BiochemicalReaction164" />
 <bp:stepProcess rdf:resource="#Catalysis34" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep195">
 <bp:stepProcess rdf:resource="#BiochemicalReaction165" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep196">
 <bp:stepProcess rdf:resource="#BiochemicalReaction166" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence378">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep197">
 <bp:stepProcess rdf:resource="#BiochemicalReaction167" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence377">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep198">
 <bp:stepProcess rdf:resource="#BiochemicalReaction168" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep199">
 <bp:stepProcess rdf:resource="#Pathway32" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence379">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence396">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence395">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence398">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence397">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence392">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence391">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence394">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence393">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence390">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence389">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence388">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence399">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction63">
 <bp:evidence rdf:resource="#Evidence67" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK- and TYK2-dependent MCL1 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction64">
 <bp:evidence rdf:resource="#Evidence70" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ceritinib-resistant ALK mutants don&apos;t bind ceritinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction65">
 <bp:evidence rdf:resource="#Evidence72" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">crizotinib-resistant ALK mutants don&apos;t bind crizotinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction66">
 <bp:evidence rdf:resource="#Evidence74" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">lorlatinib-resistant ALK mutants don&apos;t bind lorlatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction60">
 <bp:evidence rdf:resource="#Evidence64" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK- and p-STAT3-dependent IRF4 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction61">
 <bp:evidence rdf:resource="#Evidence65" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK mutants phosphorylate SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction62">
 <bp:evidence rdf:resource="#Evidence66" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK-dependent TYK2 phosphorylation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction67">
 <bp:evidence rdf:resource="#Evidence76" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ASP-3026- resistant ALK mutants don&apos;t bind ASP-3026</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction68">
 <bp:evidence rdf:resource="#Evidence78" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">brigatinib-resistant ALK mutants don&apos;t bind brigatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction69">
 <bp:evidence rdf:resource="#Evidence80" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NVP-TAE684-resistant ALK mutants don&apos;t bind NVP-TAE684</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep145">
 <bp:stepProcess rdf:resource="#BiochemicalReaction121" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep146">
 <bp:stepProcess rdf:resource="#BiochemicalReaction122" />
 <bp:stepProcess rdf:resource="#Catalysis26" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep147">
 <bp:stepProcess rdf:resource="#BiochemicalReaction123" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep148">
 <bp:stepProcess rdf:resource="#BiochemicalReaction124" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep149">
 <bp:stepProcess rdf:resource="#BiochemicalReaction125" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep140">
 <bp:stepProcess rdf:resource="#BiochemicalReaction118" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep141">
 <bp:stepProcess rdf:resource="#BiochemicalReaction119" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep142">
 <bp:stepProcess rdf:resource="#BiochemicalReaction120" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep143">
 <bp:stepProcess rdf:resource="#Pathway24" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep144">
 <bp:stepProcess rdf:resource="#Pathway25" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction52">
 <bp:evidence rdf:resource="#Evidence56" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AcK685-pY705,S727 STAT3 dimer binds DNMT1 promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis18">
 <bp:controlled rdf:resource="#BiochemicalReaction102" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction53">
 <bp:evidence rdf:resource="#Evidence57" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPK1 phsophorylates ZC3HCF1 in a NPM-ALK-dependent manner</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis19">
 <bp:controlled rdf:resource="#BiochemicalReaction107" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction54">
 <bp:evidence rdf:resource="#Evidence58" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK- and STAT3-dependent TWIST gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction55">
 <bp:evidence rdf:resource="#Evidence59" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-Y705, S727 STAT3 dimer binds ICOS promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction50">
 <bp:evidence rdf:resource="#Evidence54" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT3-, DNMT1 and NPM1-ALK-dependent ZAP70 gene silencing</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction51">
 <bp:evidence rdf:resource="#Evidence55" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK-stimulated PRF1 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction56">
 <bp:evidence rdf:resource="#Evidence60" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK-dependent JUNB translation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction57">
 <bp:evidence rdf:resource="#Evidence61" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK- and STAT3-dependent ICOS gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction58">
 <bp:evidence rdf:resource="#Evidence62" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">pY-STAT3 binds the IRF4 promoter downstream of NPM1-ALK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction59">
 <bp:evidence rdf:resource="#Evidence63" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK-dependent CEBPB gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep156">
 <bp:stepProcess rdf:resource="#BiochemicalReaction132" />
 <bp:stepProcess rdf:resource="#Catalysis28" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep157">
 <bp:stepProcess rdf:resource="#BiochemicalReaction133" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep158">
 <bp:stepProcess rdf:resource="#BiochemicalReaction134" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep159">
 <bp:stepProcess rdf:resource="#Catalysis29" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction135" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis10">
 <bp:controlled rdf:resource="#BiochemicalReaction74" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis11">
 <bp:controlled rdf:resource="#BiochemicalReaction80" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis12">
 <bp:controlled rdf:resource="#BiochemicalReaction84" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep150">
 <bp:stepProcess rdf:resource="#BiochemicalReaction126" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis13">
 <bp:controlled rdf:resource="#BiochemicalReaction86" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep151">
 <bp:stepProcess rdf:resource="#BiochemicalReaction127" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis14">
 <bp:controlled rdf:resource="#BiochemicalReaction88" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep152">
 <bp:stepProcess rdf:resource="#BiochemicalReaction128" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis15">
 <bp:controlled rdf:resource="#BiochemicalReaction91" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep153">
 <bp:stepProcess rdf:resource="#BiochemicalReaction129" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis16">
 <bp:controlled rdf:resource="#BiochemicalReaction95" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep154">
 <bp:stepProcess rdf:resource="#BiochemicalReaction130" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis17">
 <bp:controlled rdf:resource="#BiochemicalReaction96" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep155">
 <bp:stepProcess rdf:resource="#BiochemicalReaction131" />
 <bp:stepProcess rdf:resource="#Catalysis27" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction41">
 <bp:evidence rdf:resource="#Evidence45" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">miR-21 RISC binds DNMT1 mRNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis29">
 <bp:controlled rdf:resource="#BiochemicalReaction135" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction42">
 <bp:evidence rdf:resource="#Evidence46" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Translation of DNMT1 mRNA is repressed by miR-21</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction43">
 <bp:evidence rdf:resource="#Evidence47" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AcK685 pY705,S727 STAT3 binds the MIR21 gene</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction44">
 <bp:evidence rdf:resource="#Evidence48" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK-dependent repression of pRB phosphorylation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction40">
 <bp:evidence rdf:resource="#Evidence44" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK-, STAT3- and MECP2-dependent STAT5A gene repression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction49">
 <bp:evidence rdf:resource="#Evidence53" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Crizotinib-driven IL10RA gene expression in NPM1-ALK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction45">
 <bp:evidence rdf:resource="#Evidence49" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-Y705,S727 STAT3 dimer binds NOTCH gene</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction46">
 <bp:evidence rdf:resource="#Evidence50" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK- and p-STAT3-dependent NOTCH gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction47">
 <bp:evidence rdf:resource="#Evidence51" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MECP2 binds the STAT5A gene</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction48">
 <bp:evidence rdf:resource="#Evidence52" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT3, DNMT1 and HDAC1 bind PTPN6 gene</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep167">
 <bp:stepProcess rdf:resource="#Pathway27" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep168">
 <bp:stepProcess rdf:resource="#BiochemicalReaction142" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep169">
 <bp:stepProcess rdf:resource="#Pathway28" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis20">
 <bp:controlled rdf:resource="#BiochemicalReaction109" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis21">
 <bp:controlled rdf:resource="#BiochemicalReaction110" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis22">
 <bp:controlled rdf:resource="#BiochemicalReaction111" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep160">
 <bp:stepProcess rdf:resource="#BiochemicalReaction136" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis23">
 <bp:controlled rdf:resource="#BiochemicalReaction114" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep161">
 <bp:stepProcess rdf:resource="#BiochemicalReaction137" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis24">
 <bp:controlled rdf:resource="#BiochemicalReaction116" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep162">
 <bp:stepProcess rdf:resource="#BiochemicalReaction138" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis25">
 <bp:controlled rdf:resource="#BiochemicalReaction117" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep163">
 <bp:stepProcess rdf:resource="#BiochemicalReaction139" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis26">
 <bp:controlled rdf:resource="#BiochemicalReaction122" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep164">
 <bp:stepProcess rdf:resource="#BiochemicalReaction140" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis27">
 <bp:controlled rdf:resource="#BiochemicalReaction131" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep165">
 <bp:stepProcess rdf:resource="#BiochemicalReaction141" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis28">
 <bp:controlled rdf:resource="#BiochemicalReaction132" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep166">
 <bp:stepProcess rdf:resource="#Pathway26" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction30">
 <bp:evidence rdf:resource="#Evidence34" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK binds NPM1 and FOXM1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction31">
 <bp:evidence rdf:resource="#Evidence35" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK translocates to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction32">
 <bp:evidence rdf:resource="#Evidence36" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">JUNB- and NPM1-ALK-mediated GZMB gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction33">
 <bp:evidence rdf:resource="#Evidence37" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK-dependent JUNB gene transcription</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction38">
 <bp:evidence rdf:resource="#Evidence42" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT3-dependent DNMT1 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction39">
 <bp:evidence rdf:resource="#Evidence43" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">JUNB dimer binds GZMB promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction34">
 <bp:evidence rdf:resource="#Evidence38" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK fusion dimer binds SKP1:CUL1:RBX1:ZC3HC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction35">
 <bp:evidence rdf:resource="#Evidence39" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK-dependent BCL2A1 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction36">
 <bp:evidence rdf:resource="#Evidence40" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT3-dependent MIR-21 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction37">
 <bp:evidence rdf:resource="#Evidence41" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DNMT1-dependent PTPN6 gene silencing</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep178">
 <bp:stepProcess rdf:resource="#BiochemicalReaction150" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep179">
 <bp:stepProcess rdf:resource="#BiochemicalReaction151" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis30">
 <bp:controlled rdf:resource="#BiochemicalReaction144" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis31">
 <bp:controlled rdf:resource="#BiochemicalReaction153" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep170">
 <bp:stepProcess rdf:resource="#Pathway29" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis32">
 <bp:controlled rdf:resource="#BiochemicalReaction157" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep171">
 <bp:stepProcess rdf:resource="#BiochemicalReaction143" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis33">
 <bp:controlled rdf:resource="#BiochemicalReaction162" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep172">
 <bp:stepProcess rdf:resource="#BiochemicalReaction144" />
 <bp:stepProcess rdf:resource="#Catalysis30" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis34">
 <bp:controlled rdf:resource="#BiochemicalReaction164" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep173">
 <bp:stepProcess rdf:resource="#BiochemicalReaction145" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis35">
 <bp:controlled rdf:resource="#BiochemicalReaction176" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep174">
 <bp:stepProcess rdf:resource="#BiochemicalReaction146" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis36">
 <bp:controlled rdf:resource="#BiochemicalReaction177" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep175">
 <bp:stepProcess rdf:resource="#BiochemicalReaction147" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis37">
 <bp:controlled rdf:resource="#BiochemicalReaction181" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep176">
 <bp:stepProcess rdf:resource="#BiochemicalReaction148" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis38">
 <bp:controlled rdf:resource="#BiochemicalReaction183" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep177">
 <bp:stepProcess rdf:resource="#BiochemicalReaction149" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis39">
 <bp:controlled rdf:resource="#BiochemicalReaction184" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep101">
 <bp:stepProcess rdf:resource="#BiochemicalReaction84" />
 <bp:stepProcess rdf:resource="#Catalysis12" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep585">
 <bp:stepProcess rdf:resource="#BiochemicalReaction437" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep102">
 <bp:stepProcess rdf:resource="#BiochemicalReaction85" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep586">
 <bp:stepProcess rdf:resource="#Pathway150" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep103">
 <bp:stepProcess rdf:resource="#BiochemicalReaction86" />
 <bp:stepProcess rdf:resource="#Catalysis13" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep587">
 <bp:stepProcess rdf:resource="#BiochemicalReaction438" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep104">
 <bp:stepProcess rdf:resource="#BiochemicalReaction87" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep588">
 <bp:stepProcess rdf:resource="#BiochemicalReaction439" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep105">
 <bp:stepProcess rdf:resource="#BiochemicalReaction88" />
 <bp:stepProcess rdf:resource="#Catalysis14" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence408">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep589">
 <bp:stepProcess rdf:resource="#BiochemicalReaction440" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep106">
 <bp:stepProcess rdf:resource="#BiochemicalReaction89" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence407">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep107">
 <bp:stepProcess rdf:resource="#BiochemicalReaction90" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep108">
 <bp:stepProcess rdf:resource="#BiochemicalReaction91" />
 <bp:stepProcess rdf:resource="#Catalysis15" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence409">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence404">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence403">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence406">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence405">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep580">
 <bp:stepProcess rdf:resource="#Pathway147" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence400">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep581">
 <bp:stepProcess rdf:resource="#BiochemicalReaction435" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep582">
 <bp:stepProcess rdf:resource="#Pathway148" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence402">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep583">
 <bp:stepProcess rdf:resource="#BiochemicalReaction436" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep100">
 <bp:stepProcess rdf:resource="#BiochemicalReaction83" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence401">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep584">
 <bp:stepProcess rdf:resource="#Pathway149" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction96">
 <bp:evidence rdf:resource="#Evidence116" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with ligand-responsive p-6Y-EGFR mutants)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction97">
 <bp:evidence rdf:resource="#Evidence117" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of PI3K to complex of GRB2:GAB1 and ligand-responsive p-6Y-EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction98">
 <bp:evidence rdf:resource="#Evidence118" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of CBL to ligand-responsive p-6Y-EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence420">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction99">
 <bp:evidence rdf:resource="#Evidence119" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Non-covalent tyrosine kinase inhibitors bind and inactivate sensitive ligand-responsive EGFR cancer mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction92">
 <bp:evidence rdf:resource="#Evidence112" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of ligand-responsive EGFR mutants to chaperoning proteins HSP90 and CDC37</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction93">
 <bp:evidence rdf:resource="#Evidence113" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of SHC1 to p-6Y-EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction94">
 <bp:evidence rdf:resource="#Evidence114" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of GRB2:SOS1 complex to phosphorylated ligand-responsive EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction95">
 <bp:evidence rdf:resource="#Evidence115" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Conversion of PIP2 to PIP3 by PI3K bound to ligand-responsive p-6Y-EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep109">
 <bp:stepProcess rdf:resource="#Pathway19" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction308">
 <bp:evidence rdf:resource="#Evidence400" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 ECD mutants and EGFR phosphorylate SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction309">
 <bp:evidence rdf:resource="#Evidence401" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3K bound to phosphorylated heterodimers of ERBB2 ECD mutants and EGFR converts PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction306">
 <bp:evidence rdf:resource="#Evidence398" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS guanyl nucleotide exchange mediated by the p-6Y- ERBB2 ECD mutants:EGF:p-6Y-EGFR:p-SHC1:GRB2:SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction307">
 <bp:evidence rdf:resource="#Evidence399" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 ECD mutants bind trastuzumab</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction304">
 <bp:evidence rdf:resource="#Evidence396" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 ECD mutants and EGFR bind PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction305">
 <bp:evidence rdf:resource="#Evidence397" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 ECD mutants and EGFR phosphorylate PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep112">
 <bp:stepProcess rdf:resource="#BiochemicalReaction93" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction302">
 <bp:evidence rdf:resource="#Evidence394" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS activation by SOS1 bound to phosphorylated heterodimers of ERBB2 ECD mutants and EGFR through GRB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep596">
 <bp:stepProcess rdf:resource="#BiochemicalReaction445" />
 <bp:stepProcess rdf:resource="#Catalysis124" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep113">
 <bp:stepProcess rdf:resource="#BiochemicalReaction94" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction303">
 <bp:evidence rdf:resource="#Evidence395" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GRB2:SOS1 binds to phosphorylated heterodimers of ERBB2 ECD mutants and EGFR</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep597">
 <bp:stepProcess rdf:resource="#BiochemicalReaction446" />
 <bp:stepProcess rdf:resource="#Catalysis125" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep114">
 <bp:stepProcess rdf:resource="#BiochemicalReaction95" />
 <bp:stepProcess rdf:resource="#Catalysis16" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction300">
 <bp:evidence rdf:resource="#Evidence392" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 ECD mutants and EGFR recruit GRB2:SOS1 through SHC1 </bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep598">
 <bp:stepProcess rdf:resource="#Pathway153" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep115">
 <bp:stepProcess rdf:resource="#BiochemicalReaction96" />
 <bp:stepProcess rdf:resource="#Catalysis17" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction301">
 <bp:evidence rdf:resource="#Evidence393" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 ECD mutants and EGFR, in complex with GRB2:GAB1, bind PI3K</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep599">
 <bp:stepProcess rdf:resource="#Catalysis126" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction447" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep116">
 <bp:stepProcess rdf:resource="#BiochemicalReaction97" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence419">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep117">
 <bp:stepProcess rdf:resource="#BiochemicalReaction98" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence418">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep118">
 <bp:stepProcess rdf:resource="#BiochemicalReaction99" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep119">
 <bp:stepProcess rdf:resource="#BiochemicalReaction100" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence415">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence414">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence417">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep590">
 <bp:stepProcess rdf:resource="#Pathway151" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence416">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep591">
 <bp:stepProcess rdf:resource="#Pathway152" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence411">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep592">
 <bp:stepProcess rdf:resource="#BiochemicalReaction441" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence410">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep593">
 <bp:stepProcess rdf:resource="#BiochemicalReaction442" />
 <bp:stepProcess rdf:resource="#Catalysis123" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep110">
 <bp:stepProcess rdf:resource="#Pathway20" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence413">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep594">
 <bp:stepProcess rdf:resource="#BiochemicalReaction443" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep111">
 <bp:stepProcess rdf:resource="#BiochemicalReaction92" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence412">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep595">
 <bp:stepProcess rdf:resource="#BiochemicalReaction444" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction85">
 <bp:evidence rdf:resource="#Evidence103" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PLC-gamma 1 binds to p-EGFRvIII mutant</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction86">
 <bp:evidence rdf:resource="#Evidence104" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with p-EGFRvIII)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction87">
 <bp:evidence rdf:resource="#Evidence105" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HSP90 is inactivated by binding to benzaquinoid ansamycins</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence431">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction88">
 <bp:evidence rdf:resource="#Evidence106" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Trans-autophosphorylation of EGFRvIII mutant dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence430">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction81">
 <bp:evidence rdf:resource="#Evidence99" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of GRB2:GAB1 complex to p-EGFRvIII mutant</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction82">
 <bp:evidence rdf:resource="#Evidence100" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of PI3K to complex of GRB2:GAB1 and p-EGFRvIII</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction83">
 <bp:evidence rdf:resource="#Evidence101" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">EGFRvIII does not bind CBL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction84">
 <bp:evidence rdf:resource="#Evidence102" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of PLC-gamma 1 by p-EGFRvIII mutant</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction319">
 <bp:evidence rdf:resource="#Evidence412" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 KD mutants bind TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction89">
 <bp:evidence rdf:resource="#Evidence107" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of GRB2:SOS1 complex to phosphorylated EGFRvIII</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction317">
 <bp:evidence rdf:resource="#Evidence410" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3K bound to phosphorylated heterodimers of ERBB2 KD mutants and ERBB3 converts PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction318">
 <bp:evidence rdf:resource="#Evidence411" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS activation by SOS1 bound to phosphorylated heterodimers of ERBB2 KD mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction315">
 <bp:evidence rdf:resource="#Evidence408" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 KD mutants and EGFR bind GRB2:GAB1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction316">
 <bp:evidence rdf:resource="#Evidence409" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 KD mutants bind SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep123">
 <bp:stepProcess rdf:resource="#BiochemicalReaction104" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction313">
 <bp:evidence rdf:resource="#Evidence406" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 KD mutants heterodimerize</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep124">
 <bp:stepProcess rdf:resource="#BiochemicalReaction105" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction314">
 <bp:evidence rdf:resource="#Evidence407" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 KD mutants recruit GRB2:SOS1 through SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep125">
 <bp:stepProcess rdf:resource="#BiochemicalReaction106" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction311">
 <bp:evidence rdf:resource="#Evidence404" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 KD mutants bind trastuzumab</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep126">
 <bp:stepProcess rdf:resource="#Catalysis19" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction107" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction312">
 <bp:evidence rdf:resource="#Evidence405" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 KD mutants phosphorylate SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep127">
 <bp:stepProcess rdf:resource="#BiochemicalReaction108" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep128">
 <bp:stepProcess rdf:resource="#Catalysis20" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction109" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction310">
 <bp:evidence rdf:resource="#Evidence403" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS activation by SOS1 bound to phosphorylated heterodimers of ERBB2 KD mutants and EGFR</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence429">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep129">
 <bp:stepProcess rdf:resource="#BiochemicalReaction110" />
 <bp:stepProcess rdf:resource="#Catalysis21" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence426">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence425">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction90">
 <bp:evidence rdf:resource="#Evidence108" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of phosphorylated PLC-gamma 1 from p-EGFRvIII mutant</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence428">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction91">
 <bp:evidence rdf:resource="#Evidence109" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Conversion of PIP2 to PIP3 by PI3K bound to phosphorylated EGFRvIII</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence427">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence422">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep120">
 <bp:stepProcess rdf:resource="#BiochemicalReaction101" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence421">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep121">
 <bp:stepProcess rdf:resource="#Catalysis18" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction102" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence424">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep122">
 <bp:stepProcess rdf:resource="#BiochemicalReaction103" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence423">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction74">
 <bp:evidence rdf:resource="#Evidence92" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with phosphorylated SHC1 and p-EGFRvIII)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence440">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction75">
 <bp:evidence rdf:resource="#Evidence93" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">EGFRvIII mutant binds chaperone proteins HSP90 and CDC37</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction76">
 <bp:evidence rdf:resource="#Evidence94" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">EGFRvIII cancer variant does not bind EGF ligand</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence442">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction77">
 <bp:evidence rdf:resource="#Evidence95" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of SHC1 to p-5Y-EGFRvIII</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence441">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway6">
 <bp:pathwayOrder rdf:resource="#PathwayStep69" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction64" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence69" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ceritinib-resistant ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ceritinib is a type I TKI that is effective against ALK driven cancers and is approved for treatment of NSCLC. Ceritinib is a second-generation TKI that shows activity against a number of crizotinib-resistant ALK alleles, however, resistance to ceritinib has also been documented. This pathway describes ALK mutants that are resistant to inhibition with ceritinib (reviewed in Lovly and Pao, 2012; Lin et al, 2017; Della Corte et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction70">
 <bp:evidence rdf:resource="#Evidence82" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">alectinib resistant ALK mutants don&apos;t bind alectinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway7">
 <bp:pathwayOrder rdf:resource="#PathwayStep71" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction65" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence71" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">crizotinib-resistant ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Crizotinib is a type I tyrosine kinase inhibitor that is approved for treatment of ALK-positive non-small cell lung cancer. Crizotinib is also effective against ALCL and IMTs. Development of resistance to crizotinib is not uncommon, however, with patients acquiring secondary mutations or amplifications of the ALK gene that limit the effectiveness of the drug. This pathway describes ALK mutants that are resistant to crizotinib-mediated inhibition (reviewed in Roskoski, 2013; Lin et al, 2017; Della Corte et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction71">
 <bp:evidence rdf:resource="#Evidence84" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK mutants bind type I TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway8">
 <bp:pathwayOrder rdf:resource="#PathwayStep73" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction66" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence73" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">lorlatinib-resistant ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Lorlatinib is a third generation tyrosine kinase inhibitor with effectiveness against ALK and ROS rearranged cancers. This pathway describes ALK mutants that are resistant to inhibition by lorlatinib (Yoda et al, 2018; Takahashi et al, 2020; reviewed in Della Corte et al, 2018; Lin et al, 2017; Facchinietti et al, 2016).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction72">
 <bp:evidence rdf:resource="#Evidence88" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Covalent tyrosine kinase inhibitors bind and inhibit wild-type EGF:EGFR dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway9">
 <bp:pathwayOrder rdf:resource="#PathwayStep75" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction67" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence75" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ASP-3026-resistant ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ASP3026 is a second generation tyrosine kinase inhibitor with activity against ALK fusions in non-small cell lung cancers (NSCLC) and anaplastic large cell lymphomas (ALCLs). This pathway describes ALK mutants that are resistant to inhibition by ASP3026 (Amin et al, 2016; Katayama et al, 2014; George et al, 2008; Mori et al, 2014; reviewed Roskoski, 2013; Lovly and Pao, 2012)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction73">
 <bp:evidence rdf:resource="#Evidence89" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Inactivation of over-expressed wild type EGFR by Cetuximab recombinant antibody</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway2">
 <bp:pathwayOrder rdf:resource="#PathwayStep2" />
 <bp:pathwayOrder rdf:resource="#PathwayStep67" />
 <bp:pathwayOrder rdf:resource="#PathwayStep82" />
 <bp:pathwayComponent rdf:resource="#Pathway13" />
 <bp:pathwayComponent rdf:resource="#Pathway3" />
 <bp:pathwayComponent rdf:resource="#Pathway5" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by ALK in cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Anaplastic lymphoma kinase (ALK) was first identified in the context of an oncogenic fusion with nucleophosmin (NPM) in anaplastic large cell lymphoma (ALCL) (Morris et al, 1994). NPM-ALK fusions occur in approximately 75-80% of ALCL cases and at lower frequencies in other cancers, including non-small cell lung cancer, neuroblastoma and inflammatory myofibroblastic tumors (IFTs) (Morris et al, 1994; Shiota et al, 1994; reviewed in Della Corte et al, 2018; Werner et al, 2017).   In addition to NPM, fusions of ALK with nearly 30 other 5&apos; partners have since been identified, although these tend to occur at lower frequencies in the cancers in which they appear (reviewed in Chiarle et al, 2008; Della Corte et al, 2018; Roskoski, 2013; Hallberg and Palmer, 2016). In general, ALK fusions combine the 5&apos; end of the partner gene which contributes a dimerization domain with the intracellular portion of the ALK receptor including the kinase domain, and lead to constitutive signaling by virtue of the partner-domain mediated dimerization (reviewed in Roskoski, 2013; Della Corte et al, 2018).   In addition to translocation events that lead to fusion proteins, the ALK gene also contributes to oncogenesis as a result of gene amplification and overexpression events, as well as being subject to activating missense mutations (reviewed in Della Corte et al, 2018; Hallberg and Palmer, 2016).    Oncogenic ALK activity can be targeted with tyrosine kinase inhibitors, although resistance often arises due to secondary mutations or activation of bypass pathways (reviewed in Roskoski, 2013; Della Corte et al, 2018; Hallberg and Palmer, 2016; Werner et al, 2017; Lovly and Pao, 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway3">
 <bp:pathwayOrder rdf:resource="#PathwayStep21" />
 <bp:pathwayOrder rdf:resource="#PathwayStep65" />
 <bp:pathwayOrder rdf:resource="#PathwayStep20" />
 <bp:pathwayOrder rdf:resource="#PathwayStep64" />
 <bp:pathwayOrder rdf:resource="#PathwayStep23" />
 <bp:pathwayOrder rdf:resource="#PathwayStep22" />
 <bp:pathwayOrder rdf:resource="#PathwayStep66" />
 <bp:pathwayOrder rdf:resource="#PathwayStep25" />
 <bp:pathwayOrder rdf:resource="#PathwayStep24" />
 <bp:pathwayOrder rdf:resource="#PathwayStep27" />
 <bp:pathwayOrder rdf:resource="#PathwayStep26" />
 <bp:pathwayOrder rdf:resource="#PathwayStep18" />
 <bp:pathwayOrder rdf:resource="#PathwayStep17" />
 <bp:pathwayOrder rdf:resource="#PathwayStep19" />
 <bp:pathwayOrder rdf:resource="#PathwayStep10" />
 <bp:pathwayOrder rdf:resource="#PathwayStep3" />
 <bp:pathwayOrder rdf:resource="#PathwayStep31" />
 <bp:pathwayOrder rdf:resource="#PathwayStep4" />
 <bp:pathwayOrder rdf:resource="#PathwayStep12" />
 <bp:pathwayOrder rdf:resource="#PathwayStep5" />
 <bp:pathwayOrder rdf:resource="#PathwayStep11" />
 <bp:pathwayOrder rdf:resource="#PathwayStep6" />
 <bp:pathwayOrder rdf:resource="#PathwayStep14" />
 <bp:pathwayOrder rdf:resource="#PathwayStep7" />
 <bp:pathwayOrder rdf:resource="#PathwayStep13" />
 <bp:pathwayOrder rdf:resource="#PathwayStep8" />
 <bp:pathwayOrder rdf:resource="#PathwayStep16" />
 <bp:pathwayOrder rdf:resource="#PathwayStep9" />
 <bp:pathwayOrder rdf:resource="#PathwayStep15" />
 <bp:pathwayOrder rdf:resource="#PathwayStep30" />
 <bp:pathwayOrder rdf:resource="#PathwayStep29" />
 <bp:pathwayOrder rdf:resource="#PathwayStep28" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction63" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction20" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction21" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction22" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction61" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction62" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction27" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction28" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction23" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction24" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction25" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction26" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction10" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction11" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction9" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction8" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction7" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction16" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction17" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction18" />
 <bp:pathwayComponent rdf:resource="#Pathway4" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction19" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction12" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction13" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction14" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction15" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction6" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction5" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction4" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction3" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction2" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence3" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by ALK fusions and activated point mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK is activated in a range of cancers as a result of amplification or overexpression, fusion event or activating point mutations, resulting, in general, in constitutive activation of intracellular signaling. The major pathways initiated downstream of activated ALK are STAT3 and, to a lesser extent, STAT5 signaling and signaling through the MAP kinase, PI3K/AKT and PLC gamma cascades (reviewed in Della Corte et al, 2018; Hallberg and Palmer, 2013; Hallberg and Palmer, 2016; Chiarle et al, 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway4">
 <bp:pathwayOrder rdf:resource="#PathwayStep43" />
 <bp:pathwayOrder rdf:resource="#PathwayStep42" />
 <bp:pathwayOrder rdf:resource="#PathwayStep45" />
 <bp:pathwayOrder rdf:resource="#PathwayStep44" />
 <bp:pathwayOrder rdf:resource="#PathwayStep47" />
 <bp:pathwayOrder rdf:resource="#PathwayStep46" />
 <bp:pathwayOrder rdf:resource="#PathwayStep49" />
 <bp:pathwayOrder rdf:resource="#PathwayStep48" />
 <bp:pathwayOrder rdf:resource="#PathwayStep61" />
 <bp:pathwayOrder rdf:resource="#PathwayStep60" />
 <bp:pathwayOrder rdf:resource="#PathwayStep41" />
 <bp:pathwayOrder rdf:resource="#PathwayStep63" />
 <bp:pathwayOrder rdf:resource="#PathwayStep40" />
 <bp:pathwayOrder rdf:resource="#PathwayStep62" />
 <bp:pathwayOrder rdf:resource="#PathwayStep39" />
 <bp:pathwayOrder rdf:resource="#PathwayStep32" />
 <bp:pathwayOrder rdf:resource="#PathwayStep54" />
 <bp:pathwayOrder rdf:resource="#PathwayStep53" />
 <bp:pathwayOrder rdf:resource="#PathwayStep34" />
 <bp:pathwayOrder rdf:resource="#PathwayStep56" />
 <bp:pathwayOrder rdf:resource="#PathwayStep33" />
 <bp:pathwayOrder rdf:resource="#PathwayStep55" />
 <bp:pathwayOrder rdf:resource="#PathwayStep36" />
 <bp:pathwayOrder rdf:resource="#PathwayStep58" />
 <bp:pathwayOrder rdf:resource="#PathwayStep35" />
 <bp:pathwayOrder rdf:resource="#PathwayStep57" />
 <bp:pathwayOrder rdf:resource="#PathwayStep38" />
 <bp:pathwayOrder rdf:resource="#PathwayStep37" />
 <bp:pathwayOrder rdf:resource="#PathwayStep59" />
 <bp:pathwayOrder rdf:resource="#PathwayStep50" />
 <bp:pathwayOrder rdf:resource="#PathwayStep52" />
 <bp:pathwayOrder rdf:resource="#PathwayStep51" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction41" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction42" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction43" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction44" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction60" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction40" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction49" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction29" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction45" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction46" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction47" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction48" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction30" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction52" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction31" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction53" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction32" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction54" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction33" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction55" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction50" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction51" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction38" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction39" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction34" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction56" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction35" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction57" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction36" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction58" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction37" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction59" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence32" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear events stimulated by ALK signaling in cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling through oncogenic forms of ALK activate nuclear events that drive cellular survival, escape from apoptosis and transformation (reviewed in Della Corte et al, 2018; Roskoski, 2013; Chiarle et al, 2008). Changes to gene expression are effected both by epigenetic mechanisms and by inducing expression of key transcription factors and cell cycle regulators, among other critical targets. Many of these gene expression events are dependent on activation of STAT3 and to a lesser extent, MAP kinase signaling downstream of ALK (reviewed in Hallberg and Palmer, 2013; Hallberg and Palmer, 2016; Ducray et al, 2019). Unique among fusion proteins identified to date, the well-studied NPM-ALK fusion appears to be partially localized to the nucleus by virtue of oligomerization with endogenous full-length NPM.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway5">
 <bp:pathwayOrder rdf:resource="#PathwayStep76" />
 <bp:pathwayOrder rdf:resource="#PathwayStep78" />
 <bp:pathwayOrder rdf:resource="#PathwayStep68" />
 <bp:pathwayOrder rdf:resource="#PathwayStep70" />
 <bp:pathwayOrder rdf:resource="#PathwayStep80" />
 <bp:pathwayOrder rdf:resource="#PathwayStep72" />
 <bp:pathwayOrder rdf:resource="#PathwayStep74" />
 <bp:pathwayComponent rdf:resource="#Pathway6" />
 <bp:pathwayComponent rdf:resource="#Pathway7" />
 <bp:pathwayComponent rdf:resource="#Pathway8" />
 <bp:pathwayComponent rdf:resource="#Pathway9" />
 <bp:pathwayComponent rdf:resource="#Pathway12" />
 <bp:pathwayComponent rdf:resource="#Pathway11" />
 <bp:pathwayComponent rdf:resource="#Pathway10" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence68" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Drug resistance of ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aberrant ALK activity arises through fusions, point mutations, overexpression or amplifications and has been shown to be an oncogenic driver in a number of cancers including anaplastic large cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), inflammatory myofibroblastic tumors (IMTs) neuroblastomas and more (reviewed in Della Corte et al, 2018; Lin et al, 2017). As a result, ALK is a promising therapeutic target for inhibition with tyrosine kinase inhibitors. Crizotinib, ceritinib, brigatinib, alectinib and lorlatinib are all approved for the treatment of ALK-driven cancers, however resistance commonly develops either as a result of accumulating secondary mutations, or through activation of bypass pathways that remove the dependence on ALK signaling (reviewed in Della Corte et al, 2017; Roskoski, 2013; Lin et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction78">
 <bp:evidence rdf:resource="#Evidence96" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated SHC1 in complex with p-5Y-EGFRvIII recruits GRB2:SOS1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction328">
 <bp:evidence rdf:resource="#Evidence422" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 TMD/JMD mutants and EGFR phosphorylate PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction79">
 <bp:evidence rdf:resource="#Evidence97" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of EGFRvIII mutant</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction329">
 <bp:evidence rdf:resource="#Evidence423" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 TMD/JMD mutants phosphorylate SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction326">
 <bp:evidence rdf:resource="#Evidence419" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3K bound to phosphorylated heterodimers of ERBB2 KD mutants and EGFR converts PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway1">
 <bp:pathwayOrder rdf:resource="#PathwayStep1" />
 <bp:pathwayOrder rdf:resource="#PathwayStep84" />
 <bp:pathwayOrder rdf:resource="#PathwayStep134" />
 <bp:pathwayOrder rdf:resource="#PathwayStep234" />
 <bp:pathwayOrder rdf:resource="#PathwayStep356" />
 <bp:pathwayOrder rdf:resource="#PathwayStep433" />
 <bp:pathwayOrder rdf:resource="#PathwayStep326" />
 <bp:pathwayOrder rdf:resource="#PathwayStep513" />
 <bp:pathwayOrder rdf:resource="#PathwayStep590" />
 <bp:pathwayOrder rdf:resource="#PathwayStep263" />
 <bp:pathwayOrder rdf:resource="#PathwayStep351" />
 <bp:pathwayOrder rdf:resource="#PathwayStep253" />
 <bp:pathwayOrder rdf:resource="#PathwayStep550" />
 <bp:pathwayOrder rdf:resource="#PathwayStep199" />
 <bp:pathwayComponent rdf:resource="#Pathway80" />
 <bp:pathwayComponent rdf:resource="#Pathway151" />
 <bp:pathwayComponent rdf:resource="#Pathway2" />
 <bp:pathwayComponent rdf:resource="#Pathway95" />
 <bp:pathwayComponent rdf:resource="#Pathway55" />
 <bp:pathwayComponent rdf:resource="#Pathway21" />
 <bp:pathwayComponent rdf:resource="#Pathway32" />
 <bp:pathwayComponent rdf:resource="#Pathway43" />
 <bp:pathwayComponent rdf:resource="#Pathway75" />
 <bp:pathwayComponent rdf:resource="#Pathway116" />
 <bp:pathwayComponent rdf:resource="#Pathway14" />
 <bp:pathwayComponent rdf:resource="#Pathway58" />
 <bp:pathwayComponent rdf:resource="#Pathway79" />
 <bp:pathwayComponent rdf:resource="#Pathway137" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of signal transduction by growth factor receptors and second messengers</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling processes are central to human physiology (e.g., Pires-da Silva    Sommer 2003), and their disruption by either germ-line and somatic mutation can lead to serious disease. Here, the molecular consequences of mutations affecting visual signal transduction and signaling by diverse growth factors are annotated.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction327">
 <bp:evidence rdf:resource="#Evidence421" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 TMD/JMD heterodimers trans-autophosphorylate</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep134">
 <bp:stepProcess rdf:resource="#Pathway21" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction324">
 <bp:evidence rdf:resource="#Evidence417" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 KD mutants and EGFR phosphorylate PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep135">
 <bp:stepProcess rdf:resource="#Pathway22" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction325">
 <bp:evidence rdf:resource="#Evidence418" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 KD mutants trans-autophosphorylate</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep136">
 <bp:stepProcess rdf:resource="#Pathway23" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction322">
 <bp:evidence rdf:resource="#Evidence415" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 KD mutants and EGFR bind PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep137">
 <bp:stepProcess rdf:resource="#BiochemicalReaction115" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction323">
 <bp:evidence rdf:resource="#Evidence416" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 KD mutants and EGFR bind GRB2:SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep138">
 <bp:stepProcess rdf:resource="#BiochemicalReaction116" />
 <bp:stepProcess rdf:resource="#Catalysis24" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction320">
 <bp:evidence rdf:resource="#Evidence413" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 KD mutants and ERBB3 bind PI3K</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep139">
 <bp:stepProcess rdf:resource="#Catalysis25" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction117" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction321">
 <bp:evidence rdf:resource="#Evidence414" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 KD mutants and EGFR, in complex with GRB2:GAB1, bind PI3K</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence437">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence436">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence439">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction80">
 <bp:evidence rdf:resource="#Evidence98" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of SHC1 by p-5Y-EGFRvIII</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence438">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep130">
 <bp:stepProcess rdf:resource="#BiochemicalReaction111" />
 <bp:stepProcess rdf:resource="#Catalysis22" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence433">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep131">
 <bp:stepProcess rdf:resource="#BiochemicalReaction112" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence432">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep132">
 <bp:stepProcess rdf:resource="#BiochemicalReaction113" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence435">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep133">
 <bp:stepProcess rdf:resource="#BiochemicalReaction114" />
 <bp:stepProcess rdf:resource="#Catalysis23" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence434">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep538">
 <bp:stepProcess rdf:resource="#Pathway131" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep539">
 <bp:stepProcess rdf:resource="#BiochemicalReaction409" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction339">
 <bp:evidence rdf:resource="#Evidence433" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 TMD/JMD mutants recruit GRB2:SOS1 through SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction337">
 <bp:evidence rdf:resource="#Evidence431" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 TMD/JMD mutants hetrodimerize</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction338">
 <bp:evidence rdf:resource="#Evidence432" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 TMD/JMD mutants and EGFR bind GRB2:SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction335">
 <bp:evidence rdf:resource="#Evidence429" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 TMD/JMD mutants bind pertuzumab</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep541">
 <bp:stepProcess rdf:resource="#BiochemicalReaction410" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis80">
 <bp:controlled rdf:resource="#BiochemicalReaction268" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction336">
 <bp:evidence rdf:resource="#Evidence430" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 TMD/JMD mutants bind trastuzumab</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep542">
 <bp:stepProcess rdf:resource="#Pathway133" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis81">
 <bp:controlled rdf:resource="#BiochemicalReaction270" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction333">
 <bp:evidence rdf:resource="#Evidence427" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated ERBB2 TMD/JMD heterodimers bind SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep543">
 <bp:stepProcess rdf:resource="#BiochemicalReaction411" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis82">
 <bp:controlled rdf:resource="#BiochemicalReaction271" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction334">
 <bp:evidence rdf:resource="#Evidence428" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 TMD/JMD mutants bind TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep544">
 <bp:stepProcess rdf:resource="#Pathway134" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis83">
 <bp:controlled rdf:resource="#BiochemicalReaction272" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction331">
 <bp:evidence rdf:resource="#Evidence425" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS activation by SOS1 bound to phosphorylated heterodimers of ERBB2 TMD/JMD mutants and EGFR</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep545">
 <bp:stepProcess rdf:resource="#BiochemicalReaction412" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis84">
 <bp:controlled rdf:resource="#BiochemicalReaction273" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction332">
 <bp:evidence rdf:resource="#Evidence426" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS activation by SOS1 bound to phosphorylated heterodimers of ERBB2 TMD/JMD mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep546">
 <bp:stepProcess rdf:resource="#Pathway135" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis85">
 <bp:controlled rdf:resource="#BiochemicalReaction276" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep547">
 <bp:stepProcess rdf:resource="#BiochemicalReaction413" />
</bp:PathwayStep>

<bp:Provenance rdf:ID="Provenance1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Reactome</bp:name>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">http://www.reactome.org</bp:comment>
</bp:Provenance>

<bp:Catalysis rdf:ID="Catalysis86">
 <bp:controlled rdf:resource="#BiochemicalReaction281" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction330">
 <bp:evidence rdf:resource="#Evidence424" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 TMD/JMD mutants and EGFR bind PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep548">
 <bp:stepProcess rdf:resource="#Pathway136" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis87">
 <bp:controlled rdf:resource="#BiochemicalReaction282" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis88">
 <bp:controlled rdf:resource="#BiochemicalReaction284" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis89">
 <bp:controlled rdf:resource="#BiochemicalReaction296" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep540">
 <bp:stepProcess rdf:resource="#Pathway132" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep549">
 <bp:stepProcess rdf:resource="#BiochemicalReaction414" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction348">
 <bp:evidence rdf:resource="#Evidence453" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">gilteritinib-resistant FLT3 mutants don&apos;t bind gilteritinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction349">
 <bp:evidence rdf:resource="#Evidence455" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">quizartinib-resistant FLT3 mutants don&apos;t bind quizartinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis90">
 <bp:controlled rdf:resource="#BiochemicalReaction302" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction346">
 <bp:evidence rdf:resource="#Evidence449" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">sorafenib-resistant FLT3 mutants don&apos;t bind sorafenib</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep552">
 <bp:stepProcess rdf:resource="#Catalysis116" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction415" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis91">
 <bp:controlled rdf:resource="#BiochemicalReaction305" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction347">
 <bp:evidence rdf:resource="#Evidence451" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">lestaurtinib-resistant FLT3 mutants don&apos;t bind lestaurtinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep553">
 <bp:stepProcess rdf:resource="#Pathway139" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis92">
 <bp:controlled rdf:resource="#BiochemicalReaction306" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction344">
 <bp:evidence rdf:resource="#Evidence445" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">tandutinib-resistant FLT3 mutants don&apos;t bind tandutinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep554">
 <bp:stepProcess rdf:resource="#Catalysis117" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction416" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis93">
 <bp:controlled rdf:resource="#BiochemicalReaction309" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction345">
 <bp:evidence rdf:resource="#Evidence447" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">tamatinib-resistant FLT3 mutants don&apos;t bind tamatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep555">
 <bp:stepProcess rdf:resource="#BiochemicalReaction417" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis94">
 <bp:controlled rdf:resource="#BiochemicalReaction310" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction342">
 <bp:evidence rdf:resource="#Evidence441" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">sunitinib-resistant FLT3 mutants don&apos;t bind sunitinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep556">
 <bp:stepProcess rdf:resource="#Pathway140" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis95">
 <bp:controlled rdf:resource="#BiochemicalReaction312" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction343">
 <bp:evidence rdf:resource="#Evidence443" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">pexidartinib-resistant FLT3 mutants don&apos;t bind pexidartinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep557">
 <bp:stepProcess rdf:resource="#BiochemicalReaction418" />
 <bp:stepProcess rdf:resource="#Catalysis118" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis96">
 <bp:controlled rdf:resource="#BiochemicalReaction317" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction340">
 <bp:evidence rdf:resource="#Evidence437" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KW2449-resistant FLT3 mutants don&apos;t bind KW2449</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep558">
 <bp:stepProcess rdf:resource="#BiochemicalReaction419" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis97">
 <bp:controlled rdf:resource="#BiochemicalReaction318" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction341">
 <bp:evidence rdf:resource="#Evidence439" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">midostaurin-resistant FLT3 mutants don&apos;t bind midostaurin</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep559">
 <bp:stepProcess rdf:resource="#Pathway141" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis98">
 <bp:controlled rdf:resource="#BiochemicalReaction324" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis99">
 <bp:controlled rdf:resource="#BiochemicalReaction325" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep550">
 <bp:stepProcess rdf:resource="#Pathway137" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep551">
 <bp:stepProcess rdf:resource="#Pathway138" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction359">
 <bp:evidence rdf:resource="#Evidence470" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 fusions phosphorylate GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction357">
 <bp:evidence rdf:resource="#Evidence468" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-STAT5 dissociates from FLT3 fusion proteinsp-</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep563">
 <bp:stepProcess rdf:resource="#BiochemicalReaction423" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction358">
 <bp:evidence rdf:resource="#Evidence469" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 fusions recruit PIK3R1 through phosphorylated GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep564">
 <bp:stepProcess rdf:resource="#BiochemicalReaction424" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction355">
 <bp:evidence rdf:resource="#Evidence466" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 fusions recruit PIK3CA through PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep565">
 <bp:stepProcess rdf:resource="#BiochemicalReaction425" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction356">
 <bp:evidence rdf:resource="#Evidence467" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of FLT3 fusion proteins</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep566">
 <bp:stepProcess rdf:resource="#Catalysis120" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction426" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction353">
 <bp:evidence rdf:resource="#Evidence463" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">crenolanib-resistant FLT3 mutants don&apos;t bind crenolanib</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep567">
 <bp:stepProcess rdf:resource="#BiochemicalReaction427" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction354">
 <bp:evidence rdf:resource="#Evidence465" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 fusions activate STAT5</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep568">
 <bp:stepProcess rdf:resource="#BiochemicalReaction428" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction351">
 <bp:evidence rdf:resource="#Evidence459" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">linafinib-resistant FLT3 mutants don&apos;t bind linifanib</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep569">
 <bp:stepProcess rdf:resource="#Catalysis121" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction429" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction352">
 <bp:evidence rdf:resource="#Evidence461" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ponatinib-resistant FLT3 mutants don&apos;t bind ponatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction350">
 <bp:evidence rdf:resource="#Evidence457" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">semaxanib-resistant FLT3 mutants don&apos;t bind semaxanib&lt;br&gt;</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep560">
 <bp:stepProcess rdf:resource="#Catalysis119" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction420" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep561">
 <bp:stepProcess rdf:resource="#BiochemicalReaction421" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep562">
 <bp:stepProcess rdf:resource="#BiochemicalReaction422" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction368">
 <bp:evidence rdf:resource="#Evidence479" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated FLT3 fusions bind GRB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep574">
 <bp:stepProcess rdf:resource="#Pathway144" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction369">
 <bp:evidence rdf:resource="#Evidence480" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SOS1-mediated nucleotide exchange of RAS downstream of FLT3 fusion mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep575">
 <bp:stepProcess rdf:resource="#BiochemicalReaction432" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction366">
 <bp:evidence rdf:resource="#Evidence477" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-STAT5 binds the CDKN1A gene</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep576">
 <bp:stepProcess rdf:resource="#Pathway145" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction367">
 <bp:evidence rdf:resource="#Evidence478" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD- and STAT5-dependent CDKN1A gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep577">
 <bp:stepProcess rdf:resource="#BiochemicalReaction433" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction364">
 <bp:evidence rdf:resource="#Evidence475" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 fusions:GRB2 bind SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep578">
 <bp:stepProcess rdf:resource="#Pathway146" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction365">
 <bp:evidence rdf:resource="#Evidence476" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-STAT5 binds the NOX4 promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep579">
 <bp:stepProcess rdf:resource="#BiochemicalReaction434" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction362">
 <bp:evidence rdf:resource="#Evidence473" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT5-dependent PIM1 gene expression downstream of FLT3 ITD and fusion mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction363">
 <bp:evidence rdf:resource="#Evidence474" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD- and NOX4-dependent H2O2 production</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction360">
 <bp:evidence rdf:resource="#Evidence471" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD- and STAT5-dependent NOX4 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction361">
 <bp:evidence rdf:resource="#Evidence472" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 fusion dimers autophosphorylate</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep570">
 <bp:stepProcess rdf:resource="#BiochemicalReaction430" />
 <bp:stepProcess rdf:resource="#Catalysis122" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep571">
 <bp:stepProcess rdf:resource="#Pathway142" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep572">
 <bp:stepProcess rdf:resource="#Pathway143" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep573">
 <bp:stepProcess rdf:resource="#BiochemicalReaction431" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction379">
 <bp:evidence rdf:resource="#Evidence493" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive phosphorylation of FLT3 mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction377">
 <bp:evidence rdf:resource="#Evidence491" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of FLT3 mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction378">
 <bp:evidence rdf:resource="#Evidence492" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutants:GRB2:p-Y-GAB2 binds PTPN11</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep500">
 <bp:stepProcess rdf:resource="#BiochemicalReaction386" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction375">
 <bp:evidence rdf:resource="#Evidence489" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutants:GRB2:SOS1-mediated nucleotide exchange on RAS</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep501">
 <bp:stepProcess rdf:resource="#BiochemicalReaction387" />
 <bp:stepProcess rdf:resource="#Catalysis113" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis40">
 <bp:controlled rdf:resource="#BiochemicalReaction187" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction376">
 <bp:evidence rdf:resource="#Evidence490" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutants recruit PIK3CA through PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep502">
 <bp:stepProcess rdf:resource="#BiochemicalReaction388" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis41">
 <bp:controlled rdf:resource="#BiochemicalReaction189" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction373">
 <bp:evidence rdf:resource="#Evidence486" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT mutants bind type II TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep503">
 <bp:stepProcess rdf:resource="#BiochemicalReaction389" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis42">
 <bp:controlled rdf:resource="#BiochemicalReaction192" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction374">
 <bp:evidence rdf:resource="#Evidence487" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT mutants bind type I TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep504">
 <bp:stepProcess rdf:resource="#BiochemicalReaction390" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis43">
 <bp:controlled rdf:resource="#BiochemicalReaction200" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction371">
 <bp:evidence rdf:resource="#Evidence482" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-STAT5 translocates to nucleus downstream of mutant FLT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis44">
 <bp:controlled rdf:resource="#BiochemicalReaction201" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction372">
 <bp:evidence rdf:resource="#Evidence484" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CBL mutants don&apos;t ubiquitinate FLT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis45">
 <bp:controlled rdf:resource="#BiochemicalReaction202" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis46">
 <bp:controlled rdf:resource="#BiochemicalReaction204" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction370">
 <bp:evidence rdf:resource="#Evidence481" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 fusions:GRB2 bind GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis47">
 <bp:controlled rdf:resource="#BiochemicalReaction206" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis48">
 <bp:controlled rdf:resource="#BiochemicalReaction207" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis49">
 <bp:controlled rdf:resource="#BiochemicalReaction209" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep505">
 <bp:stepProcess rdf:resource="#BiochemicalReaction391" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep506">
 <bp:stepProcess rdf:resource="#BiochemicalReaction392" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep507">
 <bp:stepProcess rdf:resource="#BiochemicalReaction393" />
 <bp:stepProcess rdf:resource="#Catalysis114" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep508">
 <bp:stepProcess rdf:resource="#BiochemicalReaction394" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep509">
 <bp:stepProcess rdf:resource="#BiochemicalReaction395" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction388">
 <bp:evidence rdf:resource="#Evidence503" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PTPN11:p-STAT5 translocates to nucleus downstream of mutant FLT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep510">
 <bp:stepProcess rdf:resource="#BiochemicalReaction396" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction389">
 <bp:evidence rdf:resource="#Evidence504" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-STAT5 binds the NOX4 promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep511">
 <bp:stepProcess rdf:resource="#BiochemicalReaction397" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis50">
 <bp:controlled rdf:resource="#BiochemicalReaction211" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction386">
 <bp:evidence rdf:resource="#Evidence501" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PTPN11:p-STAT5 binds BCL2L1 promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep512">
 <bp:stepProcess rdf:resource="#BiochemicalReaction398" />
 <bp:stepProcess rdf:resource="#Catalysis115" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis51">
 <bp:controlled rdf:resource="#BiochemicalReaction214" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction387">
 <bp:evidence rdf:resource="#Evidence502" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD- and NOX4-dependent H2O2 production</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep513">
 <bp:stepProcess rdf:resource="#Pathway116" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis52">
 <bp:controlled rdf:resource="#BiochemicalReaction216" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction384">
 <bp:evidence rdf:resource="#Evidence499" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD- and STAT5-dependent BCL2L1 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep514">
 <bp:stepProcess rdf:resource="#Pathway117" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis53">
 <bp:controlled rdf:resource="#BiochemicalReaction217" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction385">
 <bp:evidence rdf:resource="#Evidence500" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT5-dependent PIM1 gene expression downstream of FLT3 ITD and fusion mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep515">
 <bp:stepProcess rdf:resource="#Pathway118" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis54">
 <bp:controlled rdf:resource="#BiochemicalReaction220" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction382">
 <bp:evidence rdf:resource="#Evidence497" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-STAT5 dissociates from mutant FLT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis55">
 <bp:controlled rdf:resource="#BiochemicalReaction223" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction383">
 <bp:evidence rdf:resource="#Evidence498" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD- and STAT5-dependent NOX4 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis56">
 <bp:controlled rdf:resource="#BiochemicalReaction225" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction380">
 <bp:evidence rdf:resource="#Evidence494" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutant dimers:GRB2 bind SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis57">
 <bp:controlled rdf:resource="#BiochemicalReaction227" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction381">
 <bp:evidence rdf:resource="#Evidence495" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutants:GRB2 bind GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis58">
 <bp:controlled rdf:resource="#BiochemicalReaction228" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis59">
 <bp:controlled rdf:resource="#BiochemicalReaction229" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep516">
 <bp:stepProcess rdf:resource="#BiochemicalReaction399" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep517">
 <bp:stepProcess rdf:resource="#Pathway119" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep518">
 <bp:stepProcess rdf:resource="#BiochemicalReaction400" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep519">
 <bp:stepProcess rdf:resource="#Pathway120" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep520">
 <bp:stepProcess rdf:resource="#BiochemicalReaction401" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction399">
 <bp:evidence rdf:resource="#Evidence517" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AXIN mutants destabilize the destruction complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep521">
 <bp:stepProcess rdf:resource="#Pathway121" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis60">
 <bp:controlled rdf:resource="#BiochemicalReaction230" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep522">
 <bp:stepProcess rdf:resource="#Pathway122" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis61">
 <bp:controlled rdf:resource="#BiochemicalReaction231" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction397">
 <bp:evidence rdf:resource="#Evidence512" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutants recruit PIK3R1 through phosphorylated GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep523">
 <bp:stepProcess rdf:resource="#BiochemicalReaction402" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis62">
 <bp:controlled rdf:resource="#BiochemicalReaction236" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction398">
 <bp:evidence rdf:resource="#Evidence513" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutants phosphorylate GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep524">
 <bp:stepProcess rdf:resource="#Pathway123" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis63">
 <bp:controlled rdf:resource="#BiochemicalReaction239" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction395">
 <bp:evidence rdf:resource="#Evidence510" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-STAT5 translocates to nucleus downstream of mutant FLT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep525">
 <bp:stepProcess rdf:resource="#BiochemicalReaction403" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis64">
 <bp:controlled rdf:resource="#BiochemicalReaction240" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction396">
 <bp:evidence rdf:resource="#Evidence511" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutant dimers bind GRB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep526">
 <bp:stepProcess rdf:resource="#Pathway124" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis65">
 <bp:controlled rdf:resource="#BiochemicalReaction243" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction393">
 <bp:evidence rdf:resource="#Evidence508" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD mutants phosphorylate STAT5</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis66">
 <bp:controlled rdf:resource="#BiochemicalReaction245" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction394">
 <bp:evidence rdf:resource="#Evidence509" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD mutants bind STAT5 through GAB2:PTPN11</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis67">
 <bp:controlled rdf:resource="#BiochemicalReaction246" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction391">
 <bp:evidence rdf:resource="#Evidence506" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-STAT5 binds the CDKN1A gene</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis68">
 <bp:controlled rdf:resource="#BiochemicalReaction249" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction392">
 <bp:evidence rdf:resource="#Evidence507" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD- and STAT5-dependent CDKN1A gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis69">
 <bp:controlled rdf:resource="#BiochemicalReaction254" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction390">
 <bp:evidence rdf:resource="#Evidence505" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PTPN11:p-STAT5 dissociates from mutant FLT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep527">
 <bp:stepProcess rdf:resource="#BiochemicalReaction404" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep528">
 <bp:stepProcess rdf:resource="#Pathway125" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep529">
 <bp:stepProcess rdf:resource="#Pathway126" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep530">
 <bp:stepProcess rdf:resource="#BiochemicalReaction405" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep531">
 <bp:stepProcess rdf:resource="#Pathway127" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis70">
 <bp:controlled rdf:resource="#BiochemicalReaction255" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep532">
 <bp:stepProcess rdf:resource="#BiochemicalReaction406" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis71">
 <bp:controlled rdf:resource="#BiochemicalReaction256" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep533">
 <bp:stepProcess rdf:resource="#Pathway128" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis72">
 <bp:controlled rdf:resource="#BiochemicalReaction258" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep534">
 <bp:stepProcess rdf:resource="#BiochemicalReaction407" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis73">
 <bp:controlled rdf:resource="#BiochemicalReaction259" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep535">
 <bp:stepProcess rdf:resource="#Pathway129" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis74">
 <bp:controlled rdf:resource="#BiochemicalReaction260" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep536">
 <bp:stepProcess rdf:resource="#Pathway130" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis75">
 <bp:controlled rdf:resource="#BiochemicalReaction261" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep537">
 <bp:stepProcess rdf:resource="#BiochemicalReaction408" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis76">
 <bp:controlled rdf:resource="#BiochemicalReaction262" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis77">
 <bp:controlled rdf:resource="#BiochemicalReaction263" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis78">
 <bp:controlled rdf:resource="#BiochemicalReaction265" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis79">
 <bp:controlled rdf:resource="#BiochemicalReaction267" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence297">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence296">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence299">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence298">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence293">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence292">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence295">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence294">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence291">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence290">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep700">
 <bp:stepProcess rdf:resource="#BiochemicalReaction531" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep701">
 <bp:stepProcess rdf:resource="#BiochemicalReaction532" />
 <bp:stepProcess rdf:resource="#Catalysis161" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep702">
 <bp:stepProcess rdf:resource="#BiochemicalReaction533" />
 <bp:stepProcess rdf:resource="#Catalysis162" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence289">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep703">
 <bp:stepProcess rdf:resource="#BiochemicalReaction534" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep704">
 <bp:stepProcess rdf:resource="#BiochemicalReaction535" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep705">
 <bp:stepProcess rdf:resource="#Catalysis163" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction536" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep706">
 <bp:stepProcess rdf:resource="#BiochemicalReaction537" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep707">
 <bp:stepProcess rdf:resource="#BiochemicalReaction538" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep708">
 <bp:stepProcess rdf:resource="#BiochemicalReaction539" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence693">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence692">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence211">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence695">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence210">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence694">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence691">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence690">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence209">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence206">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence205">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence689">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence208">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence207">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence202">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence686">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence201">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence685">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence204">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence688">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence203">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence687">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence220">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence222">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence221">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence217">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence216">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence219">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence218">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence213">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence697">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence212">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence696">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence215">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence699">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence214">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence698">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence231">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence230">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence233">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence232">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence228">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence227">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence229">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence224">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence223">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence226">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence225">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence242">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence241">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence244">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence243">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence240">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence239">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence238">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence235">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence234">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence237">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence236">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence253">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence252">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence255">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence254">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence251">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence250">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence249">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence246">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence245">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence248">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence247">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence264">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence263">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence266">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence265">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence260">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway92">
 <bp:pathwayOrder rdf:resource="#PathwayStep387" />
 <bp:pathwayOrder rdf:resource="#PathwayStep398" />
 <bp:pathwayOrder rdf:resource="#PathwayStep388" />
 <bp:pathwayOrder rdf:resource="#PathwayStep399" />
 <bp:pathwayOrder rdf:resource="#PathwayStep389" />
 <bp:pathwayOrder rdf:resource="#PathwayStep400" />
 <bp:pathwayOrder rdf:resource="#PathwayStep390" />
 <bp:pathwayOrder rdf:resource="#PathwayStep391" />
 <bp:pathwayOrder rdf:resource="#PathwayStep392" />
 <bp:pathwayOrder rdf:resource="#PathwayStep393" />
 <bp:pathwayOrder rdf:resource="#PathwayStep394" />
 <bp:pathwayOrder rdf:resource="#PathwayStep395" />
 <bp:pathwayOrder rdf:resource="#PathwayStep396" />
 <bp:pathwayOrder rdf:resource="#PathwayStep386" />
 <bp:pathwayOrder rdf:resource="#PathwayStep397" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction308" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction309" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction306" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction307" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction304" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction305" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction302" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction303" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction300" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction301" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction298" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction299" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction296" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction297" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction295" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence386" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by ERBB2 ECD mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 extracellular domain (ECD) mutants harbor missense mutations that lead to substitutions of amino acid residues in the heterodimerization arm contact surface, involved in formation of ERBB2 heterodimers. The functionally studied ERBB2 ECD mutants, ERBB2 G309A (Bose et al. 2013), ERBB2 G309E (Greulich et al. 2012) and ERBB2 S310F (Greulich et al. 2012) seem to preferntially heterodimerize with EGFR. Heterodimerization of ERBB2 G309E involves formation of disulfide bonds (Greulich et al. 2012). ERBB2 S310F shows stronger activation of downstream signaling than ERBB2 G309A and ERBB2 G309E, and is hyperphosphorylated on tyrosine residues in the C-tail (Greulich et al. 2012), while the C-tail phosphorylation of ERBB2 G309A (Bose et al. 2013) and ERBB2 G309E (Greulich et al. 2012) is comparable to the wild type ERBB2.  RAS signaling and PLCgamma1 signaling are activated dowsntream of all three ERBB2 ECD mutants, ERBB2 G309A (Bose et al. 2013), ERBB2 G309E (Greulich et al. 2012) and ERBB2 S310F (Greulich et al. 2012), as evidenced by activating phosphorylation on ERKs (MAPK1 and MAPK3) and PLCG1, respectively. ERBB2 G309E and ERBB2 S310F also activate PI3K/AKT signaling, demonstrated by activating phosphorylation of AKT1 (Greulich et al. 2012). Activation of PI3K/AKT signaling downstream of ERBB2 G309A has not been tested. Signaling downstream of ERBB2 S310Y has been poorly characterized and it is annotated as a candidate. Many regulators of cell migration show increased phosphorylation in cells expressing ERBB2 G309E and ERBB2 S310F (Greulich et al. 2012). Comapred with the wild type ERBB2, ERBB2 G309E, ERBB2 S310F and ERBB2 S310Y are more sensitive to the ERBB2-directed therapeutic antibody trastuzumab (herceptin) and to tyrosine kinase inhibitors lapatinib, neratinib and afatinib (Greulich et al. 2012). ERBB2 G309A was also responsive to trastuzumab, lapatinib and neratinib (Bose et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway91">
 <bp:pathwayOrder rdf:resource="#PathwayStep384" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction294" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence384" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Drug resistance in ERBB2 TMD/JMD mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">With respect to pertuzumab, a therapeutic antibody that block ligand-driven heterodimerization of ERBB2, ERBB2 R678Q is sensitive to pertuzumab, while ERBB2 V659E, ERBB2 G660D, ERBB2 G660R and probably ERBB2 Q709L are resistant (Pahuja et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence262">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway90">
 <bp:pathwayOrder rdf:resource="#PathwayStep382" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction293" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence382" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistance of ERBB2 KD mutants to lapatinib</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes resistance of ERBB2 KD mutants to tyrosine kinase inhibitor lapatinib (Trowe et al. 2008, Kancha et al. 2011, Bose et al. 2013, Rexer et al. 2013, Yang et al. 2015, Hanker et al. 2017, Cocco et al. 2018, Nagano et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence261">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway96">
 <bp:pathwayOrder rdf:resource="#PathwayStep439" />
 <bp:pathwayOrder rdf:resource="#PathwayStep453" />
 <bp:pathwayOrder rdf:resource="#PathwayStep443" />
 <bp:pathwayOrder rdf:resource="#PathwayStep455" />
 <bp:pathwayOrder rdf:resource="#PathwayStep445" />
 <bp:pathwayOrder rdf:resource="#PathwayStep435" />
 <bp:pathwayOrder rdf:resource="#PathwayStep457" />
 <bp:pathwayOrder rdf:resource="#PathwayStep447" />
 <bp:pathwayOrder rdf:resource="#PathwayStep437" />
 <bp:pathwayOrder rdf:resource="#PathwayStep459" />
 <bp:pathwayOrder rdf:resource="#PathwayStep449" />
 <bp:pathwayOrder rdf:resource="#PathwayStep461" />
 <bp:pathwayOrder rdf:resource="#PathwayStep451" />
 <bp:pathwayOrder rdf:resource="#PathwayStep441" />
 <bp:pathwayComponent rdf:resource="#Pathway99" />
 <bp:pathwayComponent rdf:resource="#Pathway98" />
 <bp:pathwayComponent rdf:resource="#Pathway97" />
 <bp:pathwayComponent rdf:resource="#Pathway105" />
 <bp:pathwayComponent rdf:resource="#Pathway106" />
 <bp:pathwayComponent rdf:resource="#Pathway107" />
 <bp:pathwayComponent rdf:resource="#Pathway108" />
 <bp:pathwayComponent rdf:resource="#Pathway109" />
 <bp:pathwayComponent rdf:resource="#Pathway110" />
 <bp:pathwayComponent rdf:resource="#Pathway100" />
 <bp:pathwayComponent rdf:resource="#Pathway101" />
 <bp:pathwayComponent rdf:resource="#Pathway102" />
 <bp:pathwayComponent rdf:resource="#Pathway103" />
 <bp:pathwayComponent rdf:resource="#Pathway104" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence435" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Drug resistance of FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 is mutated in ~30% of acute myeloid leukemias (AML), with internal tandem duplications (ITDs) representing the majority of these mutations and activating point mutants occurring at lower frequency. FLT3 mutations also occur at lower rates in other cancers (reviewed in Kazi and Roonstrand, 2018; Daver et al, 2019; Larroas-Garcia and Baer, 2017). Mutation of FLT3 has been identified as a driver in progression of AML and in consequence is a promising therapeutic target. A number of first and second generation inhibitors have been demonstrated to have activity against FLT3, but accumulation of secondary mutations leads to the development of resistance. These secondary mutations further shift the equilibrium of the receptor toward the activated state, making even the second-generation type II TKIs less effective. In consequence, considerable effort is devoted to discovery of type II and, in particular, type I TKIs that are active against highly activated FLT3 alleles (reviewed in Daver et al, 2019; Staudt et al, 2018; Lim et al, 2017; Klug et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway95">
 <bp:pathwayOrder rdf:resource="#PathwayStep487" />
 <bp:pathwayOrder rdf:resource="#PathwayStep434" />
 <bp:pathwayOrder rdf:resource="#PathwayStep482" />
 <bp:pathwayOrder rdf:resource="#PathwayStep484" />
 <bp:pathwayOrder rdf:resource="#PathwayStep463" />
 <bp:pathwayComponent rdf:resource="#Pathway96" />
 <bp:pathwayComponent rdf:resource="#Pathway111" />
 <bp:pathwayComponent rdf:resource="#Pathway112" />
 <bp:pathwayComponent rdf:resource="#Pathway113" />
 <bp:pathwayComponent rdf:resource="#Pathway114" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence434" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 signaling in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 is a type III receptor tyrosine kinase (RTK). The extracellular domain consists of 5 immunoglobulin (Ig) domains that contribute to dimerization and ligand binding. The intracellular region has a juxtamembrane domain that plays a role in autoinhibiting the receptor in the absence of ligand, and a bi-lobed kinase region with an activation loop and the catalytic cleft (reviewed in Klug et al, 2018). Signaling through FLT3 occurs after ligand-induced dimerization and transautophosphorylation, and promotes signaling through the MAP kinase, PI3K and STAT5 pathways, among others. FLT3 signaling promotes cellular proliferation and differentiation and contributes to haematopoeisis. FLT3 is mutated in up to 30% of acute myeloid leukemias. ~25% of the FLT3 mutations in AML cases occur as internal tandem duplications (ITDs) either in the juxtamembrane domain region encoded by exon 14 or the tyrosine kinase domain (TKD), while ~7-10% of AML cases contain FLT3 missense mutations in the TKD (reviewed in Klug et al, 2018; Daver et al, 2019). These mutations all support ligand-independent activation of the receptor and result in constitutive activation and signaling (Zheng et al, 2004; reviewed in Klug et al, 2018; Kazi and Roonstrand, 2019). In rare cases, the FLT3 locus is also subject to translocations that generate constitutively active fusion proteins (reviewed in Kazi and Roonstrand, 2019). Oncogenic FLT3 activity can be targeted with tyrosine kinase inhibitors, although resistance often arises due to secondary mutations or activation of bypass pathways (reviewed in Staudt et al, 2018; Daver et al, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway94">
 <bp:pathwayOrder rdf:resource="#PathwayStep428" />
 <bp:pathwayOrder rdf:resource="#PathwayStep429" />
 <bp:pathwayOrder rdf:resource="#PathwayStep420" />
 <bp:pathwayOrder rdf:resource="#PathwayStep431" />
 <bp:pathwayOrder rdf:resource="#PathwayStep421" />
 <bp:pathwayOrder rdf:resource="#PathwayStep432" />
 <bp:pathwayOrder rdf:resource="#PathwayStep422" />
 <bp:pathwayOrder rdf:resource="#PathwayStep423" />
 <bp:pathwayOrder rdf:resource="#PathwayStep424" />
 <bp:pathwayOrder rdf:resource="#PathwayStep425" />
 <bp:pathwayOrder rdf:resource="#PathwayStep426" />
 <bp:pathwayOrder rdf:resource="#PathwayStep427" />
 <bp:pathwayOrder rdf:resource="#PathwayStep430" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction328" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction339" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction329" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction337" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction327" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction338" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction335" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction336" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction333" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction334" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction331" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction332" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction330" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence420" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by ERBB2 TMD/JMD mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recurrent missense mutations in regions encoding the transmembrane domain (TMD) and the juxtamembrane domain (JMD) are frequently reported in cancer. The ERBB2 TMD mutants include ERBB2 V659E, ERBB2 V659K, ERBB2 G660D, ERBB2 G660R, ERBB2 S653C, ERBB2 R677L and ERBB2 R678Q. The ERBB2 JMD mutants include ERBB2 E693K and ERBB2 Q709L. ERBB2 TMD mutants  ERBB2 V659E, ERBB2 G660D and S653C (de Martino et al. 2014) are known to be activating. ERBB2 TMD/JMD mutants ERBB2 R678Q, ERBB2 E693K, and ERBB2 Q709L mutations may be activating when co-expressed with a wild type ERBB2 receptor (Pahuja et al. 2018). TMD and JMD mutations can activate ERBB2 signaling by improving the active dimer interface or by stabilizing the active conformation. TMD/JMD mutants that are activating in the presence of wild type ERBB2, such as ERBB2 R678Q, may form homodimers with the wild type ERBB2 (Pahuja et al. 2018).  Based on trans-autophosphorylation of ERBB2 and its dimerization partners EGFR and ERBB3, the following ERBB2 TMD/JMD mutants are assumed to form heterodimers with EGFR and ERBB3: ERBB2 S653C (de Martino et al. 2014) ERBB2 R678Q (Bose et al. 2013, Pahuja et al. 2018).  Phosphorylation of tyrosine residues in the C-tail of ERBB2 was shown for the following ERBB2 TMD/JMD mutants: ERBB2 V659E (Pahuja et al. 2018); ERBB2 V659K (Pahuja et al. 2018); ERBB2 G660D (Pahuja et al. 2018); ERBB2 G660R (Pahuja et al. 2018); ERBB2 S653C (de Martino et al. 2014 - phosphorylation at Y1248 demonstrated); ERBB2 R677L (Pahuja et al. 2018); ERBB2 R678Q (Bose et al. 2013; de Martino et al. 2014 - phosphorylation at Y1248 demonstrated; Pahuja et al. 2018); ERBB2 Q709L (Pahuja et al. 2018)  Phosphorylation of tyrosine residues in the C-tail of EGFR was demonstrated for ERBB2 S653C (de Martino et al. 2014 - phosphorylation at Y1068) and ERBB2 R678Q (Bose et al. 2013; de Martino et al. 2014 - phosphorylation at Y1068).  Phosphorylation of tyrosine residues in the C-tail of ERBB3 was demonstrated for ERBB2 S653C (de Martino et al. 2014 - phosphorylation at Y1197) and ERBB2 R678Q (Bose et al. 2013; de Martino et al. 2014 - phosphorylation at Y1197).  Activation of downstream RAS signaling was shown for ERBB2 S653C (de Martino et al. 2014) and ERBB2 R678Q (Bose et al. 2013, de Martino et al. 2014) through activating tyrosine phosphorylation on ERKs (MAPK1 and MAPK3) and SHC1.  Activation of downstream PLCG1 signaling was demonstrated for ERBB2 R678Q, through activating tyrosine phosphorylation on PLCG1 (Bose et al. 2013).  Activation of PI3K/AKT signaling by ERBB2 TMD/JMD mutants has not been tested.  Signaling by ERBB2 V659K, ERBB2 G660D, ERBB2 G660R, ERBB2 R677L, ERBB2 E693K and ERBB2 Q709L has not been sufficiently studied and they are annotated as candidates.  The following ERBB2 TMD/JMD mutants are sensitive to  the therapeutic antibody trastuzumab (herceptin): ERBB2 V659E (Pahuja et al. 2018); ERBB2 G660D (Pahuja et al. 2018); ERBB2 G660R (Pahuja et al. 2018); ERBB2 R678Q (Bose et al. 2013, Pahuja et al. 2018); ERBB2 Q709L (Pahuja et al. 2018);  With respect to pertuzumab, a therapeutic antibody that block ligand-driven heterodimerization of ERBB2, ERBB2 R678Q is sensitive to pertuzumab, while ERBB2 V659E, ERBB2 G660D, ERBB2 G660R and probably ERBB2 Q709L are resistant (Pahuja et al. 2018).  The following ERBB2 TMD/JMD mutants are sensitive to lapatinib: ERBB2 S653C (de Martino et al. 2014); ERBB2 R678Q (Bose et al. 2013);  The following ERBB2 TMD/JMD mutants are sensitive to neratinib: ERBB2 V659E (Pahuja et al. 2018); ERBB2 G660D (Pahuja et al. 2018); ERBB2 G660R (Pahuja et al. 2018); ERBB2 R678Q (Bose et al. 2013, Pahuja et al. 2018); ERBB2 Q709L (Pahuja et al. 2018);  The following ERBB2 TMD/JMD mutants are sensitive to afatinib: ERBB2 G660D (Pahuja et al. 2018); ERBB2 G660R (Pahuja et al. 2018); ERBB2 S653C (de Martino et al. 2014); ERBB2 R678Q (Pahuja et al. 2018); ERBB2 Q709L (Pahuja et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway93">
 <bp:pathwayOrder rdf:resource="#PathwayStep406" />
 <bp:pathwayOrder rdf:resource="#PathwayStep417" />
 <bp:pathwayOrder rdf:resource="#PathwayStep407" />
 <bp:pathwayOrder rdf:resource="#PathwayStep418" />
 <bp:pathwayOrder rdf:resource="#PathwayStep408" />
 <bp:pathwayOrder rdf:resource="#PathwayStep409" />
 <bp:pathwayOrder rdf:resource="#PathwayStep410" />
 <bp:pathwayOrder rdf:resource="#PathwayStep411" />
 <bp:pathwayOrder rdf:resource="#PathwayStep412" />
 <bp:pathwayOrder rdf:resource="#PathwayStep402" />
 <bp:pathwayOrder rdf:resource="#PathwayStep413" />
 <bp:pathwayOrder rdf:resource="#PathwayStep403" />
 <bp:pathwayOrder rdf:resource="#PathwayStep414" />
 <bp:pathwayOrder rdf:resource="#PathwayStep404" />
 <bp:pathwayOrder rdf:resource="#PathwayStep415" />
 <bp:pathwayOrder rdf:resource="#PathwayStep405" />
 <bp:pathwayOrder rdf:resource="#PathwayStep416" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction319" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction317" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction318" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction315" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction326" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction316" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction313" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction324" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction314" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction325" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction311" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction322" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction312" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction323" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction320" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction310" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction321" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence402" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by ERBB2 KD Mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the kinase domain (KD) of ERBB2 result in constitutive activation of ERBB2 signaling, facilitate heterodimerization of ERBB2 with other EGFR family members and increase the signaling intensity, leading to cellular transformation (Kancha et al. 2011). Only a subset of potential heterodimerization partners has been tested for most ERBB2 KD mutant proteins, so our annotations here are correspondingly limited. ERBB2 L755S and ERBB2 V777L cancer variants were shown to heterodimerize with ERBB3 (HER3) at a higher rate than wild type ERBB2 (Croessmann et al. 2019). Increased activity of ERBB2 L755S, ERBB2 L755P, ERBB2 V777L, ERBB2 D769H, ERBB2 D769Y, ERBB2 V842I, ERBB2 R896C and ERBB2 G778_P780dup in the presence of either EGFR (Kancha et al. 2011, Bose et al. 2013) or ERBB3 (Kancha et al. 2011, Bose et al. 2013, Collier et al. 2013) as a heterodimerization partner was also observed. The interplay of ERBB2 G778_P780dup, ERBB2 I767M and ERBB2 R896C with ERBB3 has not been tested. ERBB2 L869R mutant shows increased activity in the presence of ERBB3, which is further augmented in the presence of dimerization-facilitating ERBB3 E928G mutants (Hanker et al. 2017). The interplay of ERBB2 L869R with EGFR has not been tested. Heterodimerization of ERBB2 KD mutants with ERBB4 has not been tested and ERBB4 is a candidate heterodimerization partner for these KD variants. ERBB2 H878Y mutant has ten times higher kinase activity than the wild type ERBB2 (Hu, Wan et al. 2015; Hu, Hu et al. 2015), but its heterodimerization properties have not been studied and it is therefore annotated as a candidate.  Ligand requirements have not been studied in the context of heterodimerization of ERBB2 KD mutants, but it is assumed that ligands are required.  The signaling properties of ERBB2 L755M (Gonzalez-Alonso et al. 2015), ERBB2 L755W (COSMIC database: Forbes et al. 2017), ERBB2 V777E (Dietz et al. 2017), ERBB2 V777M (Lee et al. 2006, Ross et al. 2016, Zehir et al. 2017), ERBB2 D769N (Tschui et al. 2015), ERBB2 V842E (Siroy et al. 2015), ERBB2 R896H (Cancer Genome Atlas Research Network 2011), ERBB2 L869Q (Lee et al. 2006) and ERBB2 H878R (Trowe et al. 2008, Zehir et al. 2017) have not been experimentally tested, but they are predicted to be pathogenic (COSMIC database: Forbes et al. 2017) and they are annotated as candidates. ERBB2 T733I (Trowe et al. 2008), ERBB2 T798I (Trowe et al. 2008, Hanker et al. 2017) and ERBB2 T798M (Hanker et al. 2017) usually occur as secondary ERBB2 mutations and are responsible for treatment failure. On their own, ERBB2 T733I and ERBB2 T798I appear to be weakly transforming compared with the other ERBB2 KD mutants. As their signaling properties have been poorly studied, ERBB2 T733I, ERBB2 T798I and ERBB2 T798M are annotated as candidates. The binding of ERBB2 KD mutants to ERBIN and the HSP90:CDC37 chaperone:co-chaperone complex has not been tested but is assumed to occur similarly to the wild type ERBB2. Signaling by ERBB2 KD mutants has been organized into subpathways based on the current knowledge of biology of these mutants (heterodimerization, downstream signaling, drug interaction) and on the sequence similarity of their mutations.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway99">
 <bp:pathwayOrder rdf:resource="#PathwayStep440" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction342" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence440" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">sunitinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sunitinib is a first generation type II tyrosine kinase inhibitor with broad specifity for receptor tyrosine kinases, including FLT3. This pathway describes FLT3 mutants that show resistance to sunitinib-mediated inhibition (reviewed in Kazi and Roonstrand, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway98">
 <bp:pathwayOrder rdf:resource="#PathwayStep438" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction341" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence438" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">midostaurin-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Midostaurin, also known as PKC412, is a type I tyrosine kinase inhibitor with activity against FLT3 (reviewed in Kazi and Roonstrand, 2019; Luskin and DeAngelo, 2017). This pathway describes FTL3 mutants that are resistant to inhibition by midostaurin.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway97">
 <bp:pathwayOrder rdf:resource="#PathwayStep436" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction340" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence436" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KW2449-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KW-2449 is a second generation, type I aurora kinase and FLT3 tyrosine kinase inhibitor, Despite effectiveness against a number of FLT3 mutant alleles, it has been withdrawn from development due to poor pharmacodynamics (reviewed in Larrosa-Garcia and Baer, 2017; Kazi and Roonstrand, 2019). This pathway describes FLT3 mutants that are resistant to inhibition by KW-2449.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence257">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence256">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence259">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence258">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence275">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence274">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence277">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence276">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence271">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway81">
 <bp:pathwayOrder rdf:resource="#PathwayStep365" />
 <bp:pathwayOrder rdf:resource="#PathwayStep358" />
 <bp:pathwayOrder rdf:resource="#PathwayStep359" />
 <bp:pathwayOrder rdf:resource="#PathwayStep360" />
 <bp:pathwayOrder rdf:resource="#PathwayStep361" />
 <bp:pathwayOrder rdf:resource="#PathwayStep362" />
 <bp:pathwayOrder rdf:resource="#PathwayStep363" />
 <bp:pathwayOrder rdf:resource="#PathwayStep364" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction278" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction279" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction285" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction283" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction284" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction281" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction282" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction280" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence358" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive Signaling by Overexpressed ERBB2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Overexpression of ERBB2 (HER2), usually as a consequence of ERBB2 gene amplification, results in formation of ERBB2 homodimers. Under normal conditions, only ERBB2 heterodimers form, as ERBB2 is expressed at low levels. ERBB2 homodimerization leads to activation of ERBB2 signaling in the absence of growth factors. Signaling by ERBB2 homodimers mainly activates the RAS/RAF/MAPK signaling cascade, while PI3K/AKT signaling is not significantly affected (Pickl and Ries 2009). Trastuzumab (Herceptin), a recombinant antibody clinically approved as an anti-cancer therapeutic for ERBB2-overexpressing cancers, preferentially binds to ERBB2 homodimers (Pickl and Ries 2009). Accurate functional analysis of ERBB2 signaling may require 3D instead of 2D cell culture (Pickl and Ries 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence270">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway80">
 <bp:pathwayOrder rdf:resource="#PathwayStep366" />
 <bp:pathwayOrder rdf:resource="#PathwayStep357" />
 <bp:pathwayOrder rdf:resource="#PathwayStep401" />
 <bp:pathwayOrder rdf:resource="#PathwayStep419" />
 <bp:pathwayOrder rdf:resource="#PathwayStep383" />
 <bp:pathwayOrder rdf:resource="#PathwayStep385" />
 <bp:pathwayComponent rdf:resource="#Pathway81" />
 <bp:pathwayComponent rdf:resource="#Pathway92" />
 <bp:pathwayComponent rdf:resource="#Pathway91" />
 <bp:pathwayComponent rdf:resource="#Pathway94" />
 <bp:pathwayComponent rdf:resource="#Pathway82" />
 <bp:pathwayComponent rdf:resource="#Pathway93" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence357" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by ERBB2 in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Gene amplification of the ERBB2 (HER2) oncogene is observed across various different cancer types. In addition to HER2 gene amplification, sequencing of tumour samples have revealed HER2 mutations, which fall within three major regions:  the extracellular domain (ECD), transmembrane domain/ juxtamembrane domain (TMD/JMD) and kinase domain (KD). Based on the functional studies of their catalytic activity, signaling and drug sensitivity, as well as their time of occurence with respect to treatment, these mutation can be classified as primary mutations, that can be activating or silent, and may confer drug resistance, and secondary mutations, associated with development of drug resistance upon initial response to targeted therapy.  Overexpression of ERBB2 (HER2) protein, usually as a consequence of ERBB2 gene amplification, leads to formation of constitutively active, growth factor independent, ERBB2 homodimers, which are sensitive to the therapeutic antibody trastuzumab (herceptin) (Pickl and Ries 2009). Co-overexpression of ERBB2 and its dimerization partner ERBB3 leads to formation of both ERBB2 homodimers and ERRB2:ERBB3 heterodimers and is associated with chemotherapy resistance and reduced relapse-free and overall survival (Spears et al. 2012).  Mutations in the kinase domain (KD) of ERBB2 result in constitutive activation of ERBB2 signaling, facilitate heterodimerization of ERBB2 with other EGFR family members and increase the signaling intensity (Kancha et al. 2011). Functionally studied ERBB2 KD mutants include ERBB2 L755S, ERBB2 L755P, ERBB2 I767M, ERBB2 D769H, ERBB2 V777L, ERBB2 G778_P780dup, ERBB2 T798I, ERBB2 T798M, ERBB2 V842I, ERBB2 T862A, ERBB2 L869R, ERBB2 H878Y and ERBB2 R896C (Kancha et al. 2011, Bose et al. 2013, Collier et al. 2013, Hu, Wan et al. 2015; Hu, Hu et al. 2015, Hanker et al. 2017, Croessmann et al. 2019).  Sensitivity to tyrosine kinase inhibitors (TKIs) and the therapeutic antibody trastuzumab (herceptin) differs between different ERBB2 KD mutants (Bose et al. 2013, Rexer et al. 2013, Nagano et al. 2018).  ERBB2 extracellular domain (ECD) mutants harbor missense mutations that lead to substitutions of amino acid residues in the heterodimerization arm contact surface, involved in formation of ERBB2 heterodimers (Greulich et al. 2012).  Recurrent missense mutations in regions encoding the transmembrane domain (TMD) and the juxtamembrane domain (JMD) are frequently reported in cancer. TMD and JMD mutations can activate ERBB2 signaling by improving the active dimer interface or by stabilizing the active conformation (Ou et al. 2017, Pahuja et al. 2018).  ERBB2 TMD/JMD mutants differ in their sensitivity to the therapeutic antibody pertuzumab, which blocks ligand-driven heterodimerization of ERBB2 (Pahuja et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence273">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence272">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway85">
 <bp:pathwayOrder rdf:resource="#PathwayStep372" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction288" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence372" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistance of ERBB2 KD mutants to neratinib</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes resistance of ERBB2 KD mutants to tyrosine kinase inhibitor neratinib (Hanker et al. 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway84">
 <bp:pathwayOrder rdf:resource="#PathwayStep370" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction287" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence370" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistance of ERBB2 KD mutants to tesevatinib</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes resistance of ERBB2 KD mutants to tyrosine kinase inhibitor tesevatinib (Trowe et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway83">
 <bp:pathwayOrder rdf:resource="#PathwayStep368" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction286" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence368" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistance of ERBB2 KD mutants to sapitinib</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes resistance of ERBB2 KD mutants to tyrosine kinase inhibitor sapitinib (Nagano et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway82">
 <bp:pathwayOrder rdf:resource="#PathwayStep377" />
 <bp:pathwayOrder rdf:resource="#PathwayStep367" />
 <bp:pathwayOrder rdf:resource="#PathwayStep379" />
 <bp:pathwayOrder rdf:resource="#PathwayStep369" />
 <bp:pathwayOrder rdf:resource="#PathwayStep381" />
 <bp:pathwayOrder rdf:resource="#PathwayStep371" />
 <bp:pathwayOrder rdf:resource="#PathwayStep373" />
 <bp:pathwayOrder rdf:resource="#PathwayStep375" />
 <bp:pathwayComponent rdf:resource="#Pathway90" />
 <bp:pathwayComponent rdf:resource="#Pathway85" />
 <bp:pathwayComponent rdf:resource="#Pathway84" />
 <bp:pathwayComponent rdf:resource="#Pathway83" />
 <bp:pathwayComponent rdf:resource="#Pathway89" />
 <bp:pathwayComponent rdf:resource="#Pathway88" />
 <bp:pathwayComponent rdf:resource="#Pathway87" />
 <bp:pathwayComponent rdf:resource="#Pathway86" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence367" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Drug resistance in ERBB2 KD mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 kinase domain (KD) mutants vary in their resistance to various tyrosine kinase inhibitors and therapeutic antibody trastuzumab (herceptin). The following ERBB2 KD mutants are resistant to the therapeutic antibody trastuzumab (herceptin):  ERBB2 L755P (Nagano et al. 2018); ERBB2 L755S (Nagano et al. 2018); ERBB2 I767M (Bose et al. 2013); ERBB2 D769Y (Nagano et al. 2018); ERBB2 V777L (Nagano et al. 2018); ERBB2 G778_P780dup (Bose et al. 2013, Nagano et al. 2018); ERBB2 T798M (Rexer et al. 2013); ERBB2 V842I (Nagano et al. 2018); ERBB2 T862A (Nagano et al. 2018); ERBB2 L869R (Hanker et al. 2017);  For ERBB2 R896C, both resistance (Bose et al. 2013) and sensitivity (Nagano et al. 2018) to trastuzumab have been reported. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway89">
 <bp:pathwayOrder rdf:resource="#PathwayStep380" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction292" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence380" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistance of ERBB2 KD mutants to AEE788</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes resistance of ERBB2 KD mutants to tyrosine kinase inhibitor AEE788 (Kancha et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway88">
 <bp:pathwayOrder rdf:resource="#PathwayStep378" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction291" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence378" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistance of ERBB2 KD mutants to trastuzumab</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes resistance of ERBB2 KD mutants to therapeutic antibody trastuzumab (herceptin) (Bose et al. 2013, Rexer et al. 2013, Hanker et al. 2017, Nagano et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway87">
 <bp:pathwayOrder rdf:resource="#PathwayStep376" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction290" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence376" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistance of ERBB2 KD mutants to afatinib</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes resistance of ERBB2 KD mutants to tyrosine kinase inhibitor afatinib (Rexer et al. 2013, Hanker et al. 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway86">
 <bp:pathwayOrder rdf:resource="#PathwayStep374" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction289" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence374" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistance of ERBB2 KD mutants to osimertinib</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes resistance of ERBB2 KD mutants to tyrosine kinase inhibitor osimertinib (Hanker et al. 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence268">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence267">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence269">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence286">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence285">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence288">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence287">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence282">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway70">
 <bp:pathwayOrder rdf:resource="#PathwayStep321" />
 <bp:pathwayOrder rdf:resource="#PathwayStep313" />
 <bp:pathwayComponent rdf:resource="#Pathway72" />
 <bp:pathwayComponent rdf:resource="#Pathway71" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence313" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by RAS mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Members of the RAS gene family were the first oncogenes to be identified, and mutations in RAS are present in ~20-30% of human cancers (reviewed in Prior et al, 2012). Mutations in the KRAS gene are the most prevalent, and are found with high frequency in colorectal cancer, non-small cell lung cancer and pancreatic cancer, among others. The reasons for the lower prevalence of HRAS and NRAS mutations in human cancers are not fully understood, but may reflect gene-specific functions as well as differential codon usage and spatio-temporal regulation (reviewed in Prior et al, 2012; Stephen et al, 2014; Pylayeva-Gupta et al, 2011). Activating RAS mutations contribute to cellular proliferation, transformation and survival by activating the MAPK signaling pathway, the AKT pathway and the RAL GDS pathway, among others (reviewed in Stephen et al, 2014; Pylayeva-Gupta et al, 2011).  Although the frequency and distribution varies between RAS genes and cancer types, the vast majority of activating RAS mutations occur at one of three residues - G12, G13 and Q61. Mutations at these sites favour the RAS:GTP bound form and yield constitutively active versions of the protein (reviewed in Prior et al, 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence281">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence284">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence283">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway74">
 <bp:pathwayOrder rdf:resource="#PathwayStep325" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction252" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence325" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by RAS GAP mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes RAS mutants whose intrinsic GTPase activity can&apos;t be stimulated by GTPase activating proteins (GAPs). These RAS mutants therefore support increased RAS pathway activity (reviewed in Prior et al, 2012; Pylayeva and Gupta, 2011, King et al, 2013; Cox and Der, 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway73">
 <bp:pathwayOrder rdf:resource="#PathwayStep323" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction251" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence323" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by RAS GTPase mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes RAS mutants with decreased intrinsic GTPase activity that therefore support increased RAS pathway activity (reviewed in Prior et al, 2012; Pylayeva and Gupta, 2011, King et al, 2013; Cox and Der, 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence280">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway72">
 <bp:pathwayOrder rdf:resource="#PathwayStep322" />
 <bp:pathwayOrder rdf:resource="#PathwayStep324" />
 <bp:pathwayComponent rdf:resource="#Pathway74" />
 <bp:pathwayComponent rdf:resource="#Pathway73" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence322" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS GTPase cycle mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS proteins cycle between an active GTP-bound state and an inactive GDP-bound state. GTPase activating proteins (GAPs) stimulate the low intrinsic GTPase activity of RAS proteins, converting the active to the inactive form, while guanine nucleotide exchange factors (GEFs) stimulate the intrinsic dissociation of GDP, allowing its replacement with GTP and consequent activation of RAS. Disease-causing mutations in RAS promote constitutive signaling by favouring the accumulation of RAS:GTP. The vast majority of these mutations are loss of function mutations at G12, G13 and Q61. These mutations disrupt the GTPase activity of RAS proteins by interfering with nucleophilic attack on the gamma phosphate of GTP. A smaller proportion of RAS mutations increase the intrinsic GDP dissociation rate, while other mutations interfere with RAS interactions with GAPs (reviewed in Prior et al, 2012; Pylayeva-Gupta et al, 2011; Stephen et al, 2014; Samatar and Poulikakos, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway71">
 <bp:pathwayOrder rdf:resource="#PathwayStep314" />
 <bp:pathwayOrder rdf:resource="#PathwayStep315" />
 <bp:pathwayOrder rdf:resource="#PathwayStep316" />
 <bp:pathwayOrder rdf:resource="#PathwayStep317" />
 <bp:pathwayOrder rdf:resource="#PathwayStep318" />
 <bp:pathwayOrder rdf:resource="#PathwayStep319" />
 <bp:pathwayOrder rdf:resource="#PathwayStep320" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction247" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction248" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction245" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction246" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction244" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction250" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction249" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence314" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling downstream of RAS mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Disease-causing mutations in RAS favour the active RAS:GTP bound form and yield constitutively active forms of the protein (reviewed in Prior et al, 2011; Maertens and Cichowski, 2014).  Mutations in RAS contribute to cellular proliferation, transformation and survival by activating the MAPK signaling pathway, the AKT pathway and the RAL GDS pathway, among others (reviewed in Stephen et al, 2014; Pylayeva-Gupta et al, 2011)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway78">
 <bp:pathwayOrder rdf:resource="#PathwayStep350" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction273" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence350" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PTEN Loss of Function in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function mutations affecting the phosphatase domain of PTEN are frequently found in sporadic cancers (Kong et al. 1997, Lee et al. 1999, Han et al. 2000), as well as in PTEN hamartoma tumor syndromes (PHTS) (Marsh et al. 1998). PTEN can also be inactivated by gene deletion or epigenetic silencing, or indirectly by overexpression of microRNAs that target PTEN mRNA (Huse et al. 2009). Cells with deficient PTEN function have increased levels of PIP3, and therefore increased AKT activity. For a recent review, please refer to Hollander et al. 2011.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway77">
 <bp:pathwayOrder rdf:resource="#PathwayStep332" />
 <bp:pathwayOrder rdf:resource="#PathwayStep343" />
 <bp:pathwayOrder rdf:resource="#PathwayStep333" />
 <bp:pathwayOrder rdf:resource="#PathwayStep344" />
 <bp:pathwayOrder rdf:resource="#PathwayStep334" />
 <bp:pathwayOrder rdf:resource="#PathwayStep345" />
 <bp:pathwayOrder rdf:resource="#PathwayStep335" />
 <bp:pathwayOrder rdf:resource="#PathwayStep346" />
 <bp:pathwayOrder rdf:resource="#PathwayStep336" />
 <bp:pathwayOrder rdf:resource="#PathwayStep347" />
 <bp:pathwayOrder rdf:resource="#PathwayStep337" />
 <bp:pathwayOrder rdf:resource="#PathwayStep348" />
 <bp:pathwayOrder rdf:resource="#PathwayStep338" />
 <bp:pathwayOrder rdf:resource="#PathwayStep339" />
 <bp:pathwayOrder rdf:resource="#PathwayStep340" />
 <bp:pathwayOrder rdf:resource="#PathwayStep341" />
 <bp:pathwayOrder rdf:resource="#PathwayStep331" />
 <bp:pathwayOrder rdf:resource="#PathwayStep342" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction258" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction269" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction259" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction256" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction267" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction257" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction268" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction265" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction255" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction266" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction263" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction264" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction261" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction272" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction262" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction270" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction260" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction271" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence331" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive Signaling by AKT1 E17K in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">While AKT1 gene copy number, expression level and phosphorylation are often increased in cancer, only one low frequency point mutation has been repeatedly reported in cancer and functionally studied. This mutation represents a substitution of a glutamic acid residue with lysine at position 17 of AKT1, and acts by enabling AKT1 to bind PIP2. PIP2-bound AKT1 is phosphorylated by TORC2 complex and by PDPK1 that is always present at the plasma membrane, due to low affinity for PIP2. Therefore, E17K substitution abrogates the need for PI3K in AKT1 activation (Carpten et al. 2007, Landgraf et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway76">
 <bp:pathwayOrder rdf:resource="#PathwayStep328" />
 <bp:pathwayOrder rdf:resource="#PathwayStep329" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction254" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction253" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence328" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive Signaling by Aberrant PI3K in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by PI3K/AKT is frequently constitutively activated in cancer via gain-of-function mutations in one of the two PI3K subunits - PI3KCA (encoding the catalytic subunit p110alpha) or PIK3R1 (encoding the regulatory subunit p85alpha). Gain-of-function mutations activate PI3K signaling by diverse mechanisms. Mutations affecting the helical domain of PIK3CA and mutations affecting nSH2 and iSH2 domains of PIK3R1 impair inhibitory interactions between these two subunits while preserving their association. Mutations in the catalytic domain of PIK3CA enable the kinase to achieve an active conformation. PI3K complexes with gain-of-function mutations therefore produce PIP3 and activate downstream AKT in the absence of growth factors (Huang et al. 2007, Zhao et al. 2005, Miled et al. 2007, Horn et al. 2008, Sun et al. 2010, Jaiswal et al. 2009, Zhao and Vogt 2010, Urick et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway75">
 <bp:pathwayOrder rdf:resource="#PathwayStep327" />
 <bp:pathwayOrder rdf:resource="#PathwayStep349" />
 <bp:pathwayOrder rdf:resource="#PathwayStep330" />
 <bp:pathwayComponent rdf:resource="#Pathway78" />
 <bp:pathwayComponent rdf:resource="#Pathway77" />
 <bp:pathwayComponent rdf:resource="#Pathway76" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence327" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3K/AKT Signaling in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Class IA PI3K is a heterodimer of a p85 regulatory subunit (encoded by PIK3R1, PIK3R2 or PIK3R3) and a p110 catalytic subunit (encoded by PIK3CA, PIK3CB or PIK3CD). In the absence of activating signals, the regulatory subunit stabilizes the catalytic subunit while inhibiting its activity. The complex becomes activated when extracellular signals stimulate the phosphorylation of the cytoplasmic domains of transmembrane receptors or receptor-associated proteins. The p85 regulatory subunit binds phosphorylated motifs of activator proteins, which induces a conformational change that relieves p85-mediated inhibition of the p110 catalytic subunit and enables PI3K to phosphorylate PIP2 to form PIP3. The phosphoinositide kinase activity of PI3K is opposed by the phosphoinositide phosphatase activity of PTEN.   PIP3 acts as a messenger that recruits PDPK1 (PDK1) and AKT (AKT1, AKT2 or AKT3) to the plasma membrane. PDPK1 also possesses a low affinity for PIP2, so small amounts of PDPK1 are always present at the membrane. Binding of AKT to PIP3 induces a conformational change that enables TORC2 complex to phosphorylate AKT at a conserved serine residue (S473 in AKT1). Phosphorylation at the serine residue enables AKT to bind to PDPK1 and exposes a conserved threonine residue (T308) that is phosphorylated by PDPK1. AKT phosphorylated at both serine and threonine residues dissociates from the plasma membrane and acts as a serine/threonine kinase that phosphorylates a number of cytosolic and nuclear targets involved in regulation of cell metabolism, survival and gene expression.  For a recent review, please refer to Manning and Cantley, 2007.     Signaling by PI3K/AKT is frequently constitutively activated in cancer. This activation can be via gain-of-function mutations in PI3KCA (encoding catalytic subunit p110alpha), PIK3R1 (encoding regulatory subunit p85alpha) and AKT1. The PI3K/AKT pathway can also be constitutively activated by loss-of-function mutations in tumor suppressor genes such as PTEN.   Gain-of-function mutations activate PI3K signaling by diverse mechanisms. Mutations affecting the helical domain of PIK3CA and mutations affecting nSH2 and iSH2 domains of PIK3R1 impair inhibitory interactions between these two subunits while preserving their association. Mutations in the catalytic domain of PIK3CA enable the kinase to achieve an active conformation. PI3K complexes with gain-of-function mutations therefore produce PIP3 and activate downstream AKT in the absence of growth factors (Huang et al. 2007, Zhao et al. 2005, Miled et al. 2007, Horn et al. 2008, Sun et al. 2010, Jaiswal et al. 2009, Zhao and Vogt 2010, Urick et al. 2011).  While AKT1 gene copy number, expression level and phosphorylation are often increased in cancer, only one low frequency point mutation has been repeatedly reported in cancer and functionally studied. This mutation represents a substitution of a glutamic acid residue with lysine at position 17 of AKT1, and acts by enabling AKT1 to bind PIP2. PIP2-bound AKT1 is phosphorylated by TORC2 complex and by PDPK1 that is always present at the plasma membrane, due to low affinity for PIP2. Therefore, E17K substitution abrogates the need for PI3K in AKT1 activation (Carpten et al. 2007, Landgraf et al. 2008).    Loss-of-function mutations affecting the phosphatase domain of PTEN are frequently found in sporadic cancers (Kong et al. 1997, Lee et al. 1999, Han et al. 2000), as well as in PTEN hamartoma tumor syndromes (PHTS) (Marsh et al. 1998). PTEN can also be inactivated by gene deletion or epigenetic silencing, or indirectly by overexpression of microRNAs that target PTEN mRNA (Huse et al. 2009). Cells with deficient PTEN function have increased levels of PIP3, and therefore increased AKT activity. For a recent review, please refer to Hollander et al. 2011.  Because of their clear involvement in human cancers, PI3K and AKT are targets of considerable interest in the development of small molecule inhibitors. Although none of the currently available inhibitors display preference for mutant variants of PIK3CA or AKT, several inhibitors targeting the wild-type kinases are undergoing clinical trials. These include dual PI3K/mTOR inhibitors, class I PI3K inhibitors, pan-PI3K inhibitors, and pan-AKT inhibitors. While none have yet been approved for clinical use, these agents show promise for future therapeutics. In addition, isoform-specific PI3K and AKT inhibitors are currently being developed, and may provide more specific treatments along with reduced side-effects. For a recent review, please refer to Liu et al. 2009.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway79">
 <bp:pathwayOrder rdf:resource="#PathwayStep354" />
 <bp:pathwayOrder rdf:resource="#PathwayStep355" />
 <bp:pathwayOrder rdf:resource="#PathwayStep352" />
 <bp:pathwayOrder rdf:resource="#PathwayStep353" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction276" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction277" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction274" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction275" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence352" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by LTK in cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LTK is a member of the anaplastic lymphoma kinase (ALK)/LTK subfamily within the insulin receptor superfamily of RTKs. LTK encodes an 864-amino-acid protein consisting of extracellular, transmembrane, and tyrosine kinase domains and a short carboxy terminus. The LTK kinase domain shares 80% identity with ALK (Roll and Reuther, 2012). The biological role of LTK is not well defined under normal physiological conditions, and unlike ALK, a clear role for LTK in cancer is also not yet well established. LTK is overexpressed in leukemia, and high expression of LTK in early-stage non-small cell lung cancer (NSCLC) has been associated with greater risk of metastasis (Mueller-Tidow et al, 2005; Roll and Reuther, 2012). More recently, a novel CLIP1-LTK fusion protein has been identified in a small proportion of NSCLC cases (Izumi et al, 2021).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence279">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence278">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway63">
 <bp:pathwayOrder rdf:resource="#PathwayStep289" />
 <bp:pathwayOrder rdf:resource="#PathwayStep291" />
 <bp:pathwayComponent rdf:resource="#Pathway65" />
 <bp:pathwayComponent rdf:resource="#Pathway64" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence289" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by MRAS-complex mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A complex of MRAS, SHOC2 and the phosphatase PP1 contributes to the activation of RAF proteins by removing an inhibitory phosphorylation that mediates binding to 14-3-3 (also known as YWHAB) proteins (Rodriguez-Viciano et al, 2006; Young et al, 2013;reviewed in Simanshu et al, 2017; Lavoie and Therrien, 2015). Activating and inactivating mutations in each of the components of this dephosphorylating complex have been identified in RASopathies as well as at low frequency in some cancers (Cordeddu et al, 2009; Hannig et al, 2014; Gripp et al, 2016; Higgin et al, 2017; Motta et al, 2016; Motta et al, 2019a,b).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway62">
 <bp:pathwayOrder rdf:resource="#PathwayStep281" />
 <bp:pathwayOrder rdf:resource="#PathwayStep282" />
 <bp:pathwayOrder rdf:resource="#PathwayStep283" />
 <bp:pathwayOrder rdf:resource="#PathwayStep284" />
 <bp:pathwayOrder rdf:resource="#PathwayStep285" />
 <bp:pathwayOrder rdf:resource="#PathwayStep286" />
 <bp:pathwayOrder rdf:resource="#PathwayStep287" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction225" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction226" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction223" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction224" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction221" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction222" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction220" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence281" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Paradoxical activation of RAF signaling by kinase inactive BRAF</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">While BRAF-specific inhibitors inhibit MAPK/ERK activation in the presence of the BRAF V600E mutant, paradoxical activation of ERK signaling has been observed after treatment of cells with inhibitor in the presence of WT BRAF (Wan et al, 2004; Garnett et al, 2005; Heidorn et al, 2010; Hazivassiliou et al, 2010; Poulikakos et al, 2010). This paradoxical ERK activation is also seen in cells expressing kinase-dead or impaired versions of BRAF such as D594V, which occur with low frequency in some cancers (Wan et al, 2004; Heidorn et al, 2010).  Unlike BRAF V600E, which occurs exclusively of activating RAS mutations, kinase-impaired versions of BRAF are coincident with RAS mutations in human cancers, and indeed, paradoxical activation of ERK signaling in the presence of inactive BRAF is enhanced in the presence of oncogenic RAS (Heidorn et al, 2010; reviewed in Holderfield et al, 2014).  Although the details remain to be worked out, paradoxical ERK activation in the presence of inactive BRAF appears to rely on enhanced dimerization with and transactivation of CRAF (Heidorn et al, 2010; Hazivassiliou et al, 2010; Poulikakos et al, 2010;  Roring et al, 2012; Rajakulendran et al, 2009; Holderfield et al, 2013; Freeman et al, 2013; reviewed in Roskoski, 2010; Samatar and Poulikakos, 2014; Lavoie and Therrien, 2015). RAF inhibitors can promote association of RAF-RAS interaction and enhanced RAF dimerization through disruption of intramolecular interactions between the kinase domain and its N-terminal regulatory region. Moreover, specific BRAF inhibitors can only occupy one protomer within the transcactivated BRAF dimer due to negative co-operativity leading to paradoxical ERK activation. (Karoulia et al, 2016; Jin et al, 2017, reviewed in Karoulia et al, 2017).   </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway61">
 <bp:pathwayOrder rdf:resource="#PathwayStep277" />
 <bp:pathwayOrder rdf:resource="#PathwayStep278" />
 <bp:pathwayOrder rdf:resource="#PathwayStep279" />
 <bp:pathwayOrder rdf:resource="#PathwayStep273" />
 <bp:pathwayOrder rdf:resource="#PathwayStep274" />
 <bp:pathwayOrder rdf:resource="#PathwayStep275" />
 <bp:pathwayOrder rdf:resource="#PathwayStep276" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction214" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction215" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction213" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction218" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction219" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction216" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction217" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence273" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by RAF1 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAF1, also known as CRAF, is mutated in a number of germline RASopathies including Noonan Syndrome, Costello Syndrome and others, and also at low frequency in a number of cancers (reviewed in Rauen, 2013; Samatar and Poulikakos, 2015). Activating mutations cluster around conserved region 2 (CR2) which is required for regulation of the protein and the activation segment in CR3 (reviewed in Rauen, 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway60">
 <bp:pathwayOrder rdf:resource="#PathwayStep271" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction212" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence271" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS signaling downstream of NF1 loss-of-function variants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF1 is a RAS GAP that stimulates the intrinsic RAS GTPase activity, thereby shifting the RAS pathway towards the inactive state (reviewed in King et al, 2013).  Loss-of-function mutations in NF1 have been identified both in germline diseases like neurofibromatosis 1 and in a range of sporadically occurring cancers.  These mutations, which range from complete gene deletions to missense or frameshift mutations, generally decrease NF1 protein levels and abrogate RAS GAP activity in the cells, resulting in constitutive RAS pathway activation (reviewed in Maertens and Cichowski, 2014; Tidyman and Rauen, 2009; Ratner and Miller, 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway67">
 <bp:pathwayOrder rdf:resource="#PathwayStep299" />
 <bp:pathwayOrder rdf:resource="#PathwayStep300" />
 <bp:pathwayOrder rdf:resource="#PathwayStep301" />
 <bp:pathwayOrder rdf:resource="#PathwayStep302" />
 <bp:pathwayOrder rdf:resource="#PathwayStep296" />
 <bp:pathwayOrder rdf:resource="#PathwayStep297" />
 <bp:pathwayOrder rdf:resource="#PathwayStep298" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction236" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction234" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction235" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction232" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction233" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction230" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction231" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence296" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by moderate kinase activity BRAF mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In addition to the highly prevalent and activating V600E BRAF mutations, numerous moderately activating and less common mutations have also been identified in human cancers (Forbes et al, 2015).  Unlike the case for their highly activating counterparts, signaling through these mutant versions of BRAF depends both upon RAS binding and RAF dimerization (Wan et al, 2004; Freeman et al, 2013; Roring et al, 2012; reviewed in Lito et al, 2013; Lavoie and Therrien, 2015)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway66">
 <bp:pathwayOrder rdf:resource="#PathwayStep294" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction229" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence294" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by MAP2K mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activating mutations in MAP2K1 and MAP2K2, the genes encoding MEK1 and MEK2, have been identified at low frequency in a variety of cancers as well as in germline diseases such as Noonan syndrome, cardiofaciocutaneous syndromes and other RASopathies (reviewed in Samatar and Poulikakos, 2014; Bezniakow et al, 2014; Rauen, 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway65">
 <bp:pathwayOrder rdf:resource="#PathwayStep292" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction228" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence292" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SHOC2 M1731 mutant abolishes MRAS complex function</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes the effect of a loss-of-function mutation in SHOC2 on RAF activation (Rodriguez-Viciano et al, 2006; Hannig et al, 2014). How both loss- and gain-of-function SHOC2 mutants can  contribute to RAF pathway activation remains to be elucidated.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway64">
 <bp:pathwayOrder rdf:resource="#PathwayStep290" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction227" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence290" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Gain-of-function MRAS complexes activate RAF signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes the effect of activating mutations of MRAS-complex components on RAF activation (reivewed in Simanshu et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep266">
 <bp:stepProcess rdf:resource="#BiochemicalReaction208" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep267">
 <bp:stepProcess rdf:resource="#BiochemicalReaction209" />
 <bp:stepProcess rdf:resource="#Catalysis49" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep268">
 <bp:stepProcess rdf:resource="#BiochemicalReaction210" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway69">
 <bp:pathwayOrder rdf:resource="#PathwayStep311" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction243" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence311" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by MAPK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in ERK proteins (MAPK1 and MAPK2) are rare, with mutations reported in ~8% of cervical cancers and 1.5% of head and neck squamous cell carcinomas (Ojesina et al, 2014; Cancer Genome Atlas, 2015; reviewed in Najafi et al, 2019). MAPK proteins with activating mutations are often still dependent on upstream phosphorylation by MAP2K proteins, but support sustained downstream signaling by virtue of being resistant to inactivating dephosphorylations (reviewed in Samatar and Poulikakos, 2014; Liu et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep269">
 <bp:stepProcess rdf:resource="#Catalysis50" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction211" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway68">
 <bp:pathwayOrder rdf:resource="#PathwayStep304" />
 <bp:pathwayOrder rdf:resource="#PathwayStep305" />
 <bp:pathwayOrder rdf:resource="#PathwayStep306" />
 <bp:pathwayOrder rdf:resource="#PathwayStep307" />
 <bp:pathwayOrder rdf:resource="#PathwayStep308" />
 <bp:pathwayOrder rdf:resource="#PathwayStep309" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction237" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction241" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction242" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction240" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction238" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction239" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence304" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by high-kinase activity BRAF mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BRAF is mutated in about 8% of human cancers, with high prevalence in hairy cell leukemia, melanoma, papillary thyroid and ovarian carcinomas, colorectal cancer and a variety of other tumors (Davies et al, 2002; reviewed in Samatar and Poulikakos, 2014). Most BRAF mutations fall in the activation loop region of the kinase or the adjacent glycine rich region. These mutations promote increased kinase activity either by mimicking the effects of activation loop phosphorylations or by promoting the active conformation of the enzyme (Davies et al, 2002; Wan et al, 2004). Roughly 90% of BRAF mutants are represented by the single missense mutation BRAF V600E (Davies et al, 2002; Wan et al, 2004). Other highly active kinase mutants of BRAF include BRAF G469A and BRAF T599dup. G469 is in the glycine rich region of the kinase domain which plays a role in orienting ATP for catalysis, while T599 is one of the two conserved regulatory phosphorylation sites of the activation loop. Each of these mutants has highly enhanced basal kinase activities, phosphorylates MEK and ERK in vitro and in vivo and is transforming when expressed in vivo (Davies et al, 2002; Wan et al, 2004; Eisenhardt et al, 2011). Further functional characterization shows that these highly active mutants are largely resistant to disruption of the BRAF dimer interface, suggesting that they are able to act as monomers (Roring et al, 2012; Brummer et al, 2006; Freeman et al, 2013; Garnett et al, 2005). Activating BRAF mutations occur for the most part independently of RAS activating mutations, and RAS activity levels are generally low in BRAF mutant cells. Moreover, the kinase activity of these mutants is only slightly elevated by coexpression of G12V KRAS, and biological activity of the highly active BRAF mutants is independent of RAS binding (Brummer et al, 2006; Wan et al, 2004; Davies et al, 2002; Garnett et al, 2005). Although BRAF V600E is inhibited by RAF inhibitors such as vemurafenib, resistance frequently develops, in some cases mediated by the expression of a splice variant that lacks the RAS binding domain and shows elevated dimerization compared to the full length V600E mutant (Poulikakos et al, 2011; reviewed in Lito et al, 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep260">
 <bp:stepProcess rdf:resource="#BiochemicalReaction204" />
 <bp:stepProcess rdf:resource="#Catalysis46" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep261">
 <bp:stepProcess rdf:resource="#BiochemicalReaction205" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep262">
 <bp:stepProcess rdf:resource="#Catalysis47" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction206" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep263">
 <bp:stepProcess rdf:resource="#Pathway58" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep264">
 <bp:stepProcess rdf:resource="#Pathway59" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep265">
 <bp:stepProcess rdf:resource="#BiochemicalReaction207" />
 <bp:stepProcess rdf:resource="#Catalysis48" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway52">
 <bp:pathwayOrder rdf:resource="#PathwayStep249" />
 <bp:pathwayOrder rdf:resource="#PathwayStep251" />
 <bp:pathwayComponent rdf:resource="#Pathway54" />
 <bp:pathwayComponent rdf:resource="#Pathway53" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence249" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss of Function of TGFBR2 in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function of transforming growth factor-beta receptor II (TGFBR2) is most prevalent in colorectal cancer. Over 60% of colorectal cancers with microsatellite instability (MSI) harbor inactivating mutations in both alleles of TGFBR2, mostly 1 or 2 bp deletions in the 10 bp adenine repeat that codes for three lysine residues in the extracellular domain of TGFBR2. These small deletions result in a frameshift and a premature stop codon (Markowitz et al. 1995). TGFBR2 kinase domain (KD) mutations are found in ~20% of microsatellite stable (MSS) colorectal cancers and these are mostly missense mutations that results in substitution of conserved amino acids in the kinase domain (Grady et al. 1999), likely impairing the catalytic activity of TGFBR2 KD mutants. The silencing of TGFBR2 gene via promoter methylation has been reported in B-cell lymphoma (Chen et al. 2007). Knockout of murine Tgfbr2 in colonic epithelium promotes azoxymethane-induced colon cancer formation (Biswas et al. 2004) and increases the number of adenomas and adenocarcinomas in Apc+/- mice (Munoz et al. 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway51">
 <bp:pathwayOrder rdf:resource="#PathwayStep247" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction197" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence247" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TGFBR1 LBD Mutants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the ligand-binding domain (LBD) of TGF-beta receptor 1 (TGFBR1) have been reported as germline mutations in Ferguson-Smith tumor (multiple self-healing squamous epithelioma - MSSE), an autosomal-dominant skin cancer condition (Ferguson-Smith et al. 1934, Ferguson-Smith et al. 1971), with tumors frequently showing loss of heterozygosity of the wild-type TGFBR1 allele (Goudie et al. 2011). Somatic mutations in the LBD of TGFBR1 have been reported in esophageal carcinoma (Dulak et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway50">
 <bp:pathwayOrder rdf:resource="#PathwayStep245" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction196" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence245" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TGFBR1 KD Mutants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the kinase domain (KD) of TGF-beta receptor 1 (TGFBR1) have been found in Ferguson-Smith tumor i.e. multiple self-healing squamous epithelioma - MSSE (Goudie et al. 2011), breast cancer (Chen et al. 1998), ovarian cancer (Chen et al. 2001) and head-and-neck cancer (Chen et al. 2001). KD mutations reported in MSSE are nonsense and frameshift mutations that cause premature termination of TGFBR1 translation, resulting in truncated receptors that lack substantial portions of the kinase domain, or cause nonsense-mediated decay of mutant transcripts. A splice site KD mutation c.806-2A&gt;C is predicted to result in the skipping of exon 5 and the absence of KD amino acid residues 269-324 from the mutant receptor. The splice site mutant is expressed at the cell surface but unresponsive to TGF-beta stimulation (Goudie et al. 2004).   TGFBR1 KD mutations reported in breast, ovarian and head-and-neck cancer are missense mutations, and it appears that these mutant proteins are partially functional but that their catalytic activity or protein stability is decreased (Chen et al. 1998, Chen et al. 2001a and b). These mutants are not shown.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway56">
 <bp:pathwayOrder rdf:resource="#PathwayStep255" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction200" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence255" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HHAT G278V doesn&apos;t palmitoylate Hh-Np</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A loss-of-function mutation in HHAT that abrogates palmitoylation of Hh ligand is associated with Syndromic 46, XY Disorder of Sex Development, which results in testis dysgenesis (Callier et al, 2014). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway55">
 <bp:pathwayOrder rdf:resource="#PathwayStep256" />
 <bp:pathwayOrder rdf:resource="#PathwayStep254" />
 <bp:pathwayComponent rdf:resource="#Pathway57" />
 <bp:pathwayComponent rdf:resource="#Pathway56" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence254" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hh mutants abrogate ligand secretion</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hh signaling is required for a number of developmental processes, and mutations that disrupt the normal processing and biogenesis of Hh ligand can result in neonatal abnormalities.  SHH is one of a number of genes that have been associated with the congenital disorder holoprosencephaly, which causes abnormalities in brain and craniofacial development (Roessler et al, 2009; reviewed in Roessler and Muenke, 2011).  SHH variants associated with the condition affect the autocatalytic processing of the precursor and dramatically impair the production of the secreted active Hh-Np, abrogating signaling (reviewed in Pan et al, 2013). Aberrant Hh signaling is also associated with gondal dysgenesis syndromes in which palmitoylation of DHH is abrogated by mutation of the acyltransferase HHAT (Callier et al, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway54">
 <bp:pathwayOrder rdf:resource="#PathwayStep252" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction199" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence252" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TGFBR2 MSI Frameshift Mutants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The short adenine repeat in the coding sequence of TGF-beta receptor II (TGFBR2) gene is frequently targeted by loss-of-function frameshift mutations in colon cancers with microsatellite instability (MSI). The 1- or 2-bp deletions in the adenine stretch of TGFBR2 cDNA introduce a premature stop codon that leads to degradation of the majority of mutant transcripts through nonsense-mediated decay or to production of a truncated TGFBR2 that cannot be presented on the cell surface. Cells that harbor TGFBR2 MSI frameshift mutations are resistant to TGF-beta (TGFB1)-mediated growth inhibition.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway53">
 <bp:pathwayOrder rdf:resource="#PathwayStep250" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction198" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence250" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TGFBR2 Kinase Domain Mutants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Missense mutations in the kinase domain (KD) of TGF-beta receptor II (TGFBR2) are found in ~20% of microsatellite stable (MSS) colon cancers and make affected tumors resistant to TGF-beta (TGFB1)-mediated growth inhibition (Grady et al. 1999). While both alleles of TGFBR2 are affected by inactivating mutations in MSS colorectal cancer (Grady et al. 1999), a study of MSS esophageal carcinoma indicates that TGFBR2 KD mutations may function in a dominant-negative way (Tanaka et al. 2000). KD mutations in TGFBR2 are rarely reported in microsatellite instable (MSI) colorectal cancer (Parsons et al. 1995, Takenoshita et al. 1997).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep277">
 <bp:stepProcess rdf:resource="#Catalysis53" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction217" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway59">
 <bp:pathwayOrder rdf:resource="#PathwayStep266" />
 <bp:pathwayOrder rdf:resource="#PathwayStep267" />
 <bp:pathwayOrder rdf:resource="#PathwayStep268" />
 <bp:pathwayOrder rdf:resource="#PathwayStep269" />
 <bp:pathwayOrder rdf:resource="#PathwayStep265" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction210" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction211" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction209" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction207" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction208" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence265" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by BRAF and RAF1 fusions</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In addition to the more prevalent point mutations, BRAF and RAF1 are also subject to activation as a result of translocation events that yield truncated or fusion products (Jones et al, 2008; Cin et al, 2011; Palanisamy et al, 2010; Ciampi et al, 2005; Stransky et al, 2014; Hutchinson et al, 2013; Zhang et al, 2013; Lee et al, 2012; Ricarte-Filho et al, 2013; reviewed in Lavoie and Therrien et al, 2015). In general these events put the C-terminal kinase domain of BRAF or RAF1 downstream of an N-terminal sequence provided by a partner protein. This removes the N-terminal region of the RAF protein, relieving the autoinhibition imposed by this region of the protein. In addition, some but not all of the fusion partner proteins have been shown to contain coiled-coil or other dimerization domains. Taken together, the fusion proteins are thought to dimerize constitutively and activate downstream signaling (Jones et al, 2008; Lee et al, 2012; Hutchinson et al, 2013; Ciampi et al, 2005; Cin et al, 2011; Stransky et al, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep278">
 <bp:stepProcess rdf:resource="#BiochemicalReaction218" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway58">
 <bp:pathwayOrder rdf:resource="#PathwayStep288" />
 <bp:pathwayOrder rdf:resource="#PathwayStep310" />
 <bp:pathwayOrder rdf:resource="#PathwayStep312" />
 <bp:pathwayOrder rdf:resource="#PathwayStep303" />
 <bp:pathwayOrder rdf:resource="#PathwayStep280" />
 <bp:pathwayOrder rdf:resource="#PathwayStep270" />
 <bp:pathwayOrder rdf:resource="#PathwayStep293" />
 <bp:pathwayOrder rdf:resource="#PathwayStep272" />
 <bp:pathwayOrder rdf:resource="#PathwayStep295" />
 <bp:pathwayOrder rdf:resource="#PathwayStep264" />
 <bp:pathwayComponent rdf:resource="#Pathway59" />
 <bp:pathwayComponent rdf:resource="#Pathway69" />
 <bp:pathwayComponent rdf:resource="#Pathway68" />
 <bp:pathwayComponent rdf:resource="#Pathway70" />
 <bp:pathwayComponent rdf:resource="#Pathway63" />
 <bp:pathwayComponent rdf:resource="#Pathway62" />
 <bp:pathwayComponent rdf:resource="#Pathway61" />
 <bp:pathwayComponent rdf:resource="#Pathway60" />
 <bp:pathwayComponent rdf:resource="#Pathway67" />
 <bp:pathwayComponent rdf:resource="#Pathway66" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence264" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Oncogenic MAPK signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The importance of the RAS/RAF/MAPK cascade in regulating cellular proliferation, differentiation and survival is highlighted by the fact that components of the pathway are mutated with high frequency in a large number of human cancers. Activating mutations in RAS are found in approximately one third of human cancers, while ~8% of tumors express an activated form of BRAF. RAS pathway activation is also achieved in a smaller subset of cancers by loss-of-function mutations in negative regulators of RAS signaling, such as the RAS GAP NF1(reviewed in Prior et al, 2012; Pylayeva-Gupta et al, 2011; Stephen et al, 2014; Lavoie and Therrien, 2015; Lito et al, 2013; Samatar and Poulikakos, 2014; Maertens and Cichowski, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep279">
 <bp:stepProcess rdf:resource="#BiochemicalReaction219" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway57">
 <bp:pathwayOrder rdf:resource="#PathwayStep257" />
 <bp:pathwayOrder rdf:resource="#PathwayStep258" />
 <bp:pathwayOrder rdf:resource="#PathwayStep259" />
 <bp:pathwayOrder rdf:resource="#PathwayStep260" />
 <bp:pathwayOrder rdf:resource="#PathwayStep261" />
 <bp:pathwayOrder rdf:resource="#PathwayStep262" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction203" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction204" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction201" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction202" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction205" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction206" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence257" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hh mutants are degraded by ERAD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hh signaling is required for a number of developmental processes, and mutations that disrupt the normal processing and biogenesis of Hh ligand can result in neonatal abnormalities.  SHH is one of a number of genes that have been associated with the congenital disorder holoprosencephaly, which causes abnormalities in brain and craniofacial development (Roessler et al, 2009; reviewed in Roessler and Muenke, 2011).  SHH variants associated with the condition affect the autocatalytic processing of the precursor and dramatically impair the production of the secreted active Hh-Np, abrogating signaling (reviewed in Pan et al, 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep270">
 <bp:stepProcess rdf:resource="#Pathway60" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep271">
 <bp:stepProcess rdf:resource="#BiochemicalReaction212" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep272">
 <bp:stepProcess rdf:resource="#Pathway61" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep273">
 <bp:stepProcess rdf:resource="#BiochemicalReaction213" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep274">
 <bp:stepProcess rdf:resource="#BiochemicalReaction214" />
 <bp:stepProcess rdf:resource="#Catalysis51" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep275">
 <bp:stepProcess rdf:resource="#BiochemicalReaction215" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep276">
 <bp:stepProcess rdf:resource="#Catalysis52" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction216" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway41">
 <bp:pathwayOrder rdf:resource="#PathwayStep224" />
 <bp:pathwayOrder rdf:resource="#PathwayStep225" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction184" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction185" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence224" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by cytosolic PDGFRA and PDGFRB fusion proteins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In addition to activating missense mutations and in-frame deletions, PDGFRA and PDGFRB are also subject to gene fusion events arising from chromosomal rearrangements. PDGFR fusions often consist of the cytosolic domain of the receptor tyrosine kinase fused to the N-terminal oligomerization domain of an intracellular protein, leading to ligand-independent dimerization and constitutive activation (reviewed in Wang et al, 2016; Appiah-Kubi et al, 2017). To date there are about 35 identified PDGFR fusion partners, most of which form fusions with PDGFRB (reviewed in Appiah-Kubi et al, 2017). The most common cytosolic fusion partners of PDGFRA is FIP1L1, an RNA processing factor (Cools et al, 2003; Stover et al, 2006; Simon et al, 2008; Andrae et al, 2008; Ozawa et al, 2010; Appiah-Kubi et al, 2017). Fusion partners with PDGFRB are numerous but occurrence of these proteins is rare (Hidalgo-Curtis et al, 2010; reviewed in Wang et al, 2016; Appiah-Kubi et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway40">
 <bp:pathwayOrder rdf:resource="#PathwayStep222" />
 <bp:pathwayOrder rdf:resource="#PathwayStep216" />
 <bp:pathwayOrder rdf:resource="#PathwayStep217" />
 <bp:pathwayOrder rdf:resource="#PathwayStep218" />
 <bp:pathwayOrder rdf:resource="#PathwayStep219" />
 <bp:pathwayOrder rdf:resource="#PathwayStep220" />
 <bp:pathwayOrder rdf:resource="#PathwayStep221" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction179" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction177" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction178" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction182" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction183" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction180" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction181" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence216" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by PDGFRA extracellular domain mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the extracellular domain of receptor tyrosine kinases like PDGRFA have the potential to interfere with glycosylation, which is required for proper trafficking to the cell surface. Versions of PDGFRA bearing mutations in the extracellular domain have been identified in some cancers, and while some of these are inactive, some have also been shown to signal constitutively from the endoplasmic reticulum (Ip et al, 2018; Velghe et al, 2014; Ozawa et al, 2010; Paugh et al, 2013; Clarke et al, 2003). PDGFRA Y288C carries a mutation in the extracellular domain of the receptor that prevents the normal trafficking of the protein to the plasma membrane. PDGFRA Y288C is trapped in the endoplasmic reticulum membrane, from where it is able to signal constitutively in the absence of ligand (Ip et al, 2018). Similarly, a version of PDGFRA bearing an in-frame deletion of exons 8 and 9 has been identified in glioblastoma. The resulting protein is constitutively active in the absence of ligand despite the low fraction of protein expressed at the cell surface (Clarke et al, 2003; Ozawa et al, 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway45">
 <bp:pathwayOrder rdf:resource="#PathwayStep237" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction193" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence237" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SMAD2/3 MH2 Domain Mutants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the MH2 domain of SMAD2 and SMAD3 affect their ability to form heterotrimers with SMAD4, thereby impairing TGF-beta signaling (Fleming et al. 2013).  The SMAD2 and SMAD3 MH2 domain residues most frequently targeted by missense mutations are those that are homologous to SMAD4 MH2 domain residues shown to be involved in the formation of SMAD heterotrimers. Asp300 of SMAD2 and Asp258 of SMAD3 correspond to the frequently mutated Asp351 of SMAD4. Pro305 of SMAD2 corresponds to the frequently mutated Pro356 of SMAD4, while Ala354 of SMAD2 corresponds to Ala406 of SMAD4. Arg268 of SMAD3 corresponds to the frequently mutated Arg361 of SMAD4. SMAD2 and SMAD3 MH2 domain mutations have been examined in most detail in colorectal cancer (Fleming et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway44">
 <bp:pathwayOrder rdf:resource="#PathwayStep236" />
 <bp:pathwayOrder rdf:resource="#PathwayStep238" />
 <bp:pathwayComponent rdf:resource="#Pathway46" />
 <bp:pathwayComponent rdf:resource="#Pathway45" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence236" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss of Function of SMAD2/3 in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function of SMAD2 and SMAD3 in cancer occurs less frequently than the loss of SMAD4 function and was studied in most detail in colorectal cancer (Fleming et al. 2013).  Similarly to SMAD4, coding sequence mutations in SMAD2 and SMAD3 in cancer cluster in the MH2 domain, involved in the formation of transcriptionally active heterotrimers with SMAD4. Another region of SMAD2 and SMAD3 that is frequently mutated in cancer is the phosphorylation motif Ser-Ser-X-Ser at the very C-terminus (Fleming et al. 2013). The phosphorylation of this conserved motif by the activated TGF-beta receptor complex is an essential step in SMAD2 and SMAD3 activation and a prerequisite for the formation of heterotrimers with SMAD4 (Chacko et al. 2001, Chacko et al. 2004).  Smad2 knockout mice die at embryonic day 8.5, with impaired visceral endoderm function and deficiency in mesoderm formation. Smad2+/- heterozygotes appear normal and are fertile (Hamamoto et al. 2002). While polyps of compound Smad2+/-;Apc+/- mice show no difference in the number, size or histopathology from the polyps of Apc+/- mice (Takaku et al. 2002, Hamamoto et al. 2002), Smad2+/-;Apc+/- mice develop extremely large intestinal tumors and multiple invasive cancers not observed in Apc+/- mice. Therefore, loss of Smad2 does not contribute to initiation of intestinal tumorigenesis, but accelerates malignant progression (Hamamoto et al. 2002). Smad3 knockout mice are viable and fertile but die between 4 and 6 months of age from colorectal adenocarcinoma (Zhu et al. 1998), indicating that the loss of Smad3 initiates intestinal tumorigenesis.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway43">
 <bp:pathwayOrder rdf:resource="#PathwayStep235" />
 <bp:pathwayOrder rdf:resource="#PathwayStep248" />
 <bp:pathwayOrder rdf:resource="#PathwayStep240" />
 <bp:pathwayOrder rdf:resource="#PathwayStep243" />
 <bp:pathwayComponent rdf:resource="#Pathway49" />
 <bp:pathwayComponent rdf:resource="#Pathway47" />
 <bp:pathwayComponent rdf:resource="#Pathway52" />
 <bp:pathwayComponent rdf:resource="#Pathway44" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence235" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by TGF-beta Receptor Complex in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by the TGF-beta receptor complex is tumor suppressive, as it inhibits cell growth and promotes cell differentiation and apoptosis (Shipley et al. 1986, Hannon et al. 1994, Datto et al. 1995, Chen et al. 2002, Azar et al. 2009). TGF-beta signaling is frequently impaired in cancer, mostly through SMAD4 gene deletion or loss-of-function mutations (described in the pathway Loss of Function of SMAD4 in Cancer), which are especially frequent in pancreatic cancer (Hahn et al. 1996, Shi et al. 1997, Fleming et al. 2013). Signaling by TGF-beta receptor complex can also be disrupted by loss-of-function mutations in SMAD2 and SMAD3 (Fleming et al. 2013), as described in the pathway Loss of Function of SMAD2/SMAD3 in Cancer, or loss-of-function mutations in TGFBR2 (TGF-beta receptor II) (Markowitz et al. 1995, Garrigue-Antar et al. 1995, Parsons et al. 1995, Grady et al. 1999), as described in the pathway Loss of Function of TGFBR2 in Cancer, or TGFBR1 (TGF-beta receptor I) (Chen et al. 1998, Chen et al. 2001, Goudie et al. 2011), as described in the pathway Loss of Function of TGFBR1 in Cancer.  In advanced cancer, signaling by TGF-beta may be tumor promoting, as it induces epithelial-to-mesenchymal transition (EMT), thereby increasing invasiveness (Cui et al. 1996, Guasch et al. 2007, reviewed by Heldin et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway42">
 <bp:pathwayOrder rdf:resource="#PathwayStep233" />
 <bp:pathwayOrder rdf:resource="#PathwayStep227" />
 <bp:pathwayOrder rdf:resource="#PathwayStep228" />
 <bp:pathwayOrder rdf:resource="#PathwayStep229" />
 <bp:pathwayOrder rdf:resource="#PathwayStep230" />
 <bp:pathwayOrder rdf:resource="#PathwayStep231" />
 <bp:pathwayOrder rdf:resource="#PathwayStep232" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction188" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction189" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction186" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction187" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction191" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction192" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction190" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence227" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PDGFRA is a type III  transmembrane receptor tyrosine kinase. The extracellular domain consists of 5 immunoglobulin (IG) domains that contribute to dimerization and ligand binding. The intracellular region has a juxtamembrane domain that plays a role in autoinhibiting the receptor in the absence of ligand, and a bi-lobed kinase region with an activation loop and the catalytic cleft (reviewed in Klug et al, 2018). Upon ligand binding, PDGFRA undergoes dimerization and transautophosphorylation at at least 11 tyrosine residues in the intracellular domain. These phosphorylated residues are binding sites for downstream effectors of PDGFRA-responsive signaling pathways (reviewed in Klug et al, 2018; Roskoski, 2018).  PDGFRA is subject to activating mutations in a number of cancers, including gastrointestinal stromal tumors (GIST), melanoma and haematological cancers (reviewed in Corless et al, 2011; Wang et al, 2016; Roskoski, 2018). The most prevalent mutations in PDGFRA are at residue V561 in the juxtamembrane domain, N659 in the small lobe of the kinase domain and D842 in the activation loop of the kinase domain. PDGFRA is also subject to short deletions in the activation loop segment (reviewed in Roskoski, 2018). Acitvated forms of the protein may signal from the plasma membrane, similar to the wild type receptor, however there is also evidence that some mutants, notably D842V and V561D localize primarily to the Golgi membrane (Bahlawane et al, 2014). Activated PDGFRA mutants signal constitutively in the absence of ligand (reviewed in Roskoski, 2018; Wang et al, 2016; Klug et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway49">
 <bp:pathwayOrder rdf:resource="#PathwayStep244" />
 <bp:pathwayOrder rdf:resource="#PathwayStep246" />
 <bp:pathwayComponent rdf:resource="#Pathway51" />
 <bp:pathwayComponent rdf:resource="#Pathway50" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence244" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss of Function of TGFBR1 in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TGF-beta receptor 1 (TGFBR1) loss-of-function is a less frequent mechanism for inactivation of TGF-beta signaling in cancer compared to SMAD4 and TGFBR2 inactivation. Genomic deletion of TGFBR1 locus has been reported in pancreatic cancer (Goggins et al. 1998), biliary duct cancer (Goggins et al. 1998) and lymphoma (Schiemann et al. 1999), while loss-of-function mutations have been reported in breast (Chen et al. 1998) and ovarian cancer (Chen et al. 2001), metastatic head-and-neck cancer (Chen et al. 2001), and in Ferguson-Smith tumors (multiple self-healing squamous epithelioma - MSSE) (Goudie et al. 2011). Loss-of-function mutations mainly affect the ligand-binding extracellular domain of TGFBR1 and the kinase domain of TGFBR1 (Goudie et al. 2011). In the mouse model of colorectal cancer, Tgfbr1 haploinsufficiency cooperates with Apc haploinsufficiency in the development of intestinal tumors (Zeng et al. 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep288">
 <bp:stepProcess rdf:resource="#Pathway63" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway48">
 <bp:pathwayOrder rdf:resource="#PathwayStep242" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction195" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence242" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SMAD4 MH2 Domain Mutants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The MH2 domain of SMAD4 is the most frequently mutated SMAD4 region in cancer. MH2 domain mutations result in the loss of function of SMAD4 by abrogating the formation of transcriptionally active heterotrimers of SMAD4 and TGF-beta receptor complex-activated R-SMADs - SMAD2 and SMAD3 (Shi et al. 1997, Chacko et al. 2001, Chacko et al. 2004, Fleming et al. 2013).  The hotspot MH2 domain amino acid residues that are targeted by missense mutations are Asp351 (D351), Pro356 (P356) and Arg361 (R361). These three hotspot residues map to the L1 loop which is conserved in SMAD2 and SMAD3 and is involved in intermolecular interactions that contribute to the formation of SMAD heterotrimers and homotrimers (Shi et al. 1997, Fleming et al. 2013). Other frequently mutated residues in the MH2 domain of SMAD4 - Ala406 (A406), Lys428 (K428) and Arg515 (R515) - are involved in binding the phosphorylation motif (Ser-Ser-X-Ser) of SMAD2 and SMAD3, with Arg515 in the L3 loop being critical for this interaction (Chacko et al. 2001, Chacko et al. 2004, Fleming et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep289">
 <bp:stepProcess rdf:resource="#Pathway64" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway47">
 <bp:pathwayOrder rdf:resource="#PathwayStep241" />
 <bp:pathwayComponent rdf:resource="#Pathway48" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence241" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss of Function of SMAD4 in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SMAD4 was identified as a gene homozygously deleted in ~30% of pancreatic cancers and was named DPC4 (DPC stands for deleted in pancreatic cancer). SMAD4 maps to the chromosomal band 18q21.1, and about 90% of pancreatic carcinomas show allelic loss at chromosomal arm 18q (Hahn et al. 1996), while ~50% of pancreatic cancers show some alteration of the SMAD4 gene (reviewed by Schutte et al. 1999).  Based on COSMIC database (Catalogue Of Somatic Mutations In Cancer) (Forbes et al. 2011), mutations in the coding sequence of SMAD4 gene are frequently found in pancreatic cancer, biliary duct carcinoma and colorectal cancer (reviewed by Schutte et al. 1999). Germline SMAD4 mutations are the cause of juvenile polyposis, an autosomal dominant disease that predisposes affected individuals to hamartomatous polyps and gastrointestinal cancer (Howe et al. 1998). Homozygous Smad4 loss is embryonic lethal in mice (Takaku et al. 1998). Smad4 +/- heterozygotes appear normal but develop intestinal polyps between 6 and12 months of age and these polyps can progress to cancer. Loss of the remaining wild-type Smad4 allele is detectable only at later stages of tumor progression in Smad4+/- mice (Xu et al. 2000). Compound Apc+/-;Smad4+/- mice develop malignant tumors from intestinal polyps more rapidly than Apc+/- mice (Takaku et al. 1998).  SMAD4 coding sequence mutations are most frequently found in the MH2 domain and impair the formation of SMAD4 heterotrimers with phosphorylated SMAD2 and SMAD3 (Shi et al. 1997, Fleming et al. 2013), thereby impairing SMAD4:SMAD2/3 heterotrimer-mediated transcriptional regulation of TGF-beta responsive genes. MH2 domain is also involved in the formation of SMAD4 homotrimers which may play a role in SMAD4 protein stability (Shi et al. 1997).  Coding sequence mutations are also found in the MH1 domain of SMAD4. MH1 domain is involved in DNA binding (Dai et al. 1999) and it is also involved in the formation of SMAD4 homotrimers (Hata et al. 1997).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway46">
 <bp:pathwayOrder rdf:resource="#PathwayStep239" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction194" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence239" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SMAD2/3 Phosphorylation Motif Mutants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The conserved phosphorylation motif Ser-Ser-X-Ser at the C-terminus of SMAD2 and SMAD3 is subject to disruptive mutations in cancer. The last two serine residues in this conserved motif, namely Ser465 and Ser467 in SMAD2 and Ser423 and Ser425 in SMAD3, are phosphorylated by the activated TGF beta receptor complex (Macias Silva et al. 1996, Nakao et al. 1997). Once phosphorylated, SMAD2 and SMAD3 form transcriptionally active heterotrimers with SMAD4 (Chacko et al. 2001, Chacko et al. 2004). Phosphorylation motif mutants of SMAD2 and SMAD3 cannot be activated by the TGF-beta receptor complex either because serine residues are substituted with amino acid residues that cannot be phosphorylated or because the phosphorylation motif is deleted from the protein sequence or truncated (Fleming et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep280">
 <bp:stepProcess rdf:resource="#Pathway62" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep281">
 <bp:stepProcess rdf:resource="#BiochemicalReaction220" />
 <bp:stepProcess rdf:resource="#Catalysis54" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep282">
 <bp:stepProcess rdf:resource="#BiochemicalReaction221" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep283">
 <bp:stepProcess rdf:resource="#BiochemicalReaction222" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep284">
 <bp:stepProcess rdf:resource="#BiochemicalReaction223" />
 <bp:stepProcess rdf:resource="#Catalysis55" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep285">
 <bp:stepProcess rdf:resource="#BiochemicalReaction224" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep286">
 <bp:stepProcess rdf:resource="#BiochemicalReaction225" />
 <bp:stepProcess rdf:resource="#Catalysis56" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep287">
 <bp:stepProcess rdf:resource="#BiochemicalReaction226" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep290">
 <bp:stepProcess rdf:resource="#Catalysis57" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction227" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway30">
 <bp:pathwayOrder rdf:resource="#PathwayStep193" />
 <bp:pathwayComponent rdf:resource="#Pathway31" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence193" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Human NOTCH1 was cloned as a chromosome 9 gene, translocated to the T-cell beta receptor (TCBR) promoter on chromosome 7 in T-cell acute lymphoblastic leukemia (T-ALL) (Ellisen et al. 1991). The translocated gene was found to be homologous to Drosophila Notch, and was initially named TAN-1 (translocation-associated Notch homolog). Although the translocation t(7;9)(q34;q34.3) is present in a small percentage of T-ALL patients, the mutant protein is highly oncogenic and its overexpression causes T-ALL-like illness in mice (Pear et al. 1996).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction409">
 <bp:evidence rdf:resource="#Evidence540" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CTNNB1 S37 mutants aren&apos;t phosphorylated by GSK3beta</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction407">
 <bp:evidence rdf:resource="#Evidence535" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">XAV939 binds tankyrase to stabilize axin and inhibit WNT signaling</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction408">
 <bp:evidence rdf:resource="#Evidence538" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CTNNB1 S45 mutants aren&apos;t phosphorylated by CK1alpha</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway34">
 <bp:pathwayOrder rdf:resource="#PathwayStep204" />
 <bp:pathwayOrder rdf:resource="#PathwayStep206" />
 <bp:pathwayOrder rdf:resource="#PathwayStep208" />
 <bp:pathwayOrder rdf:resource="#PathwayStep210" />
 <bp:pathwayComponent rdf:resource="#Pathway38" />
 <bp:pathwayComponent rdf:resource="#Pathway37" />
 <bp:pathwayComponent rdf:resource="#Pathway36" />
 <bp:pathwayComponent rdf:resource="#Pathway35" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence204" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Drug resistance of PDGFR mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PDGFRA is mutated in ~10% of gastrointestinal stromal tumors in a mutually exclusive manner with KIT mtutations. In contrast to KIT, PDGFRA GIST mutations occur more frequently in the activation domain, rather than the juxtamembrane domain. In addition to GIST, PDGFRA is subject to missense or small in-frame deletion mutations in haematological cancers and melanoma. In contrast, missense mutations in PDGFRB are rare (Heinrich et al, 2003; Corless et al, 2005; reviewed in Corless et al, 2011). Both PDGFRA and PDGFRB are also subject to oncogenic translocation events leading to the expression of fusion proteins (Cools et al, 2003; Simon et al, 2008; Salemi et al, 2009; Ohashi et al, 2010; reviewed in Appiah-Kubi et al, 2017). Imatinib is a type II TKIs that is approved as first-line treatment of KIT- and PDGFR-driven tumors; however secondary mutations frequently contribute to the development of imatinib resistance. These secondary mutations further shift the equilibrium of the receptor toward the activated state, making imatinib and even approved second-line type II TKIs less effective. In consequence, considerable effort is devoted to discovery of type II and, in particular, type I TKIs that are active against highly activated PDGFR alleles (Smith et al, 2019; Lierman et al, 2019; reviewed in Roskoski, 2018; Klug et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction405">
 <bp:evidence rdf:resource="#Evidence531" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">APC truncation mutants have impaired AXIN binding</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway33">
 <bp:pathwayOrder rdf:resource="#PathwayStep201" />
 <bp:pathwayOrder rdf:resource="#PathwayStep202" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction169" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction170" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence201" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PDGFR mutants bind TKIs</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aberrant signaling by activated forms of PDGFR can be inhibited by tyrosine kinase inhibitors (TKIs). PDGF receptors are class III receptor tyrosine kinase receptors, also known as dual-switch. Dual-switch receptors are activated through a series of phosphorylation and conformational changes that move the receptor from the inactive form to the fully activated form. Type II TKIs bind to the inactive form of the receptor at a site adjacent to the ATP-binding cleft, while type I TKIs bind to the active form (reviewed in Roskoski, 2018; Klug et al, 2018).  Primary mutations in PDGRFA occur in the activation loop, with a minor fraction found in the juxtamembrane domain (reviewed in Roskoski, 2018; Klug et al, 2018). Juxtamembrane domain mutations affect an autoinhibitory loop, shifting the equilibrium of the receptor towards the activated state; despite this, however, juxtamembrane domain mutants remain predominantly in the inactive state and as such are susceptible to inhibition by type II TKIs. Activation loop mutations more strongly favor the active conformation of the receptor and are susceptible to inhibition by both type II and type I TKI. The most prevalent PDGFRA mutation, D842V, promotes the active conformation strongly enough to be resistant to type II TKIs (reviewed in Roskoski, 2018; Klug et al, 2018). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction406">
 <bp:evidence rdf:resource="#Evidence533" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">APC truncation mutants are not K63 polyubiquitinated</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway32">
 <bp:pathwayOrder rdf:resource="#PathwayStep200" />
 <bp:pathwayOrder rdf:resource="#PathwayStep212" />
 <bp:pathwayOrder rdf:resource="#PathwayStep223" />
 <bp:pathwayOrder rdf:resource="#PathwayStep203" />
 <bp:pathwayOrder rdf:resource="#PathwayStep215" />
 <bp:pathwayOrder rdf:resource="#PathwayStep226" />
 <bp:pathwayComponent rdf:resource="#Pathway39" />
 <bp:pathwayComponent rdf:resource="#Pathway41" />
 <bp:pathwayComponent rdf:resource="#Pathway40" />
 <bp:pathwayComponent rdf:resource="#Pathway34" />
 <bp:pathwayComponent rdf:resource="#Pathway33" />
 <bp:pathwayComponent rdf:resource="#Pathway42" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence200" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by PDGFR in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PDGFRA and PDGFRB are type III receptor tyrosine kinases that promote development and maintenance of mesenchymal tissues, including vascular smooth muscle, kidney, intestine, skin and lung, among others (reviewed in Tallquist and Kazlauskas, 2004; reviewed in Wang et al, 2016). Signaling through PDGF receptors stimulates cell proliferation and survival through activation of downstream signaling pathways including the RAS-MAP kinase cascade, PI3K signaling and STAT signaling (reviewed in Roskoski, 2018). Aberrant signaling through PDGF receptors is implicated in a number of human diseases. Point mutations in PDGFRA and, to a lesser extent, PDGFRB are implicated in a number of cancers, such as gastrointestinal stromal tumors (GIST; 5-10% mutation frequency in PDGFRA) and haematological cancers (Corless et al, 2005; Wang et al, 2016; reviewed in Klug et al, 2018). In addition, amplified signaling through the PDGF pathway can arise through gene fusion events or overexpression of ligand or receptor through gene amplification (Ozawa et al, 2010; Verhaak et al, 2010; reviewed in Appiah-Kubi et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction403">
 <bp:evidence rdf:resource="#Evidence526" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Truncated AMER1 mutants destabilize the destruction complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway31">
 <bp:pathwayOrder rdf:resource="#PathwayStep194" />
 <bp:pathwayOrder rdf:resource="#PathwayStep195" />
 <bp:pathwayOrder rdf:resource="#PathwayStep196" />
 <bp:pathwayOrder rdf:resource="#PathwayStep197" />
 <bp:pathwayOrder rdf:resource="#PathwayStep198" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction168" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction166" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction167" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction164" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction165" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence194" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 t(7;9)(NOTCH1:M1580_K2555) mutant is expressed in a small subset of T-cell acute lymphoblastic leukemia (T-ALL) patients. This mutant protein results from a translocation that joins a portion of intron 24 of the NOTCH1 gene to the promoter sequence of T-cell receptor beta (TCRB), leading to overexpression of a truncated NOTCH1 protein in T-cells and their precursors. The truncated NOTCH1 contains amino acids 1580 to 2555 of the wild-type NOTCH1, lacking almost the entire extracellular domain, including EGF and LIN12 repeats (Ellisen et al. 1991). As EGF repeats are needed for NOTCH1 interaction with its ligands (DLL1, DLL4, JAG1, JAG2), the mutant NOTCH1 t(7;9)(NOTCH1:M1580_K2555) does not bind a ligand. The constitutive activity of NOTCH1 t(7;9)(NOTCH1:M1580_K2555) is based on its constitutive proteolytic processing into NOTCH1 intracellular domain (NICD1) by ADAM10/17 protease and gamma-secretase complex, as proteolytic cleavage sites are exposed in the absence of ligand binding in the mutant protein. Constitutively produced NICD1 accumulates in the nucleus, leading to aberrant activation of NOTCH1 target genes which play important roles in the development of T lymphocytes (Washburn et al. 1997. Radtke et al. 1999, Maillard et al. 2004, Sambandam et al. 2005, Tan et al. 2005). Infection of bone marrow cells with recombinant retroviruses that code for truncated NOTCH1 that resembles t(7;9)(NOTCH1:M1580_K2555) resulted in T-ALL-like illness in a portion of mice that received the infected bone-marrow transplant, with all tumors overexpressing truncated forms of NOTCH1 (Pear et al. 1996). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction404">
 <bp:evidence rdf:resource="#Evidence528" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PORCN-inhibitor LGK974 prevents WNT ligand palmitoyltation and secretion</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway38">
 <bp:pathwayOrder rdf:resource="#PathwayStep211" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction174" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence211" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regorafenib-resistant PDGFR mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regorafenib is a type II TKI that is approved for the treatment of advanced gastrointestinal stromal tumors. Although regorafenib is effective against a number of KIT and PDGFR mutations, it only weakly inhibits the activity of the most prevalent PDGFRA allele, D842V (Evans et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep299">
 <bp:stepProcess rdf:resource="#BiochemicalReaction233" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction401">
 <bp:evidence rdf:resource="#Evidence521" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RNF43 frameshift mutants show enhanced WNT siganling</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway37">
 <bp:pathwayOrder rdf:resource="#PathwayStep209" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction173" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence209" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sunitinib-resistant PDGFR mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sunitinib is a class II TKI that is often used as a second-line treatment in PDGFR- and KIT-driven cancers that develop resistance to imatinib (reviewed in Corless et al, 2011; Klug et al, 2018). Sunintib is approved for the treatment of renal cell carcinoma, GIST and pancreatic tumors. A number of PDGFR mutations exhibit resistance to inhibition by sunitinib (Roskoski, 2007; reviewed in Roskoski, 2018; Klug et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction402">
 <bp:evidence rdf:resource="#Evidence524" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Deletions of the AMER1 gene prevent expression of AMER1 protein</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway36">
 <bp:pathwayOrder rdf:resource="#PathwayStep207" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction172" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence207" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sorafenib-resistant PDGFR mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sorafenib is a type II tyrosine kinase inhibitor that is approved for use in hepatocellular and renal cell carcinoma, and that is often used as a second-line treatment for imatinib-resistant tumors. Despite its initial efficacy, resistance to sorafenib often develops (reviewed in Molina-Ruiz et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway35">
 <bp:pathwayOrder rdf:resource="#PathwayStep205" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction171" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence205" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Imatinib-resistant PDGFR mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A number of PDGFRA mutations found in GIST and other cancers are resistant to inhibition with imatinib (reviewed in Corless et al, 2011). These include the most common allele D842V, which occurs in the activation loop of the receptor, as well as S601P and the gatekeeper mutation T674I (reviewed in Roskoski, 2018; Klug et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction400">
 <bp:evidence rdf:resource="#Evidence519" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Deletions in the AXIN1 gene prevent expression of AXIN1 protein</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway39">
 <bp:pathwayOrder rdf:resource="#PathwayStep213" />
 <bp:pathwayOrder rdf:resource="#PathwayStep214" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction175" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction176" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence213" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by membrane-tethered fusions of PDGFRA or PDGFRB</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In addition to activating missensse and in-frame deletion mutations, PDGFRA and PDGFRB are also subject to low frequency gene fusion events arising from chromosomal rearrangements. To date there are about 35 identified PDGFRA or B fusion partners, with PDGFRB being the more common partner (reviewed in Appiah-Kubi et al, 2017). Although some of the PDGF fusions proteins are cytosolic by virtue of removal of the PDGFR transmembrane region (TMD), a number of fusions retain the TMD and are linked to the plasma membrane (Hidalgo-Curtis et al, 2010; Ozawa et al, 2010; Curtis et al, 2007; Medves et al, 2010; reviewed in Appiah-Kubi et al, 2017). The most common transmembrane fusion partner of PDGFRA and PDGFRB is ETV6 (also known as TEL1), a transcriptional repressor with known ability to homodimerize (Curtis et al, 2007; Golub et al, 1994; Andrae et al, 2008; reviewed in de Braekeleer et al, 2012; Wang et al, 2016; Appiah-Kubi et al, 2017). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep291">
 <bp:stepProcess rdf:resource="#Pathway65" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep292">
 <bp:stepProcess rdf:resource="#Catalysis58" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction228" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep293">
 <bp:stepProcess rdf:resource="#Pathway66" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep294">
 <bp:stepProcess rdf:resource="#BiochemicalReaction229" />
 <bp:stepProcess rdf:resource="#Catalysis59" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep295">
 <bp:stepProcess rdf:resource="#Pathway67" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep296">
 <bp:stepProcess rdf:resource="#Catalysis60" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction230" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep297">
 <bp:stepProcess rdf:resource="#Catalysis61" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction231" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep298">
 <bp:stepProcess rdf:resource="#BiochemicalReaction232" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep219">
 <bp:stepProcess rdf:resource="#BiochemicalReaction180" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction418">
 <bp:evidence rdf:resource="#Evidence558" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of extracellular domain KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction419">
 <bp:evidence rdf:resource="#Evidence559" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of KIT extracellular domain mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway23">
 <bp:pathwayOrder rdf:resource="#PathwayStep137" />
 <bp:pathwayOrder rdf:resource="#PathwayStep138" />
 <bp:pathwayOrder rdf:resource="#PathwayStep139" />
 <bp:pathwayOrder rdf:resource="#PathwayStep140" />
 <bp:pathwayOrder rdf:resource="#PathwayStep141" />
 <bp:pathwayOrder rdf:resource="#PathwayStep142" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction115" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction116" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction120" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction119" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction117" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction118" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence137" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive Signaling by NOTCH1 HD Domain Mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The heterodimerization (HD) domain of NOTCH1, responsible for association of NOTCH1 extracellular and transmembrane regions after furin-mediated cleavage of NOTCH1 precursor, is one of the hotspots for gain-of-function NOTCH1 mutations in T-cell acute lymphoblastic leukemia (T-ALL) (Weng et al. 2004). NOTCH1 HD domain mutants are responsive to ligand binding, but the activation (through cleavage of S2 and S3 sites and release of the intracellular domain NICD1) also happens spontaneously, in the absence of DLL and JAG ligands (Malecki et al. 2006). The following NOTCH1 HD domain mutants were directly functionally studied by Malecki et al.: NOTCH1 V1576E, NOTCH1 F1592S, NOTCH1 L1593P, NOTCH1 L1596H, NOTCH1 R1598P, NOTCH1 I1616N, NOTCH1 I1616T, NOTCH1 V1676D, NOTCH1 L1678P, NOTCH1 I1680N, NOTCH1 A1701P and NOTCH1 I1718T; other frequent NOTCH1 HD domain mutants (NOTCH1 L1574P, NOTCH1 L1574Q and NOTCH1 L1600P) are assumed to behave in a similar way. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction416">
 <bp:evidence rdf:resource="#Evidence555" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of juxtamembrane domain KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway22">
 <bp:pathwayOrder rdf:resource="#PathwayStep136" />
 <bp:pathwayComponent rdf:resource="#Pathway23" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence136" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by NOTCH1 HD Domain Mutants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 heterodimerization domain mutations are frequently found in T-cell acute lymphoblastic leukemia (T-ALL) (Weng et al. 2004) and result in constitutive activity of NOTCH1 mutants (Malecki et al. 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction417">
 <bp:evidence rdf:resource="#Evidence556" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of KIT juxtamembrane domain mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway21">
 <bp:pathwayOrder rdf:resource="#PathwayStep135" />
 <bp:pathwayOrder rdf:resource="#PathwayStep169" />
 <bp:pathwayOrder rdf:resource="#PathwayStep192" />
 <bp:pathwayOrder rdf:resource="#PathwayStep143" />
 <bp:pathwayOrder rdf:resource="#PathwayStep166" />
 <bp:pathwayComponent rdf:resource="#Pathway26" />
 <bp:pathwayComponent rdf:resource="#Pathway24" />
 <bp:pathwayComponent rdf:resource="#Pathway28" />
 <bp:pathwayComponent rdf:resource="#Pathway30" />
 <bp:pathwayComponent rdf:resource="#Pathway22" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence135" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by NOTCH1 in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Human NOTCH1 was cloned as a chromosome 9 gene, translocated to the T-cell beta receptor (TCBR) promoter on chromosome 7 in T-cell acute lymphoblastic leukemia (T-ALL) (Ellisen et al. 1991). This translocation, present in only a small percentage of T-ALL patients, results in the overexpression of a truncated NOTCH1 receptor, which lacks almost the entire extracellular domain, in T lymphocytes. Oncogenic NOTCH1 mutations were subsequently found to be present in &gt;50% of T-ALL patients, with hotspots in the heterodimerization domain (HD domain) and PEST domain of NOTCH1 (Weng et al. 2004).   Normal NOTCH1 becomes activated by binding DLL (DLL1 or DLL4) or JAG (JAG1 or JAG2) ligands expressed on the surface of a neighboring cell, which leads to proteolytic cleavage of NOTCH1 by ADAM10/17 and gamma-secretase, and release of the NOTCH1 intracellular domain (NICD1) which regulates expression of genes that play important roles in the development of T lymphocytes (Washburn et al. 1997. Radtke et al. 1999, Maillard et al. 2004, Sambandam et al. 2005, Tan et al. 2005). Mutations in the HD domain, responsible for association of NOTCH1 extracellular and transmembrane regions after furin-mediated cleavage of NOTCH1 precursor, as well as the truncation of the NOTCH1 extracellular domain by the rare T-ALL translocation, enable constitutive production of NICD1, in the absence of ligand binding (Malecki et al. 2006, Ellisen et al. 1991).  Mutations in the NOTCH1 PEST domain interfere with FBXW7 (FBW7)-mediated ubiquitination and degradation of NICD1, resulting in prolonged half-life and increased transcriptional activity of NICD1, which promotes growth and division of T-lymphocytes (Weng et al. 2004, Thompson et al. 2007, O&apos;Neil et al. 2007).  Mutations in the HD domain and PEST domain of NOTCH1 are frequently found in cis in T-ALL. While HD mutations alone result in up to ~10-fold increase in NOTCH1 transcriptional activity and PEST domain mutations alone result in up to ~2-fold increase in NOTCH1 transcriptional activity, in cis mutations of HD and PEST domains act synergistically, increasing NOTCH1 transcriptional activity up to ~40-fold (Weng et al. 2004).  FBXW7 (FBW7), a component of the SCF (SKP1, CUL1, and F-box protein) ubiquitin ligase complex SCF-FBW7 involved in the degradation of NOTCH1 (Oberg et al. 2001, Wu et al. 2001, Fryer et al. 2004), is subject to loss of function mutations in T-ALL (Akhoondi et al. 2007, Thompson et al. 2007, O&apos;Neil et al. 2007) which are mutually exclusive with NOTCH1 PEST domain mutations (Thompson et al. 2007, O&apos;Neil et al. 2007).  Although gamma-secretase inhibitors (GSIs) are successfully used in vitro to inhibit NOTCH1 signaling in T-ALL cell lines, the gamma-secretase complex has many other substrates besides NOTCH. The specificity of GSIs is therefore limited and, as they are not considered to be particularly promising drugs for the clinical treatment of T-ALL (reviewed by Purow, 2012), they have not been annotated.  For a recent review of NOTCH1 signaling in cancer, please refer to Grabher et al. 2006.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction414">
 <bp:evidence rdf:resource="#Evidence550" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">misspliced mutants of LRP5 support enhanced beta-catenin-dependent signaling</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway20">
 <bp:pathwayOrder rdf:resource="#PathwayStep112" />
 <bp:pathwayOrder rdf:resource="#PathwayStep123" />
 <bp:pathwayOrder rdf:resource="#PathwayStep113" />
 <bp:pathwayOrder rdf:resource="#PathwayStep124" />
 <bp:pathwayOrder rdf:resource="#PathwayStep114" />
 <bp:pathwayOrder rdf:resource="#PathwayStep125" />
 <bp:pathwayOrder rdf:resource="#PathwayStep115" />
 <bp:pathwayOrder rdf:resource="#PathwayStep126" />
 <bp:pathwayOrder rdf:resource="#PathwayStep116" />
 <bp:pathwayOrder rdf:resource="#PathwayStep127" />
 <bp:pathwayOrder rdf:resource="#PathwayStep117" />
 <bp:pathwayOrder rdf:resource="#PathwayStep128" />
 <bp:pathwayOrder rdf:resource="#PathwayStep118" />
 <bp:pathwayOrder rdf:resource="#PathwayStep129" />
 <bp:pathwayOrder rdf:resource="#PathwayStep119" />
 <bp:pathwayOrder rdf:resource="#PathwayStep130" />
 <bp:pathwayOrder rdf:resource="#PathwayStep120" />
 <bp:pathwayOrder rdf:resource="#PathwayStep131" />
 <bp:pathwayOrder rdf:resource="#PathwayStep121" />
 <bp:pathwayOrder rdf:resource="#PathwayStep132" />
 <bp:pathwayOrder rdf:resource="#PathwayStep111" />
 <bp:pathwayOrder rdf:resource="#PathwayStep122" />
 <bp:pathwayOrder rdf:resource="#PathwayStep133" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction96" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction97" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction98" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction99" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction92" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction93" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction94" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction95" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction108" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction109" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction106" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction107" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction104" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction105" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction102" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction113" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction103" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction114" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction100" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction111" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction101" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction112" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction110" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence111" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by EGFR is frequently activated in cancer through activating mutations in the coding sequence of the EGFR gene, resulting in expression of a constitutively active mutant protein.   Epidermal growth factor receptor kinase domain mutants are present in ~16% of non-small-cell lung cancers (NSCLCs), but are also found in other cancer types, such as breast cancer, colorectal cancer, ovarian cancer and thyroid cancer. EGFR kinase domain mutants harbor activating mutations in exons 18-21 which code for the kinase domain (amino acids 712-979) . Small deletions, insertions or substitutions of amino acids within the kinase domain lock EGFR in its active conformation in which the enzyme can dimerize and undergo autophosphorylation spontaneously, without ligand binding (although ligand binding ability is preserved), and activate downstream signaling pathways that promote cell survival (Greulich et al. 2005, Zhang et al. 2006, Yun et al. 2007, Red Brewer et al. 2009).   Point mutations in the extracellular domain of EGFR are frequently found in glioblastoma. Similar to kinase domain mutations, point mutations in the extracellular domain result in constitutively active EGFR proteins that signal in the absence of ligands, but ligand binding ability and responsiveness are preserved (Lee et al. 2006).    EGFR kinase domain mutants need to maintain association with the chaperone heat shock protein 90 (HSP90) for proper functioning (Shimamura et al. 2005, Lavictoire et al. 2003). CDC37 is a co-chaperone of HSP90 that acts as a scaffold and regulator of interaction between HSP90 and its protein kinase clients. CDC37 is frequently over-expressed in cancers involving mutant kinases and acts as an oncogene (Roe et al. 2004, reviewed by Gray Jr. et al. 2008).   Over-expression of the wild-type EGFR or EGFR cancer mutants results in aberrant activation of downstream signaling cascades, namely RAS/RAF/MAP kinase signaling and PI3K/AKT signaling, and possibly signaling by PLCG1, which leads to increased cell proliferation and survival, providing selective advantage to cancer cells that harbor activating mutations in the EGFR gene (Sordella et al. 2004, Huang et al. 2007).   While growth factor activated wild-type EGFR is promptly down-regulated by internalization and degradation, cancer mutants of EGFR demonstrate prolonged activation (Lynch et al. 2004). Association of HSP90 with EGFR kinase domain mutants negatively affects CBL-mediated ubiquitination, possibly through decreasing the affinity of EGFR kinase domain mutants for phosphorylated CBL, so that CBL dissociates from the complex upon phosphorylation and cannot perform ubiquitination (Yang et al. 2006, Padron et al. 2007).    Various molecular therapeutics are being developed to target aberrantly activated EGFR in cancer. Non-covalent (reversible) small tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, selectively bind kinase domain of EGFR, competitively inhibiting ATP binding and subsequent autophosphorylation of EGFR dimers. EGFR kinase domain mutants sensitive to non-covalent TKIs exhibit greater affinity for TKIs than ATP compared with the wild-type EGFR protein, and are therefore preferential targets of non-covalent TKI therapeutics (Yun et al. 2007). EGFR proteins that harbor point mutations in the extracellular domain also show sensitivity to non-covalent tyrosine kinase inhibitors (Lee et al. 2006). EGFR kinase domain mutants harboring small insertions in exon 20 or a secondary T790M mutation are resistant to reversible TKIs (Balak et al. 2006) due to increased affinity for ATP (Yun et al. 2008), and are targets of covalent (irreversible) TKIs that form a covalent bond with EGFR cysteine residue C397. However, effective concentrations of covalent TKIs also inhibit wild-type EGFR, causing severe side effects (Zhou et al. 2009). Hence, covalent TKIs have not shown much promise in clinical trials (Reviewed by Pao and Chmielecki in 2010). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction415">
 <bp:evidence rdf:resource="#Evidence553" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive phosphorylation of kinase domain KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway27">
 <bp:pathwayOrder rdf:resource="#PathwayStep168" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction142" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence168" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss of function mutations found in FBXW7 in T-cell acute lymphoblastic leukemia are predominantly dominant negative missense mutations that target one of the three highly conserved arginine residues in the WD repeats of FBXW7 (Thompson et al. 2007, O&apos;Neil et al. 2007). These three arginine residues are part of the FBXW7 substrate binding pocket and each one of them contacts the phosphorylated threonine residue in the conserved substrate phosphodegron region (Orlicky et al. 2003). Specifically, FBXW7 interacts with the PEST domain of NOTCH1 upon phosphorylation of the PEST domain by CDK8 (Fryer et al. 2004). FBXW7 mutants are therefore unable to bind and promote ubiquitination of the NOTCH1 intracellular domain (NICD1), leading to prolonged NICD1 transcriptional activity (Thompson et al. 2007, O&apos;Neil et al. 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep222">
 <bp:stepProcess rdf:resource="#BiochemicalReaction183" />
 <bp:stepProcess rdf:resource="#Catalysis38" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction412">
 <bp:evidence rdf:resource="#Evidence546" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TFC7L2 mutants don&apos;t bind CTBP</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway26">
 <bp:pathwayOrder rdf:resource="#PathwayStep167" />
 <bp:pathwayComponent rdf:resource="#Pathway27" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence167" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FBXW7 Mutants and NOTCH1 in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FBXW7 (FBW7) is a component of the SCF (SKP1, CUL1, and F-box protein) ubiquitin ligase complex SCF-FBW7 which is involved in the degradation of NOTCH1 (Oberg et al. 2001, Wu et al. 2001, Fryer et al. 2004). Loss of function mutations in FBXW7 are frequently found in T-cell acute lymphoblastic leukemia (Akhoondi et al. 2007, Thompson et al. 2007, O&apos;Neil et al. 2007) and are mutually exclusive with NOTCH1 PEST domain mutations (Thompson et al. 2007, O&apos;Neil et al. 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep223">
 <bp:stepProcess rdf:resource="#Pathway41" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction413">
 <bp:evidence rdf:resource="#Evidence548" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Misspliced GSK3beta mutants stabilize beta-catenin levels</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway25">
 <bp:pathwayOrder rdf:resource="#PathwayStep145" />
 <bp:pathwayOrder rdf:resource="#PathwayStep156" />
 <bp:pathwayOrder rdf:resource="#PathwayStep146" />
 <bp:pathwayOrder rdf:resource="#PathwayStep157" />
 <bp:pathwayOrder rdf:resource="#PathwayStep147" />
 <bp:pathwayOrder rdf:resource="#PathwayStep158" />
 <bp:pathwayOrder rdf:resource="#PathwayStep148" />
 <bp:pathwayOrder rdf:resource="#PathwayStep159" />
 <bp:pathwayOrder rdf:resource="#PathwayStep149" />
 <bp:pathwayOrder rdf:resource="#PathwayStep160" />
 <bp:pathwayOrder rdf:resource="#PathwayStep150" />
 <bp:pathwayOrder rdf:resource="#PathwayStep161" />
 <bp:pathwayOrder rdf:resource="#PathwayStep151" />
 <bp:pathwayOrder rdf:resource="#PathwayStep162" />
 <bp:pathwayOrder rdf:resource="#PathwayStep152" />
 <bp:pathwayOrder rdf:resource="#PathwayStep163" />
 <bp:pathwayOrder rdf:resource="#PathwayStep153" />
 <bp:pathwayOrder rdf:resource="#PathwayStep164" />
 <bp:pathwayOrder rdf:resource="#PathwayStep154" />
 <bp:pathwayOrder rdf:resource="#PathwayStep165" />
 <bp:pathwayOrder rdf:resource="#PathwayStep155" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction128" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction139" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction129" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction126" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction137" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction127" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction138" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction124" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction135" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction125" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction136" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction122" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction133" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction123" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction134" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction131" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction121" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction132" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction140" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction130" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction141" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence145" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">When found in cis, HD and PEST domain mutations act synergistically, increasing NOTCH1 transcriptional activity up to ~40-fold, compared with up to ~10-fold and up to ~2-fold increase with HD mutations alone and PEST domain mutations alone, respectively (Weng et al. 2004). HD domain mutations enable spontaneous, ligand-independent, proteolytic release of the NICD1 fragment, although mutants remain responsive to ligand binding (Malecki et al. 2006), while PEST domain mutations prolong NICD1 half-life and transcriptional activity through interference with FBXW7 (FBW7)-mediated ubiquitination and degradation (Thompson et al. 2007, O&apos;Neil et al. 2007). NOTCH1 HD+PEST domain mutants annotated here are NOTCH1 L1600P;P2514Rfs*4, NOTCH1 L1600P;Q2440*, NOTCH1 L1600P;Q2395* and NOTCH1 L1574P;P2474Afs*4.  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep224">
 <bp:stepProcess rdf:resource="#BiochemicalReaction184" />
 <bp:stepProcess rdf:resource="#Catalysis39" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction410">
 <bp:evidence rdf:resource="#Evidence542" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CTNNB1 S33 mutants aren&apos;t phosphorylated by GSK3beta</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway24">
 <bp:pathwayOrder rdf:resource="#PathwayStep144" />
 <bp:pathwayComponent rdf:resource="#Pathway25" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence144" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the heterodimerization domain (HD) and PEST domain of NOTCH1 are frequently found in cis in T-cell acute lymphoblastic leukemia. While HD mutations alone result in up to ~10-fold increase in NOTCH1 transcriptional activity and PEST domain mutations alone result in up to ~2-fold increase in NOTCH1 transcriptional activity, in cis mutations of HD and PEST domains act synergistically, increasing NOTCH1 transcriptional activity up to ~40-fold (Weng et al. 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep225">
 <bp:stepProcess rdf:resource="#BiochemicalReaction185" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction411">
 <bp:evidence rdf:resource="#Evidence544" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CTNNB1 T41 mutants aren&apos;t phosphorylated by GSK3beta</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep226">
 <bp:stepProcess rdf:resource="#Pathway42" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep227">
 <bp:stepProcess rdf:resource="#BiochemicalReaction186" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway29">
 <bp:pathwayOrder rdf:resource="#PathwayStep190" />
 <bp:pathwayOrder rdf:resource="#PathwayStep180" />
 <bp:pathwayOrder rdf:resource="#PathwayStep191" />
 <bp:pathwayOrder rdf:resource="#PathwayStep178" />
 <bp:pathwayOrder rdf:resource="#PathwayStep189" />
 <bp:pathwayOrder rdf:resource="#PathwayStep179" />
 <bp:pathwayOrder rdf:resource="#PathwayStep181" />
 <bp:pathwayOrder rdf:resource="#PathwayStep171" />
 <bp:pathwayOrder rdf:resource="#PathwayStep182" />
 <bp:pathwayOrder rdf:resource="#PathwayStep172" />
 <bp:pathwayOrder rdf:resource="#PathwayStep183" />
 <bp:pathwayOrder rdf:resource="#PathwayStep173" />
 <bp:pathwayOrder rdf:resource="#PathwayStep184" />
 <bp:pathwayOrder rdf:resource="#PathwayStep174" />
 <bp:pathwayOrder rdf:resource="#PathwayStep185" />
 <bp:pathwayOrder rdf:resource="#PathwayStep175" />
 <bp:pathwayOrder rdf:resource="#PathwayStep186" />
 <bp:pathwayOrder rdf:resource="#PathwayStep176" />
 <bp:pathwayOrder rdf:resource="#PathwayStep187" />
 <bp:pathwayOrder rdf:resource="#PathwayStep177" />
 <bp:pathwayOrder rdf:resource="#PathwayStep188" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction148" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction159" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction149" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction146" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction157" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction147" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction158" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction144" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction155" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction145" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction156" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction153" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction143" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction154" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction151" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction162" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction152" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction163" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction160" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction150" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction161" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence171" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive Signaling by NOTCH1 PEST Domain Mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">As NOTCH1 PEST domain is intracellular, NOTCH1 PEST domain mutants are expected to behave as the wild-type NOTCH1 with respect to ligand binding and proteolytic cleavage mediated activation of signaling. However, once the NICD1 fragment of NOTCH1 is released, PEST domain mutations prolong its half-life and transcriptional activity through interference with FBXW7 (FBW7)-mediated ubiquitination and degradation of NICD1 (Weng et al. 2004, Thompson et al. 2007, O&apos;Neil et al. 2007). All NOTCH1 PEST domain mutants annotated here (NOTCH1 Q2395*, NOTCH1 Q2440*, NOTCH1 P2474Afs*4 and NOTCH1 P2514Rfs*4) either have a truncated PEST domain or lack the PEST domain completely.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep228">
 <bp:stepProcess rdf:resource="#Catalysis40" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction187" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway28">
 <bp:pathwayOrder rdf:resource="#PathwayStep170" />
 <bp:pathwayComponent rdf:resource="#Pathway29" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence170" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by NOTCH1 PEST Domain Mutants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutations are frequently found in T-cell acute lymphoblastic leukemia (T-ALL). PEST domain mutations interfere with ubiquitination-mediated NOTCH1 downregulation and result in prolonged half-life of the intracellular NOTCH1 fragment, NICD1, and increased NICD1 transcriptional activity (Weng et al. 2004, Thompson et al. 2007, O&apos;Neil et al. 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep229">
 <bp:stepProcess rdf:resource="#BiochemicalReaction188" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep220">
 <bp:stepProcess rdf:resource="#BiochemicalReaction181" />
 <bp:stepProcess rdf:resource="#Catalysis37" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep221">
 <bp:stepProcess rdf:resource="#BiochemicalReaction182" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction429">
 <bp:evidence rdf:resource="#Evidence570" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT mutants:PI3K catalyze synthesis of PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway12">
 <bp:pathwayOrder rdf:resource="#PathwayStep81" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction70" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence81" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">alectinib-resistant ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Alectinib is a second generation tyrosine kinase inhibitor that is approved for use in ALK positive non-small cell lung cancers (NSCLCs). Alectinib is effective against a number of ALK mutants that arise after treatment with crizotinib, however resistance to alectinib has also been reported. This pathway describes ALK mutants that are resistant to inhibition with alectinib (reviewed in Lovly and Pao, 2012; Lin et al, 2017; Della Corte et al, 2018; Hallberg and Palmer, 2016).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction427">
 <bp:evidence rdf:resource="#Evidence568" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recruitment of STATs by KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway11">
 <bp:pathwayOrder rdf:resource="#PathwayStep79" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction69" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence79" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NVP-TAE684-resistant ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NVP TAE684 is a second generation tyrosine kinase inhibitor with activity against some ALK mutants, including some that show resistance to crizotinib (George et al, 2008; Sasaki et al, 2011; Heuckmann et al, 2011; Ceccon et al, 2013). This pathway describes ALK mutants that show resistance to inhibition by NVP TAE684.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction428">
 <bp:evidence rdf:resource="#Evidence569" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of STATs downstream of KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway10">
 <bp:pathwayOrder rdf:resource="#PathwayStep77" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction68" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence77" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">brigatinib-resistant ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Brigatinib is a second generation tyrosine kinase inhibitor with activity against ALK. This pathway describes ALK mutants that are resistant to inhibition by brigatinib (reviewed in Della Corte et al, 2018; Roskoski, 2013; Lin and Pao, 2017; Hallberg and Palmer, 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction425">
 <bp:evidence rdf:resource="#Evidence566" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Disassociation and translocation of STATs to the nucleus downstream of KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction426">
 <bp:evidence rdf:resource="#Evidence567" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-KIT mutants:GRB2:SOS catalyzes nucleotide exchange on RAS</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway16">
 <bp:pathwayOrder rdf:resource="#PathwayStep87" />
 <bp:pathwayOrder rdf:resource="#PathwayStep88" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction72" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction73" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence87" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Inhibition of Signaling by Overexpressed EGFR</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recombinant monoclonal antibody Cetuximab acts as an antagonist of EGFR ligand binding, and is approved for the treatment of tumors that over-express wild-type EGFR receptor (Cunningham et al. 2004, Li et al. 2005, Burtness et al. 2005). Effective concentrations of covalent tyrosine kinase inhibitors (TKIs) inhibit wild-type EGFR, causing severe side effects (Zhou et al. 2009). Hence, covalent TKIs have not shown much promise in clinical trials (Reviewed by Pao and Chmielecki in 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep233">
 <bp:stepProcess rdf:resource="#Catalysis42" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction192" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction423">
 <bp:evidence rdf:resource="#Evidence564" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT mutants bind SFKs</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway15">
 <bp:pathwayOrder rdf:resource="#PathwayStep86" />
 <bp:pathwayComponent rdf:resource="#Pathway16" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence86" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by Overexpressed Wild-Type EGFR in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by EGFR is frequently activated in cancer through genomic amplification of the EGFR locus, resulting in over-expression of the wild-type protein (Wong et al. 1987).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep234">
 <bp:stepProcess rdf:resource="#Pathway43" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction424">
 <bp:evidence rdf:resource="#Evidence565" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated KIT mutants bind PI3K</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway14">
 <bp:pathwayOrder rdf:resource="#PathwayStep89" />
 <bp:pathwayOrder rdf:resource="#PathwayStep109" />
 <bp:pathwayOrder rdf:resource="#PathwayStep85" />
 <bp:pathwayComponent rdf:resource="#Pathway15" />
 <bp:pathwayComponent rdf:resource="#Pathway19" />
 <bp:pathwayComponent rdf:resource="#Pathway17" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence85" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by EGFR in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The pathway &quot;Signaling by EGFR in Cancer&quot; shows signaling by constitutively active EGFR cancer variants in the context of &quot;Signaling by EGFR&quot;, allowing users to compare cancer events with the wild-type EGFR events. Red lines emphasize cancer related events and physical entities, while wild-type entities and events are shaded. Please refer to &quot;Signaling by Ligand-Responsive EGFR Variants in Cancer&quot;, &quot;Signaling by EGFRvIII in Cancer&quot; and &quot;Signaling by Overexpressed Wild-Type EGFR in Cancer&quot; for detailed pathway summations.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep235">
 <bp:stepProcess rdf:resource="#Pathway44" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction421">
 <bp:evidence rdf:resource="#Evidence562" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT mutants bind GRB2-SOS</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway13">
 <bp:pathwayOrder rdf:resource="#PathwayStep83" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction71" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence83" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK mutants bind TKIs</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aberrant signaling by activated forms of ALK can be inhibited by tyrosine kinase inhibitors (TKIs). ALK, like other tyrosine kinase receptors, is activated through a series of phosphorylation and conformational changes that move the receptor from the inactive form to the fully activated form. Type II TKIs bind to the inactive form of the receptor at a site adjacent to the ATP-binding cleft, while type I TKIs bind to the active form (reviewed in Roskoski, 2013). Type I inhibitors crizotinib, brigatinib, alectinib, ceritinib and lorlatinib are all approved for treatment of ALK-dependent cancer. Development of resistance to TKIs is not uncommon, however, either through acquisition of secondary mutations or through activation of bypass pathways that remove the dependence on ALK signaling (reviewed in Lovly and Pao, 2012; Lin et al, 2017; Della Corte et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep236">
 <bp:stepProcess rdf:resource="#Pathway45" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction422">
 <bp:evidence rdf:resource="#Evidence563" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">JAK2 binds to p-KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep237">
 <bp:stepProcess rdf:resource="#BiochemicalReaction193" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway19">
 <bp:pathwayOrder rdf:resource="#PathwayStep110" />
 <bp:pathwayComponent rdf:resource="#Pathway20" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence110" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by Ligand-Responsive EGFR Variants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-responsive EGFR cancer variants harbor mutations in the kinase domain or point mutations in the extracellular domain. These altered EGFR proteins are able to signal in the absence of ligands, but their ligand binding ability is preserved and downstream signaling is potentiated when ligand is available (Greulich et al. 2005, Lee et al. 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep238">
 <bp:stepProcess rdf:resource="#Pathway46" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction420">
 <bp:evidence rdf:resource="#Evidence561" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of STATs downstream of KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway18">
 <bp:pathwayOrder rdf:resource="#PathwayStep98" />
 <bp:pathwayOrder rdf:resource="#PathwayStep97" />
 <bp:pathwayOrder rdf:resource="#PathwayStep99" />
 <bp:pathwayOrder rdf:resource="#PathwayStep92" />
 <bp:pathwayOrder rdf:resource="#PathwayStep91" />
 <bp:pathwayOrder rdf:resource="#PathwayStep94" />
 <bp:pathwayOrder rdf:resource="#PathwayStep93" />
 <bp:pathwayOrder rdf:resource="#PathwayStep96" />
 <bp:pathwayOrder rdf:resource="#PathwayStep95" />
 <bp:pathwayOrder rdf:resource="#PathwayStep101" />
 <bp:pathwayOrder rdf:resource="#PathwayStep102" />
 <bp:pathwayOrder rdf:resource="#PathwayStep103" />
 <bp:pathwayOrder rdf:resource="#PathwayStep104" />
 <bp:pathwayOrder rdf:resource="#PathwayStep105" />
 <bp:pathwayOrder rdf:resource="#PathwayStep106" />
 <bp:pathwayOrder rdf:resource="#PathwayStep107" />
 <bp:pathwayOrder rdf:resource="#PathwayStep108" />
 <bp:pathwayOrder rdf:resource="#PathwayStep100" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction74" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction85" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction75" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction86" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction76" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction87" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction77" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction88" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction81" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction82" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction83" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction84" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction78" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction89" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction79" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction90" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction80" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction91" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence91" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive Signaling by EGFRvIII</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In glioblastoma, the most prevalent EGFR mutation, present in ~25% of tumors, is the deletion of the ligand binding domain of EGFR, accompanied with amplification of the mutated allele, which results in over-expression of the mutant protein known as EGFRvIII. EGFRvIII mutant is not able to bind a ligand, but dimerizes and autophosphorylates spontaneously and is therefore constitutively active (Fernandes et al. 2001). Point mutations in the extracellular domain of EGFR are also frequently found in glioblastoma, but ligand binding ability and responsiveness are preserved (Lee et al. 2006).  Similar to EGFR kinase domain mutants, EGFRvIII mutant needs to maintain association with the chaperone heat shock protein 90 (HSP90) for proper functioning (Shimamura et al. 2005, Lavictoire et al. 2003). CDC37 is a co-chaperone of HSP90 that acts as a scaffold and regulator of interaction between HSP90 and its protein kinase clients. CDC37 is frequently over-expressed in cancers involving mutant kinases and acts as an oncogene (Roe et al. 2004, reviewed by Gray Jr. et al. 2008).  Expression of EGFRvIII mutant results in aberrant activation of downstream signaling cascades, namely RAS/RAF/MAP kinase signaling and PI3K/AKT signaling, and possibly signaling by PLCG1, which leads to increased cell proliferation and survival, providing selective advantage to cancer cells that harbor EGFRvIII (Huang et al. 2007).   EGFRvIII mutant does not autophosorylate on the tyrosine residue Y1069 (i.e. Y1045 in the mature protein), a docking site for CBL, and is therefore unable to recruit CBL ubiquitin ligase, which enables it to escape degradation (Han et al. 2006)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep239">
 <bp:stepProcess rdf:resource="#BiochemicalReaction194" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway17">
 <bp:pathwayOrder rdf:resource="#PathwayStep90" />
 <bp:pathwayComponent rdf:resource="#Pathway18" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence90" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by EGFRvIII in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">EGFRvIII (EGFR V30_R297delinsG) is the most prevalent EGFR variant in glioblastoma, but it is also found in other cancer types. In-frame deletion of the ligand binding domain in EGFRvIII is frequently accompanied with genomic amplification, resulting in over-expression of EGFRvIII. EGFRvIII dimerizes and autophosphorylates spontaneously and is therefore constitutively active (Fernandes et al. 2001)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep230">
 <bp:stepProcess rdf:resource="#BiochemicalReaction189" />
 <bp:stepProcess rdf:resource="#Catalysis41" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep231">
 <bp:stepProcess rdf:resource="#BiochemicalReaction190" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep232">
 <bp:stepProcess rdf:resource="#BiochemicalReaction191" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence310">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction438">
 <bp:evidence rdf:resource="#Evidence588" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT mutants bind type II TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction439">
 <bp:evidence rdf:resource="#Evidence589" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT mutants bind type I TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction436">
 <bp:evidence rdf:resource="#Evidence584" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nilotinib-resistant KIT mutants do not bind nilotinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction437">
 <bp:evidence rdf:resource="#Evidence586" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sorafenib-resistant KIT mutants do not bind sorafenib</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep244">
 <bp:stepProcess rdf:resource="#Pathway50" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction434">
 <bp:evidence rdf:resource="#Evidence580" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dasatinib-resistant KIT mutants do not bind dasatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep245">
 <bp:stepProcess rdf:resource="#BiochemicalReaction196" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction435">
 <bp:evidence rdf:resource="#Evidence582" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Masitinib-resistant KIT mutants do not bind masitinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep246">
 <bp:stepProcess rdf:resource="#Pathway51" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction432">
 <bp:evidence rdf:resource="#Evidence576" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sunitinib-resistant KIT mutants do not bind sunitinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep247">
 <bp:stepProcess rdf:resource="#BiochemicalReaction197" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction433">
 <bp:evidence rdf:resource="#Evidence578" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regorafenib-resistant KIT mutants do not bind regorafenib</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep248">
 <bp:stepProcess rdf:resource="#Pathway52" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence309">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction430">
 <bp:evidence rdf:resource="#Evidence571" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of JAK2 downstream of KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep249">
 <bp:stepProcess rdf:resource="#Pathway53" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence308">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction431">
 <bp:evidence rdf:resource="#Evidence574" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Imatinib-resistant KIT mutants do not bind imatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence305">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence304">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence307">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence306">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep240">
 <bp:stepProcess rdf:resource="#Pathway47" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence301">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep241">
 <bp:stepProcess rdf:resource="#Pathway48" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence300">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep242">
 <bp:stepProcess rdf:resource="#BiochemicalReaction195" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence303">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep243">
 <bp:stepProcess rdf:resource="#Pathway49" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence302">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence321">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence320">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction449">
 <bp:evidence rdf:resource="#Evidence602" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR4 Y367C mutant</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction447">
 <bp:evidence rdf:resource="#Evidence600" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR4 mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction448">
 <bp:evidence rdf:resource="#Evidence601" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of FGFR4 mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep255">
 <bp:stepProcess rdf:resource="#BiochemicalReaction200" />
 <bp:stepProcess rdf:resource="#Catalysis43" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction445">
 <bp:evidence rdf:resource="#Evidence597" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutant-associated PI3K phosphorylates PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep256">
 <bp:stepProcess rdf:resource="#Pathway57" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction446">
 <bp:evidence rdf:resource="#Evidence598" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep257">
 <bp:stepProcess rdf:resource="#BiochemicalReaction201" />
 <bp:stepProcess rdf:resource="#Catalysis44" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction443">
 <bp:evidence rdf:resource="#Evidence595" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants bind PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep258">
 <bp:stepProcess rdf:resource="#BiochemicalReaction202" />
 <bp:stepProcess rdf:resource="#Catalysis45" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction444">
 <bp:evidence rdf:resource="#Evidence596" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants:p-FRS2 binds GRB2:GAB1:PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep259">
 <bp:stepProcess rdf:resource="#BiochemicalReaction203" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction441">
 <bp:evidence rdf:resource="#Evidence593" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-4Y-PLCG1 dissociates from activated FGFR4 mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence319">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction442">
 <bp:evidence rdf:resource="#Evidence594" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants phosphorylate PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction440">
 <bp:evidence rdf:resource="#Evidence590" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT mutants bind ripretinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence316">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence315">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence318">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep250">
 <bp:stepProcess rdf:resource="#BiochemicalReaction198" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence317">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep251">
 <bp:stepProcess rdf:resource="#Pathway54" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence312">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep252">
 <bp:stepProcess rdf:resource="#BiochemicalReaction199" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence311">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep253">
 <bp:stepProcess rdf:resource="#Pathway55" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence314">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep254">
 <bp:stepProcess rdf:resource="#Pathway56" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence313">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep659">
 <bp:stepProcess rdf:resource="#BiochemicalReaction496" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction458">
 <bp:evidence rdf:resource="#Evidence612" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutant-associated PI3K phosphorylates PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction459">
 <bp:evidence rdf:resource="#Evidence613" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants bind FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction456">
 <bp:evidence rdf:resource="#Evidence610" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep662">
 <bp:stepProcess rdf:resource="#BiochemicalReaction499" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction457">
 <bp:evidence rdf:resource="#Evidence611" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants:p-FRS2 binds GRB2:GAB1:PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep663">
 <bp:stepProcess rdf:resource="#BiochemicalReaction500" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction454">
 <bp:evidence rdf:resource="#Evidence607" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants phosphorylate FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep664">
 <bp:stepProcess rdf:resource="#BiochemicalReaction501" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction455">
 <bp:evidence rdf:resource="#Evidence608" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants bind FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep665">
 <bp:stepProcess rdf:resource="#Catalysis145" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction502" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction452">
 <bp:evidence rdf:resource="#Evidence605" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants:p-FRS2:GRB2:GAB1:PIK3R1 binds PIK3CA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep666">
 <bp:stepProcess rdf:resource="#Catalysis146" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction503" />
</bp:PathwayStep>

<bp:BioSource rdf:ID="BioSource1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Homo sapiens</bp:name>
</bp:BioSource>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction453">
 <bp:evidence rdf:resource="#Evidence606" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants:p-FRS2 binds GRB2-SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep667">
 <bp:stepProcess rdf:resource="#BiochemicalReaction504" />
 <bp:stepProcess rdf:resource="#Catalysis147" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction450">
 <bp:evidence rdf:resource="#Evidence603" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive dimerization of FGFR4 Y367C mutant</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep668">
 <bp:stepProcess rdf:resource="#Pathway165" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction451">
 <bp:evidence rdf:resource="#Evidence604" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR4 kinase mutants are inhibited by PD170734</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep669">
 <bp:stepProcess rdf:resource="#BiochemicalReaction505" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep660">
 <bp:stepProcess rdf:resource="#BiochemicalReaction497" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep661">
 <bp:stepProcess rdf:resource="#BiochemicalReaction498" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction469">
 <bp:evidence rdf:resource="#Evidence627" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2 fusions dimerize</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction467">
 <bp:evidence rdf:resource="#Evidence624" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tyrosine kinase inhibitors bind to overexpressed FGFR2 variants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep673">
 <bp:stepProcess rdf:resource="#BiochemicalReaction509" />
 <bp:stepProcess rdf:resource="#Catalysis149" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction468">
 <bp:evidence rdf:resource="#Evidence626" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2 fusions autophosphorylate</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep674">
 <bp:stepProcess rdf:resource="#BiochemicalReaction510" />
 <bp:stepProcess rdf:resource="#Catalysis150" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction465">
 <bp:evidence rdf:resource="#Evidence622" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of overexpressed FGFR2 variants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep675">
 <bp:stepProcess rdf:resource="#Pathway166" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction466">
 <bp:evidence rdf:resource="#Evidence623" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of overexpressed FGFR2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep676">
 <bp:stepProcess rdf:resource="#Pathway167" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction463">
 <bp:evidence rdf:resource="#Evidence619" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aberrant alternative splicing yields a secreted FGFR2 IIIa TM disease variant</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep677">
 <bp:stepProcess rdf:resource="#BiochemicalReaction511" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction464">
 <bp:evidence rdf:resource="#Evidence621" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GP369 inhibits activation of amplified FGFR2 signaling</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep678">
 <bp:stepProcess rdf:resource="#Catalysis151" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction512" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction461">
 <bp:evidence rdf:resource="#Evidence615" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-4Y-PLCG1 dissociates from activated FGFR2 mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep679">
 <bp:stepProcess rdf:resource="#Pathway168" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction462">
 <bp:evidence rdf:resource="#Evidence618" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2IIIa TM binds ligand and full length receptors to inhibit signaling</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction460">
 <bp:evidence rdf:resource="#Evidence614" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants:p-FRS2:GRB2:GAB1:PIK3R1 binds PIK3CA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep670">
 <bp:stepProcess rdf:resource="#Catalysis148" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction506" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep671">
 <bp:stepProcess rdf:resource="#BiochemicalReaction507" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep672">
 <bp:stepProcess rdf:resource="#BiochemicalReaction508" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep200">
 <bp:stepProcess rdf:resource="#Pathway33" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction478">
 <bp:evidence rdf:resource="#Evidence637" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR2c mutants with enhanced ligand binding</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep684">
 <bp:stepProcess rdf:resource="#Pathway169" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep201">
 <bp:stepProcess rdf:resource="#BiochemicalReaction169" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction479">
 <bp:evidence rdf:resource="#Evidence638" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of FGFR2 ligand-independent mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep685">
 <bp:stepProcess rdf:resource="#BiochemicalReaction517" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep202">
 <bp:stepProcess rdf:resource="#BiochemicalReaction170" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction476">
 <bp:evidence rdf:resource="#Evidence635" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of FGFR2 point mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep686">
 <bp:stepProcess rdf:resource="#Catalysis154" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction518" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep203">
 <bp:stepProcess rdf:resource="#Pathway34" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction477">
 <bp:evidence rdf:resource="#Evidence636" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FP-1039 acts as a ligand-trap for FGFR2b-binding ligands in endometrial cancer</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep687">
 <bp:stepProcess rdf:resource="#BiochemicalReaction519" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep204">
 <bp:stepProcess rdf:resource="#Pathway35" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction474">
 <bp:evidence rdf:resource="#Evidence633" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR2 point mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep688">
 <bp:stepProcess rdf:resource="#BiochemicalReaction520" />
 <bp:stepProcess rdf:resource="#Catalysis155" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep205">
 <bp:stepProcess rdf:resource="#BiochemicalReaction171" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction475">
 <bp:evidence rdf:resource="#Evidence634" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2b mutants bind an expanded range of ligands</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep689">
 <bp:stepProcess rdf:resource="#BiochemicalReaction521" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep206">
 <bp:stepProcess rdf:resource="#Pathway36" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction472">
 <bp:evidence rdf:resource="#Evidence631" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR2b mutants with enhanced ligand binding</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep207">
 <bp:stepProcess rdf:resource="#BiochemicalReaction172" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction473">
 <bp:evidence rdf:resource="#Evidence632" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR2 ligand-independent  mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction470">
 <bp:evidence rdf:resource="#Evidence629" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Point mutants of FGFR2 bind and are inactivated by tyrosine kinase inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction471">
 <bp:evidence rdf:resource="#Evidence630" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2c mutants bind an expanded range of ligands</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep680">
 <bp:stepProcess rdf:resource="#BiochemicalReaction513" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep681">
 <bp:stepProcess rdf:resource="#Catalysis152" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction514" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep682">
 <bp:stepProcess rdf:resource="#BiochemicalReaction515" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep683">
 <bp:stepProcess rdf:resource="#Catalysis153" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction516" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep208">
 <bp:stepProcess rdf:resource="#Pathway37" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep209">
 <bp:stepProcess rdf:resource="#BiochemicalReaction173" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep211">
 <bp:stepProcess rdf:resource="#BiochemicalReaction174" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction489">
 <bp:evidence rdf:resource="#Evidence651" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive dimerization of FGFR3 cysteine mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep695">
 <bp:stepProcess rdf:resource="#BiochemicalReaction526" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep212">
 <bp:stepProcess rdf:resource="#Pathway39" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep696">
 <bp:stepProcess rdf:resource="#Catalysis159" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction527" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep213">
 <bp:stepProcess rdf:resource="#BiochemicalReaction175" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction487">
 <bp:evidence rdf:resource="#Evidence649" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR3 cysteine mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep697">
 <bp:stepProcess rdf:resource="#BiochemicalReaction528" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep214">
 <bp:stepProcess rdf:resource="#BiochemicalReaction176" />
 <bp:stepProcess rdf:resource="#Catalysis35" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction488">
 <bp:evidence rdf:resource="#Evidence650" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of FGFR3 point mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep698">
 <bp:stepProcess rdf:resource="#Catalysis160" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction529" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep215">
 <bp:stepProcess rdf:resource="#Pathway40" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction485">
 <bp:evidence rdf:resource="#Evidence645" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point, translocation and fusion mutants:p-FRS2:GRB2:GAB1:PIK3R1 binds PIK3CA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep699">
 <bp:stepProcess rdf:resource="#BiochemicalReaction530" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep216">
 <bp:stepProcess rdf:resource="#BiochemicalReaction177" />
 <bp:stepProcess rdf:resource="#Catalysis36" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction486">
 <bp:evidence rdf:resource="#Evidence646" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR3 mutants bind and are inactivated by tyrosine kinase inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep217">
 <bp:stepProcess rdf:resource="#BiochemicalReaction178" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction483">
 <bp:evidence rdf:resource="#Evidence642" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants phosphorylate FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep218">
 <bp:stepProcess rdf:resource="#BiochemicalReaction179" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction484">
 <bp:evidence rdf:resource="#Evidence644" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point, translocation and fusion mutants phosphorylate FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction481">
 <bp:evidence rdf:resource="#Evidence640" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants:p-FRS2 binds GRB2-SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction482">
 <bp:evidence rdf:resource="#Evidence641" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants phosphorylate PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction480">
 <bp:evidence rdf:resource="#Evidence639" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants bind PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep690">
 <bp:stepProcess rdf:resource="#Pathway170" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep691">
 <bp:stepProcess rdf:resource="#BiochemicalReaction522" />
 <bp:stepProcess rdf:resource="#Catalysis156" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep692">
 <bp:stepProcess rdf:resource="#BiochemicalReaction523" />
 <bp:stepProcess rdf:resource="#Catalysis157" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep693">
 <bp:stepProcess rdf:resource="#BiochemicalReaction524" />
 <bp:stepProcess rdf:resource="#Catalysis158" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep210">
 <bp:stepProcess rdf:resource="#Pathway38" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep694">
 <bp:stepProcess rdf:resource="#BiochemicalReaction525" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep615">
 <bp:stepProcess rdf:resource="#Pathway155" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep616">
 <bp:stepProcess rdf:resource="#Pathway156" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep617">
 <bp:stepProcess rdf:resource="#BiochemicalReaction462" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep618">
 <bp:stepProcess rdf:resource="#BiochemicalReaction463" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep619">
 <bp:stepProcess rdf:resource="#Pathway157" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep620">
 <bp:stepProcess rdf:resource="#BiochemicalReaction464" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction498">
 <bp:evidence rdf:resource="#Evidence662" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point, translocation and fusion mutants bind FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep621">
 <bp:stepProcess rdf:resource="#BiochemicalReaction465" />
 <bp:stepProcess rdf:resource="#Catalysis131" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction499">
 <bp:evidence rdf:resource="#Evidence663" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point, translocation and fusion mutants:p-FRS2 binds GRB2-SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep622">
 <bp:stepProcess rdf:resource="#BiochemicalReaction466" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction496">
 <bp:evidence rdf:resource="#Evidence660" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR3 fusions dimerize</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep623">
 <bp:stepProcess rdf:resource="#BiochemicalReaction467" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction497">
 <bp:evidence rdf:resource="#Evidence661" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point, translocation and fusion mutants:p-FRS2 binds GRB2:GAB1:PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep624">
 <bp:stepProcess rdf:resource="#Pathway158" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction494">
 <bp:evidence rdf:resource="#Evidence657" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR3 t(4;14) translocation mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep625">
 <bp:stepProcess rdf:resource="#BiochemicalReaction468" />
 <bp:stepProcess rdf:resource="#Catalysis132" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction495">
 <bp:evidence rdf:resource="#Evidence659" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR3 fusions</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction492">
 <bp:evidence rdf:resource="#Evidence654" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR3 point mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction493">
 <bp:evidence rdf:resource="#Evidence656" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of FGFR3 t(4;14) translocation mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction490">
 <bp:evidence rdf:resource="#Evidence652" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR3c P250R mutant</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction491">
 <bp:evidence rdf:resource="#Evidence653" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR3c P250R mutant binds to ligand with enhanced affinity</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep626">
 <bp:stepProcess rdf:resource="#BiochemicalReaction469" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep627">
 <bp:stepProcess rdf:resource="#Pathway159" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep628">
 <bp:stepProcess rdf:resource="#BiochemicalReaction470" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep629">
 <bp:stepProcess rdf:resource="#BiochemicalReaction471" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep630">
 <bp:stepProcess rdf:resource="#BiochemicalReaction472" />
 <bp:stepProcess rdf:resource="#Catalysis133" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep631">
 <bp:stepProcess rdf:resource="#BiochemicalReaction473" />
 <bp:stepProcess rdf:resource="#Catalysis134" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep632">
 <bp:stepProcess rdf:resource="#BiochemicalReaction474" />
 <bp:stepProcess rdf:resource="#Catalysis135" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep633">
 <bp:stepProcess rdf:resource="#BiochemicalReaction475" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep634">
 <bp:stepProcess rdf:resource="#BiochemicalReaction476" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep635">
 <bp:stepProcess rdf:resource="#BiochemicalReaction477" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep636">
 <bp:stepProcess rdf:resource="#BiochemicalReaction478" />
 <bp:stepProcess rdf:resource="#Catalysis136" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep637">
 <bp:stepProcess rdf:resource="#BiochemicalReaction479" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep638">
 <bp:stepProcess rdf:resource="#BiochemicalReaction480" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep639">
 <bp:stepProcess rdf:resource="#BiochemicalReaction481" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep640">
 <bp:stepProcess rdf:resource="#Catalysis137" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction482" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence709">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep641">
 <bp:stepProcess rdf:resource="#BiochemicalReaction483" />
 <bp:stepProcess rdf:resource="#Catalysis138" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence708">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep642">
 <bp:stepProcess rdf:resource="#Pathway160" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep643">
 <bp:stepProcess rdf:resource="#BiochemicalReaction484" />
 <bp:stepProcess rdf:resource="#Catalysis139" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep644">
 <bp:stepProcess rdf:resource="#BiochemicalReaction485" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence705">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep645">
 <bp:stepProcess rdf:resource="#BiochemicalReaction486" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence704">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep646">
 <bp:stepProcess rdf:resource="#Pathway161" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence707">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep647">
 <bp:stepProcess rdf:resource="#Pathway162" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence706">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence701">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence700">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence703">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence702">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep648">
 <bp:stepProcess rdf:resource="#Catalysis140" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction487" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep649">
 <bp:stepProcess rdf:resource="#BiochemicalReaction488" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep651">
 <bp:stepProcess rdf:resource="#Catalysis141" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction490" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep652">
 <bp:stepProcess rdf:resource="#BiochemicalReaction491" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep653">
 <bp:stepProcess rdf:resource="#Catalysis142" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction492" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep654">
 <bp:stepProcess rdf:resource="#Pathway163" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep655">
 <bp:stepProcess rdf:resource="#BiochemicalReaction493" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep656">
 <bp:stepProcess rdf:resource="#Catalysis143" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction494" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep657">
 <bp:stepProcess rdf:resource="#Pathway164" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep658">
 <bp:stepProcess rdf:resource="#BiochemicalReaction495" />
 <bp:stepProcess rdf:resource="#Catalysis144" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep650">
 <bp:stepProcess rdf:resource="#BiochemicalReaction489" />
</bp:PathwayStep>
</rdf:RDF>